Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843

This article has now been updated. Please use the final version.

Version 2
JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis
Yuichi Tamura, Kenya Kusunose, Yugo Yamashita, Teiji Akagi, Masanori Atsukawa, Yoshihiro Fukumoto, Ayumi Goda, Shinya Goto, Masaru Hatano, Masataka Ikeda, Keiichi Ishida, Masaharu Kataoka, Masataka Kuwana, Hiromi Matsubara, Makoto Mo, Tetsutaro Nagaoka, Takeshi Ogo, Yoshinori Okada, Seiichiro Sakao, Hirofumi Sawada, Toshiro Shinke, Nobuhiro Tanabe, Norikazu Yamada, Hiroyuki Yamagishi, Shingo Yano, Kohtaro Abe, Shiro Adachi, Kazuya Hosokawa, Nobutaka Ikeda, Takumi Inami, Masahiro Jinzaki, Masaru Kato, Takeshi Kitai, Shigetoyo Kogaki, Jun Koizumi, Yoshiteru Morio, Mari Nishizaki, Yoshito Ogihara, Keiko Ohta-Ogo, Kunihiro Shigematsu, Koichiro Sugimura, Yudai Tamura, Yu Taniguchi, Ichizo Tsujino, Keiko Uchida, Takeshi Yamamoto, Atsushi Yao, Nobuhiro Yaoita, Noriaki Emoto, Hiroaki Kitaoka, Mashio Nakamura, Hitoshi Ogino, Toru Satoh, Hiroshi Watanabe, on behalf of the Japanese Circulation Society and Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML Advance online publication

Article ID: CJ-25-1144

Version 2: August 05, 2026
Version 1: June 30, 2026
Details

Abbreviations

6MWD Six-minute walk distance
ACCP American College of Chest Physicians
ACHD Adult congenital heart disease
APTT Activated partial thromboplastin time
AVT Acute vasoreactivity testing
BNP Brain natriuretic peptide
BPA Balloon pulmonary angioplasty
CDT Catheter-directed thrombolysis
CHD Congenital heart disease
CI Cardiac index
CO Cardiac output
COPD Chronic obstructive pulmonary disease
CpcPH Combined pre- and post-capillary pulmonary hypertension
CT Computed tomography
CTD Connective tissue disease
CTEPD Chronic thromboembolic pulmonary disease
CTEPH Chronic thromboembolic pulmonary hypertension
CTPA Computed tomography pulmonary angiography
DLCO Diffusing capacity of the lungs for carbon monoxide
DOACs Direct oral anticoagulants
DPG Diastolic pressure gradient
DVT Deep venous thrombosis
ECMO Extracorporeal membrane oxygenation
ERS European Respiratory Society
ESC European Society of Cardiology
HAART Highly active anti-retroviral therapy
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
HPAH Heritable pulmonary arterial hypertension
HR Hazard ratio
ICU Intensive care unit
ILD Interstitial lung disease
iNO Inhaled nitric oxide
IPAH Idiopathic pulmonary arterial hypertension
IPC Intermittent pneumatic compression
IpcPH Isolated post-capillary pulmonary hypertension
IPF Idiopathic pulmonary fibrosis
IVC Inferior vena cava
LHD Left heart disease
LMWH Low-molecular-weight heparin
LTOT Long-term oxygen therapy
LV Left ventricle
mPAP Mean pulmonary arterial pressure
MRC Medical Research Council
NO Nitric oxide
NT-proBNP N-terminal prohormone of brain natriuretic peptide
OR Odds ratio
PAH Pulmonary arterial hypertension
PAWP Pulmonary artery wedge pressure
PCDT Pharmacomechanical catheter-directed thrombolysis
PCH Pulmonary capillary hemangiomatosis
PDE Phosphodiesterase
PE Pulmonary embolism
PEA Pulmonary endarterectomy
PESI Pulmonary Embolism Severity Index
PH Pulmonary hypertension
PoPH Portopulmonary hypertension
PPHN Persistent pulmonary hypertension of the newborn
PPS Peripheral pulmonary artery stenosis
PT-INR Prothrombin time- international normalized ratio
PTS Post-thrombotic syndrome
PVOD Pulmonary venous occlusive disease
PVR Pulmonary vascular resistance
QOL Quality of life
Qp/Qs Pulmonary blood flow/systemic blood flow ratio
RCT Randomized controlled trial
RHC Right heart catheterization
RR Relative risk
RV Right ventricle
SLE Systemic lupus erythematosus
sPESI Simplified Pulmonary Embolism Severity Index
SSc Systemic scleroderma
TRV Tricuspid regurgitation velocity
USAT Ultrasound-assisted catheter-directed thrombolysis
VA-ECMO Veno-arterial extracorporeal membrane oxygenation
VC Vital capacity
%VC Percent vital capacity
V/Q Ventilation–perfusion
VTE Venous thromboembolism
WHO World Health Organization

I. Introduction

1. Preamble

This guideline consolidates 3 documents previously issued by the Japanese Circulation Society, namely Guidelines for the Diagnosis, Treatment, and Prevention of Pulmonary Embolism and Deep Vein Thrombosis, Guidelines for the Treatment of Pulmonary Hypertension, and Statement on the Indications and Practice of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension, into a newly revised, integrated volume. Although recent advances in the diagnosis and treatment of these conditions have been remarkable, they are tightly interrelated within the pulmonary circulation. By synthesizing contemporary evidence with the practical insights of numerous experts, we aim to provide a comprehensive framework for prevention, diagnosis, and therapy across the pulmonary vascular field. On that basis, the 3 documents have been merged and revised as the 2025 Guidelines for Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis.

The Guidelines for the Diagnosis, Treatment, and Prevention of Pulmonary Embolism and Deep Vein Thrombosis were first published in 2004 and revised in 2009 and 2017.1 The 2017 edition appeared soon after direct oral anticoagulants (DOACs) became available, at a time when supporting evidence remained limited. However, in the intervening years, there have been considerable advances in the management of venous thromboembolism (VTE) with DOACs, ushering in major changes in practice, including outpatient treatment pathways based on DOAC monotherapy. In Europe and North America, guideline updates have similarly been issued since 2017,2,3 and highquality evidence, including studies originating in Japan, has expanded, particularly for unprovoked VTE and cancerassociated VTE. In addition, given the clinical importance of thrombosis in the context of COVID19, a full revision was undertaken to incorporate these developments.

The Guidelines for the Treatment of Pulmonary Hypertension were first published in 1999–2000, underwent partial revisions in 2006 and 2012, and were comprehensively revised in 2017.4 In addition, for balloon pulmonary angioplasty (BPA), a therapeutic modality that can be regarded as having originated in Japan, a dedicated Statement on the Indications and Practice of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension was issued in 2014.5 Since the previous revision, the 6th (2018) and 7th (2024) World Symposia on Pulmonary Hypertension (WSPH) have been convened, and changes to the hemodynamic definition of pulmonary hypertension have been proposed.6 Robust evidence has accumulated for pharmacotherapies across pulmonary hypertension subgroups, and data, including from Japan, have established the role of BPA. Moreover, the conceptual approach to treatment stratification has evolved from reliance on symptoms captured by the World Health Organization (WHO) functional class to pragmatic, multimodality risk stratification that has become standard practice. Because diagnostic and therapeutic paradigms have shifted substantially, a comprehensive revision was warranted. Notably, among highincome countries, this document is the first guideline to be issued following the proposals of the seventh World Symposium in 2024.

We therefore anticipate that, by incorporating evidence generated in Japan, this revision will contribute to advancing knowledge internationally in the fields of pulmonary hypertension and pulmonary vascular medicine.

2. Top 10 Key Revisions in the Present Guidelines

The 10 key revisions in this guideline are listed below.

1. One unified, endtoend guideline for pulmonary circulation

Three legacy documents, namely guidelines for the diagnosis, treatment, and prevention of pulmonary embolism and deep vein thrombosis, the pulmonary hypertension treatment guideline, and the statement on indications and techniques for BPA in chronic thromboembolic pulmonary hypertension (CTEPH), are fully integrated into a single, coherent 2025 edition covering prevention, diagnosis, interventions, and longitudinal care across the pulmonary circulation.

2. Adoption of revised definitions and classification of pulmonary hypertension from the WSPH

Proposals from the 6th (2018) and 7th (2024) WSPH, including updated hemodynamic definitions and refinements in clinical classification, are taken up and contextualized for Japanese practice.

3. Comprehensive remapping of therapeutic algorithms

Across VTE, pulmonary arterial hypertension, and CTEPH, algorithms are rewritten to reflect current evidence, risklayered goals (e.g., achieving and maintaining a lowrisk profile in pulmonary arterial hypertension), and stepup/stepacross strategies that align pharmacotherapy, intervention, and transplant referral.

4. A new stratification backbone from symptoms to multiparametric risk

The pulmonary hypertension treatment architecture moves beyond WHO functional class alone to a pragmatic, multimodal risk framework using composite clinical, biomarker, imaging, exercise, and hemodynamic signals as treatment targets and decision triggers.

5. BPA elevated and codified with Japanled evidence

Building on a decade of pioneering data from Japan, the role of BPA in CTEPH is expanded and formalized: indications, patient selection, procedural conduct, and positioning within multimodal therapy are integrated into the main treatment algorithms.

6. DOACcentric VTE care with realworld outpatient pathways

Reflecting rapid evidence accumulation since 2017, the VTE section has been overhauled to bring DOACs to the fore and to operationalize safe outpatient management models (including “DOAConly” care) where appropriate.

7. Clearer management of unprovoked and cancerassociated VTE

Recommendations are recast to incorporate the expanded, higherquality evidence base, both from Japan and internationally, on recurrence risk and anticoagulation intensity and duration in unprovoked VTE and malignancyassociated VTE.

8. Incorporation of COVID19-related thrombosis

This guideline assimilates data emerging from the pandemic, aligning prevention and treatment of COVID19-related thrombosis with contemporary VTE practice.

9. Broader, practiceready scope: prevention → diagnosis → treatment

The guideline deliberately links prevention, early detection, and definitive therapy for conditions across the pulmonary vasculature, addressing their “tight coupling” in daily practice.

10. First postWSPH7 national guideline, highlighting Japanese contributions

As the first comprehensive guideline released after the 7th WSPH (2024), this revision of the guidelines systematizes data originating from Japan, especially with regard to BPA, and is positioned to contribute to international standardsetting in pulmonary vascular medicine.

3. Class of Recommendation and Level of Evidence

In this guideline, classes of recommendation and levels of evidence are categorized as detailed in Tables 1 and 2.

Table 1.

Classes of Recommendation

Class I There is evidence and/or general agreement that a given procedure or treatment is effective and/or useful
Class IIa There is a high probability of efficacy/usefulness based on evidence and opinion
Class IIb Effectiveness/usefulness is not well established based on evidence and opinion
Class III
(No benefit)
There is evidence or general agreement that the procedure or treatment is not effective and/or useful
Class III
(Harm)
There is evidence and/or general agreement that the procedure or treatment is harmful

Table 2.

Levels of Evidence

Level A Demonstrated by multiple high-quality randomized clinical trials or meta-analyses
Level B Demonstrated by a single randomized clinical trial or large non-randomized studies
Level C Consensus from expert opinion and/or small clinical trials (including retrospective studies and case series)

II. Definition, Diagnosis, and Testing of Pulmonary Hypertension

1. Definition

1.1 Definition of Pulmonary Hypertension

Pulmonary hypertension (PH) is defined as a mean pulmonary arterial pressure (mPAP) >20 mmHg measured in the supine position at rest using right heart catheterization (RHC). Importantly, this change in the definition from the previous guidelines does not imply a recommendation for therapeutic intervention in patients previously classified as borderline PH with an mPAP of 21–24 mmHg. Further evidence is necessary to justify treatment in such patients (Recommendation Table 1).

Recommendation Table 1.

Recommendations and Levels of Evidence for the Definition of PH

  COR LOE
PH is defined as mPAP >20 mmHg at rest, measured by right heart catheterization I C
Exercise-induced PH is defined as mPAP/CO slope >3 mmHg/L/min during exercise I C

CO, cardiac output; COR, Class of Recommendation; LOE, Level of Evidence; mPAP, mean pulmonary arterial pressure; PH, pulmonary hypertension.

To distinguish precapillary PH caused by pulmonary vascular disease from elevated mPAP due to left heart disease, increased cardiac output (CO; equivalent to pulmonary blood flow), or increased intrathoracic pressure, it is necessary to include pulmonary vascular resistance (PVR) and pulmonary arterial wedge pressure (PAWP) in the definition. The 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines define precapillary PH as PVR >2 Wood units and PAWP ≤15 mmHg.7 The present guideline adopts the same thresholds. However, for PAWP, values higher than the empirically determined upper limit of 12 mmHg are commonly used in practice. Therefore, when evaluating patients with PAWP between 12 and 15 mmHg, clinicians should carefully consider risk factors and echocardiographic findings of left-sided heart failure. Hemodynamically, post-capillary PH is defined as mPAP >20 mmHg and PAWP >15 mmHg. In such cases, patients with PVR ≤2 Wood units are categorized as having isolated post-capillary PH, whereas those with PVR >2 Wood units are classified as having combined post- and precapillary PH.

1.2 Exercise PH

In healthy subjects, during exercise, mPAP does not exceed 30 mmHg when CO is 10 L/min, or the mPAP/CO slope remains ≤3 mmHg/L/min.8 Therefore, exercise PH is defined as an mPAP/CO slope >3 mmHg/L/min during exercise.9 To assess the proportional increase in mPAP relative to CO, one may plot CO on the x-axis and mPAP on the y-axis and calculate the slope. Alternatively, the change in mPAP from rest to exercise divided by the change in CO may be used as a simplified index.

2. Clinical Classification

The purpose of the clinical classification of PH is to categorize the clinical conditions associated with PH based on similar pathophysiological mechanisms, clinical and hemodynamic characteristics, and treatment strategies. This guideline adopts the classification proposed at the 7th World Symposium on Pulmonary Hypertension (WSPH-7).10 Major changes in this revision include:

• the classification of long-term responders to calcium channel blockers in idiopathic pulmonary arterial hypertension (PAH)11,12

• the categorization of PAH with features of pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis, and persistent pulmonary hypertension of the newborn as subtypes within Group 1 rather than separate subgroups

• the subclassification of some Group 2 and 3 PH subtypes by specific disease names.12

3. Diagnostic Algorithm (Recommendation Table 2)

Recommendation Table 2.

Recommendations and Levels of Evidence for the Diagnosis of PH

  COR LOE
It is recommended to perform a ventilation–perfusion (V/Q) scan or a lung perfusion scan to
assess for CTEPH in patients with PH
I C
It is recommended to perform CTPA for detailed evaluation in patients suspected of having
CTEPH
I C
It is recommended to regularly perform biochemical tests, blood tests, immunological tests, HIV
screening, and thyroid function tests to identify associated conditions in all patients with PAH
I C
It is recommended to perform an abdominal ultrasound to screen for portal hypertension I C
It is recommended to perform pulmonary function tests, including measurement of DLCO, in the
initial assessment of patients with PH
I C
It should be considered to perform chest CT in all patients with PAH IIa C
It should be considered to perform DSA in the detailed evaluation of patients with CTEPH IIa C
It is not recommended to perform open or thoracoscopic lung biopsy for general differential
diagnosis in patients with PAH
III
No benefit
C

COR, Class of Recommendation; CTPA, computed tomography pulmonary angiography; CTEPH, chronic thromboembolic pulmonary hypertension; DLCO, diffusing capacity of the lungs for carbon monoxide; DSA, digital subtraction angiography; HIV, human immunodeficiency virus; LOE, Level of Evidence; PAH, pulmonary arterial hypertension.

The differential diagnosis of patients presenting with unexplained exertional dyspnea or suspected PH is broad. In some cases, rapid clinical judgment is required, and a practical approach based on algorithms is essential. The diagnostic (Figure 1) and differential diagnosis (Figure 2) algorithms aim to facilitate smooth cooperation among primary care physicians, regional core hospitals, and PH centers capable of specialized diagnosis and treatment, enabling comprehensive evaluation at PH centers.

Figure 1.

Diagnostic algorithm for pulmonary hypertension (PH). BNP, B-type natriuretic peptide; CPET, cardiopulmonary exercise test; CT, computed tomography; CTEPH, chronic thromboembolic pulmonary hypertension; CTPA, computed tomography pulmonary angiography; DLCO, diffusing capacity of the lungs for carbon dioxide; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAH, pulmonary arterial hypertension; WHO, World Health Organization.

Figure 2.

Differential diagnostic algorithm for pulmonary hypertension (PH). * The numerical values and descriptions are for reference only; final decisions should be made on a case-by-case basis. CHD, congenital heart disease; COPD, chronic obstructive pulmonary disease; CPFE, combined pulmonary fibrosis and emphysema; CTD, connective tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; CTPA, computed tomography pulmonary angiography; DLCO, diffusing capacity of the lungs for carbon dioxide; HFpEF, heart failure with preserved ejection fraction; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; LHD, left heart disease; LVEDP, left ventricular end-diastolic pressure; mPAP, mean pulmonary arterial pressure; PAG, pulmonary angiography; PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge pressure; PCH, pulmonary capillary hemangiomatosis; PTTM, pulmonary tumor thrombotic microangiopathy; PVOD, pulmonary venous occlusive disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; V/Q, ventilation–perfusion.

3.1 Primary Care Physicians

Because PH patients typically present with non-specific symptoms, it is expected they will first consult primary care physicians. Initial evaluations should include medical and family history, physical examination (e.g., blood pressure, heart rate), chest X-ray, electrocardiogram, blood tests such as B-type natriuretic peptide/N-terminal pro B-type natriuretic peptide, and oxygen saturation. If abnormalities are detected, referral to a regional core hospital should be considered.

3.2 Regional Core Hospitals

For patients presenting with suspected PH, non-invasive tests are prioritized. Pulmonary diseases are evaluated using pulmonary function tests, arterial blood gas analysis, and chest computed tomography (CT) if needed. Cardiac assessments include echocardiography and cardiopulmonary exercise testing. Echocardiography plays a central role in the diagnostic algorithm and is useful regardless of the underlying cause of PH. It is also critical in differentiating other cardiac diseases. Based on initial findings, further evaluation or referral depends on the likelihood of PH or the identification of alternative causes.

3.3 Referral to PH Centers

If PH is moderately to highly suspected, further evaluation should be conducted at a specialized PH center. The goal is to confirm the differential diagnosis and identify the specific cause based on the current clinical classification. Urgent referral is especially important when clinical signs suggest PAH or chronic thromboembolic pulmonary hypertension (CTEPH), because timely intervention can significantly impact prognosis. Critical signs include rapidly progressive symptoms, World Health Organization (WHO) Class III or IV, right heart failure, syncope, intolerance to arrhythmia, and hemodynamic instability (e.g., hypotension, tachycardia, low CO). A ventilation–perfusion (V/Q) scan is the important initial diagnostic test for CTEPH, given its high sensitivity. If CTEPH is suspected, pulmonary angiography during RHC can provide definitive diagnosis based on characteristic imaging. This also helps determine treatment strategies, such as surgical eligibility. RHC is essential for hemodynamic evaluation and definitive diagnosis. For detailed differential diagnosis in each PH group, refer to the respective sections.

4. Diagnostic Tests

This section focuses on diagnostic tests that are relevant to the confirmation and classification of PH. Rather than providing an exhaustive list of all possible evaluations, key investigations are highlighted that play a central role in establishing the diagnosis, assessing severity, and guiding subsequent management.

4.1 Echocardiography (Recommendation Table 3)

Recommendation Table 3.

Recommendations and Levels of Evidence for Echocardiography in PH

  COR LOE
It is recommended to perform transthoracic echocardiography as the first-line non-invasive
diagnostic tool when PH is suspected
I B
It is recommended to estimate the probability of pulmonary hypertension based on the presence
of abnormal TRV and other suggestive findings on echocardiography
I B
It is recommended to maintain the current threshold of TRV >2.8 m/s when assessing the
possibility of pulmonary hypertension via echocardiography
I C
It should be considered to perform further detailed testing based on the echocardiographic
probability of PH, taking into account clinical context such as symptoms and risk factors for
PAH/CTEPH
IIa C
It may be considered to perform exercise stress echocardiography for active diagnostic
assessment in patients with intermediate probability of PH on baseline echocardiography
IIb C

COR, Class of Recommendation; CTEPH, chronic thromboembolic pulmonary hypertension; LOE, Level of Evidence; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; TRV, tricuspid regurgitation velocity.

Echocardiography serves as a gatekeeper in PH diagnosis because of its ability to estimate pulmonary artery pressure. It is recommended for patients suspected of having PH or those with comorbidities potentially associated with PH.13

Because there are multiple underlying mechanisms and presentations of PH, various echocardiographic parameters are used to assess the likelihood of PH. In addition to estimating systolic pulmonary artery pressure, other echocardiographic signs indicating PH, such as those pertaining to the ventricles, pulmonary artery, inferior vena cava (IVC), and right atrium, are evaluated. Due to potential measurement errors in estimated right atrial pressure, peak tricuspid regurgitation velocity (TRV) alone is recommended as a key variable to estimate the probability of PH. TRV can be underestimated in cases of severe tricuspid regurgitation or when the Doppler beam is not aligned with the regurgitant jet, and overestimated in high-output conditions such as liver disease or sickle cell disease. Furthermore, TRV may be inaccurate due to closure artifacts or misidentification of the peak.13 Therefore, TRV alone cannot rule out PH.14

After assessing TRV, additional indicators involving the ventricles, pulmonary artery, IVC, and right atrium (Table 3) should be considered to determine the echocardiographic probability of PH as low, intermediate, or high.7 This classification aids clinicians in deciding the need for further detailed examinations, including RHC (Figure 3).7 Although the threshold mPAP has been lowered in the definition of PH, there are currently no data supporting a corresponding lowering of the TRV threshold.15,16

Table 3.

Echocardiographic Findings Suggestive of PH by Category

Category A
The ventricles
Category B
PA
Category C
IVC and RA
RV/LV basal diameter/area ratio >1.0 RVOT acceleration time <105 ms
and/or mid-systolic notching
IVC diameter >21 mm with decreased
inspiratory collapse (<50% with a sniff or
<20% with quiet inspiration)
Flattening of the interventricular septum
(LV eccentricity index >1.1 in systole
and/or diastole)
Early diastolic pulmonary regurgitation
velocity >2.2 m/s
RA area (end-systole) >18 cm2
TAPSE/sPAP ratio <0.55 mm/mmHg PA diameter > AR diameter;
PA diameter >25 mm
 

For the diagnosis of PH, ≥2 findings from categories A–C are required. When assessing PH risk, it is essential to evaluate the presence of risk factors for left heart disease and CTEPH. Right heart catheterization should be considered depending on symptoms and clinical context. CTEPH, chronic thromboembolic pulmonary hypertension; IVC, inferior vena cava; LV, left ventricular; PA, pulmonary artery; PH, pulmonary hypertension; RA, right atrial; RV, right ventricular; RVOT, RV outflow tract; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion. (Adapted from Humbert M, et al. 2022.7) ©The European Society of Cardiology and the European Respiratory Society 2022. All rights reserved.

Figure 3.

Probability of pulmonary hypertension (PH) based on echocardiographic findings and risk assessment. (Source: Prepared based on Humbert M, et al. 2022.7)

©the European Society of Cardiology and the European Respiratory Society 2022. All rights reserved.

For PH patients with concomitant cardiac disease, echocardiography is also useful in diagnosing the underlying cardiac condition. Shunt-type congenital heart disease must not be overlooked. In PH due to left heart failure, especially heart failure with preserved ejection fraction (HFpEF), assessments of left ventricular diastolic function (e.g., left atrial size, left ventricular hypertrophy, Doppler indices) and valvular disease are important. Other indices of right ventricular function, including strain values, are useful prognostic markers in PH and may serve as supplementary indicators for disease monitoring during medical therapy.17,18

4.2 Pulmonary Function Testing

Pulmonary function testing is valuable in patients with PH primarily for identifying or excluding underlying pulmonary diseases. It is essential in differentiating Group 3 PH, such as PH due to chronic obstructive pulmonary disease or restrictive ventilatory disorders seen in pulmonary fibrosis and interstitial lung disease.

In idiopathic or heritable PAH (Group 1), spirometry (e.g., percentage vital capacity [%VC] and percentage forced expiratory volume in 1 second) is often within the normal range. However, many diseases that cause PH are associated with reduced pulmonary capillary blood volume, resulting in a reduction in the diffusing capacity of the lungs for carbon monoxide (DLCO), measured by precision pulmonary function equipment.19 In contrast, in left-to-right shunt disorders, DLCO may be elevated, reflecting increased pulmonary blood flow. In combined pulmonary fibrosis and emphysema, typically considered a “syndrome” rather than a distinct disease entity, PH is frequently present. Although spirometry results may be normal or only mildly reduced, DLCO is markedly decreased.20 In PH associated with systemic sclerosis, a disproportionate reduction in %DLCO compared to %VC (i.e., %VC / %DLCO ≥1.4–2.0) suggests the presence of PH.21

4.3 Ventilation–Perfusion Scintigraphy

A lung perfusion scan is useful in detecting perfusion defects and identifying their locations. However, perfusion defects can also occur in areas affected by parenchymal lung diseases such as atelectasis, emphysema, and pneumonia. Therefore, it is important to assess the presence of lung parenchymal abnormalities using ventilation scans, chest X-ray, or CT in conjunction.

In diseases causing narrowing or obstruction of the pulmonary vessels, such as CTEPH or vasculitis, perfusion-only defects often appear as wedge-shaped areas on perfusion scintigraphy. If both ventilation and perfusion scans are normal, CTEPH can be effectively ruled out. The reported sensitivity and specificity of perfusion scans are 90–100% and 94–100%, respectively, making them superior to contrast-enhanced chest CT in this regard.22,23 In PAH, peripheral patchy perfusion defects or a mottled perfusion pattern may be seen, and similar heterogeneous perfusion findings can occur in PVOD/pulmonary capillary hemangiomatosis.24

4.4 Cardiac Catheterization and Provocation Testing

4.4.1 Right Heart Catheterization (Recommendation Table 4)

Recommendation Table 4.

Recommendations and Levels of Evidence for RHC and Vasoreactivity Testing in PH

  COR LOE
It is recommended to perform RHC to confirm the diagnosis, classification, and severity of PH,
and to determine and assess the treatment strategy
I B
It is recommended to conduct RHC to obtain all parameters listed in Table 4 I C
It is recommended to set the zero reference level at the mid-thoracic level, corresponding to the
left atrium, for RHC in most patients
I C
It is recommended to perform all pressure measurements at end-expiration without breath-holding
during RHC
I B
It is recommended to perform vasoreactivity testing in patients with idiopathic, heritable or drug-
induced PAH (I/H/DPAH) to identify candidates for high-dose calcium channel blocker therapy
I C
It is recommended to define a positive vasoreactivity test as a decrease in mPAP ≥10 mmHg to
an absolute value of ≤40 mmHg, with a stable or increased cardiac output
I C
It is not recommended to perform vasoreactivity testing to identify candidates for calcium channel
blocker therapy in patients with PAH other than I/H/DPAH or in patients with groups 2–5 PH
III
No benefit
C
It is recommended to perform exercise or fluid challenge tests in cases of PAWP between 13 and
15 mmHg to avoid misclassification
I C

COR, Class of Recommendation; LOE, Level of Evidence; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; RHC, right heart catheterization.

RHC is needed for the diagnosis, classification, and assessment of severity and treatment response of PH. It also plays a role in assessing the eligibility of patients for heart or lung transplantation and in diagnosing congenital heart defects. Because RHC is an invasive hemodynamic test, it should be performed after appropriate non-invasive evaluation.

The incidence of serious adverse events reported by PH centers is 1.1%, with a procedure-related mortality rate of 0.055%.25 Contraindications for RHC include right-sided thrombi or tumors, recently implanted pacemakers (<1 month), mechanical right-sided valves, and acute infections. Pulmonary artery perforation is the most severe complication.

All parameters listed in Table 4 should be measured or calculated during hemodynamic assessment. At a minimum, SvO2 and SaO2 must be measured. In patients with SvO2 >75% and suspected left-to-right shunt, stepwise oxygen saturation measurements should be obtained from the superior vena cava, IVC, right atrium, right ventricle, and pulmonary artery. CO should be measured using either the direct Fick method or thermodilution (averaged over at least 3 measurements). However, thermodilution may be inaccurate in low-output states or severe tricuspid regurgitation.26,27 The indirect Fick method is considered less reliable. In congenital shunt disease, thermodilution-derived CO may be inaccurate, and the Fick method is preferred.28 Note that CO and pulmonary blood flow are usually equivalent, but differ in shunt disease.

Table 4.

Hemodynamic Variables Obtained by RHC

Measured variables Reference values
Right atrial pressure (RAP) 2–6 mmHg
Pulmonary artery systolic pressure (sPAP) 15–30 mmHg
Pulmonary artery diastolic pressure (dPAP) 4–12 mmHg
Mean pulmonary artery pressure (mPAP) 8–20 mmHg
Pulmonary artery wedge pressure (PAWP) ≤15 mmHg
Cardiac output (CO) 4–8 L/min
Mixed venous oxygen saturation (SvO2) *1 65–80%
Arterial oxygen saturation (SaO2) ≥95%
Calculated parameters Reference values
Pulmonary vascular resistance (PVR) *2 0.3–2.0 Wood units
Pulmonary vascular resistance index (PVRI) 3.0–3.5 Wood units·m2
Total pulmonary resistance (TPR) *3 <3 Wood units
Cardiac index (CI) 2.5–4.0 L/min/m2
Stroke volume (SV) 60–100 mL
Stroke volume index (SVI) 33–47 mL/m2
Pulmonary arterial compliance (PAC) *4 >2.3 mL/mmHg

*1 Output used as reference when FiO2 ≤0.6 and arterial oxygen saturation ≥75%. *2 PVR = (mPAP − PAWP) / CO. *3 PR = mPAP / CO. *4 PAC = SV / (sPAP − dPAP). RHC, right heart catheterization.

All pressure measurements, including PAWP, should be performed at end-expiration without breath-holding. In patients with significant respiratory swings (e.g., chronic obstructive pulmonary disease, obesity, during exercise), the average of 3–4 respiratory cycles should be used. If reliable PAWP cannot be obtained, consider measuring left ventricular end-diastolic pressure via left heart catheterization.

4.4.2 Vasoreactivity Testing (Recommendation Table 4)

Vasoreactivity testing identifies patients with idiopathic, heritable, or drug/toxin-associated PAH who exhibit marked hemodynamic improvement with high-dose calcium channel blockers.29,30 In other PAH forms or PH Groups 2–5, positive responses do not correlate with favorable long-term outcomes and are not recommended due to low positive rates.31

Inhaled nitric oxide (10–20 ppm for 5 min)29 or iloprost (5–20 μg for 15 min)32,33 are recommended agents. Although intravenous epoprostenol is also supported by evidence, its use is more time-consuming.29

A positive response (Sitbon criteria) is defined as a ≥10-mmHg drop in mPAP to ≤40 mmHg with unchanged or increased CO.33 Although the positive response rate to vasoreactivity testing is <10%, those patients who meet the criteria may benefit from long-term monotherapy with calcium channel blockers and have a favorable prognosis. Vasoreactivity testing should be performed at the time of initial RHC.

4.4.3 Exercise Testing

Exercise RHC is the gold standard for evaluating exercise PH.8 Exercise testing helps detect early pulmonary vascular or left heart dysfunction in patients with normal resting hemodynamics who present with dyspnea, genetic predisposition to PAH, connective tissue diseases, or suspected CTEPH.34–38

Exercise testing is typically performed in the supine position using a bicycle ergometer, often alongside expiratory gas analysis for Fick-derived CO. Load is increased via a ramp or stepwise protocol until symptom-limited. At each level, measure systemic blood pressure, heart rate, pulmonary arterial pressure, PAWP, SaO2, SvO2, and right atrial pressure.

As noted above, the mPAP/CO slope can be calculated by plotting CO (x-axis) against mPAP (y-axis). A slope >3 mmHg/L/min indicates exercise PH.

Measuring PAWP during exercise is challenging due to respiratory variation. For accurate PAWP measurement and to avoid misclassification, select pressure values near end-diastole rather than mean pressure values over the cardiac cycle, particularly in patients with large V waves or mitral valve disease.39

4.4.4 Fluid Challenge Test

Compared to exercise testing, fluid challenge with normal saline avoids intrathoracic pressure changes and does not require special equipment, making it a simple and practical test. In patients with a PAWP of 13–15 mmHg, fluid challenge or exercise testing is recommended to avoid misclassification.

For fluid challenge, administer 500 mL (7–10 mL/kg) of saline over 5–10 min. A post-challenge PAWP ≥18 mmHg is considered positive.40 Most studies have focused on identifying latent HFpEF rather than precapillary PH. Passive leg raise or leg positive pressure during RHC can also help detect latent HFpEF by increasing preload.41

4.5 Genetic Testing (Recommendation Table 5)

Recommendation Table 5.

Recommendations and Levels of Evidence for Genetic Testing in PAH

  COR LOE
It is recommended to conduct genetic counseling by PH specialists and/or clinical geneticists
when performing genetic testing for disease-associated genes in patients with PAH, especially to
ensure a full understanding of BMPR2 mutations
I A
It is recommended to conduct genetic counseling by genetic counselors or clinical geneticists
before performing genetic testing on asymptomatic relatives of patients with disease-associated
pathogenic variants, ensuring sufficient understanding
I A

COR, Class of Recommendation; LOE, Level of Evidence; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.

Pathogenic variants associated with PAH have been identified in idiopathic PAH, heritable PAH, drug/toxin-induced PAH, and PVOD. Affected genes include BMPR2 and ACVRL1,42 which are involved in pathways regulating pulmonary vascular cell proliferation.

Although the identification of genetic variants does not change the therapeutic approach, panel testing can aid diagnosis and detect related conditions. If a patient has a disease potentially associated with genetic mutations, they should be informed about the possibility of a genetic contribution. Identifying a pathogenic variant also allows for familial risk assessment and early detection.37,42

Twelve genes are internationally recognized as highly relevant to PAH, including BMPR2, ACVRL1, ATP13A3, CAV1, EIF2AK4, ENG, GDF2, KCNK3, KDR, SMAD9, SOX17, and TBX4.43 In Japan, panel testing is available as an out-of-pocket service.44 ACVRL1 and ENG are also causative genes of hereditary hemorrhagic telangiectasia, and require evaluation for associated complications. Notably, RNF213 variants (e.g., p.Arg4810Lys), related to moyamoya disease and pulmonary artery stenosis, have also been reported in patients with idiopathic PAH in Japan.45

5. Risk Stratification for PAH

This guideline proposes a new risk stratification model for PAH based on the ESC guidelines used at diagnosis and follow-up and the French registry score46 validated in Japan. An mPAP cutoff of 40 mmHg is included. Although a 4-tier model (splitting intermediate risk into low-intermediate and high-intermediate risk) has been proposed in other guidelines, Japanese data show no clear prognostic difference between the high-intermediate and high-risk groups. Similarly, the ESC guideline and WSPH-7 do not offer distinct therapeutic strategies for these categories.47 Because both groups share the same level of risk and are managed similarly, these guidelines adopt a 3-tier classification in Japan (Table 5).

Table 5.

JCS Risk Stratification Criteria at Diagnosis and Follow-up

A. List of low-risk parameters
Low-risk parameter  
WHO-FC I–II
6-minute walk distance >440 m
RAP <8 mmHg
CI ≥2.5 L/min/m2
mPAP ≤40 mmHg

B. Risk stratification model based on number of low-risk criteria
Risk category No. of low-risk
parameters
Low risk 4–5
Intermediate risk 3
High risk 0–2

CI, cardiac index; mPAP, mean pulmonary arterial pressure; RAP, right atrial pressure; WHO-FC, World Health Organization-Functional Class.

III. Group 1 Pulmonary Arterial Hypertension

This chapter focuses on therapeutic approaches and management strategies of pulmonary arterial hypertension (PAH), without addressing general epidemiology or etiological aspects.

1. Idiopathic and Heritable PAH

1.1 Treatment

1.1.1 Supportive Therapy

a. Anticoagulant Therapy

PAH is known to predispose to microthrombosis due to a hypercoagulable state.48 However, the efficacy and safety of warfarin remain unestablished, and routine use is not encouraged.

b. Diuretics

Loop diuretics and aldosterone antagonists are administered to manage right ventricular preload. For patients on high doses of loop diuretics, tolvaptan has been reported to aid in dose reduction.49 Attention is required in patients with low cardiac output to avoid low-output syndrome.

c. Long-Term Oxygen Therapy

Oxygen therapy exerts acute effects in lowering pulmonary artery pressure and pulmonary vascular resistance (PVR) in PAH. Typically, oxygen is administered to maintain PaO2 levels above 60 mmHg.

d. Iron Deficiency

Iron deficiency is common in idiopathic and heritable PAH (I/HPAH) and is correlated with worsened symptoms and higher mortality risk, regardless of the presence of anemia.50–52 Although the benefit of iron supplementation in non-anemic patients is uncertain,53 it may improve exercise tolerance and reduce PAH exacerbation-related hospitalizations. At a minimum, iron supplementation is recommended in patients with anemia.54,55 Because hepcidin levels are elevated in PAH,56 impairing gastrointestinal iron absorption, intravenous iron should also be considered in addition to oral iron.

e. Arrhythmias

Supraventricular tachycardias, particularly atrial fibrillation and atrial flutter, are frequently observed in PAH, with one study reporting a prevalence of 25%.57 Supraventricular tachycardias are particularly common in patients with congenital heart disease and are associated with elevated right atrial pressure, pulmonary arterial wedge pressure, and N-terminal pro B-type natriuretic peptide (NT-proBNP), suggesting a link with right heart failure.58 Although evidence remains limited, catheter ablation has been reported to reduce antiarrhythmic use, B-type natriuretic peptide (BNP) levels, and hospitalizations.59

1.1.2 Targeted Therapy

Rapid reduction of PAP and PVR is essential, because this is expected to suppress pulmonary vascular remodeling and reduce right ventricular afterload, ultimately improving survival.60 If the acute vasoreactivity test is positive, high-dose calcium channel blockers are likely to yield significant hemodynamic improvement and should be the first-line therapy.

If the vasoreactivity test is negative, pulmonary vasodilators are used. These agents target 3 key pathways: the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. Combination therapy aiming at hemodynamic remission is recommended. Table 6 presents the standard usage of pulmonary vasodilators in Japan.

Table 6.

Standard Usage of Drugs in Japan

Drug class (route) Agent Typical initial dose Target dose in PAH therapy
Calcium channel blockers (oral) Amlodipine 5 mg, once daily 15–30 mg, once daily *1
Nifedipine 10 mg, three times daily 20–60 mg per day, in 2–3 divided doses
(sustained release formulations may be used) *1
Endothelin receptor antagonists
(ERA) (oral)
Ambrisentan 5 mg, once daily 10 mg, once daily
Bosentan 62.5 mg, twice daily 125 mg, twice daily
Macitentan 10 mg, once daily 10 mg, once daily
PDE5 inhibitors (oral) Sildenafil 20 mg, three times daily 20 mg, three times daily
Tadalafil 20 mg, once daily 40 mg, once daily
Fixed dose combination of
ERA + PDE5 inhibitor (oral)
Macitentan + tadalafil fixed
dose combination tablet
Macitentan 10 mg + tadalafil
40 mg, once daily *2
Macitentan 10 mg + tadalafil 40 mg, once daily
sGC stimulator (oral) Riociguat 1 mg, three times daily 2.5 mg, three times daily
Prostacyclin analog (oral) Beraprost sodium 20 μg, three times daily Maximum tolerated dose
(≤60 μg per dose, three times daily)
Beraprost
(extended release)
60 μg, twice daily Maximum tolerated dose
(≤180 μg per dose, twice daily)
Prostacyclin receptor agonist
(oral)
Selexipag 200 μg, twice daily Maximum tolerated dose
(≤1,600 μg per dose, twice daily)
Prostacyclin analogs (inhaled) Iloprost 2.5 μg, 6–9 times daily 5.0 μg, 6–9 times daily *3
Treprostinil (inhaled) 18 μg, four times daily 54 μg, four times daily for PAH *4
Prostacyclin analogs
(intravenous/or subcutaneous)
Epoprostenol (intravenous,
continuous infusion)
1–2 ng/kg/min,
continuous infusion
Titrated according to tolerability and efficacy;
a typical range at 1 year after initiation is
40–60 ng/kg/min, with considerable
inter individual variation
Treprostinil (subcutaneous
or intravenous,
continuous infusion)
1–2 ng/kg/min,
continuous infusion
Titrated according to tolerability and efficacy;
a typical range at 1 year after initiation is
30–60 ng/kg/min, with considerable
inter individual variation

*1 Not indicated for PAH per se, but used in patients who are acute vasoreactivity test positive. *2 Use of the fixed dose combination is appropriate once tolerability to concomitant macitentan 10 mg and tadalafil 40 mg has been confirmed. *3 Although approved, marketing has been discontinued in Japan. *4 When treprostinil inhalation is used for PH associated with interstitial lung disease (ILD PH), the target dose is 72 μg four times daily. PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.

a. Oral Combination Therapy

Initial combination therapy with ambrisentan 10 mg and tadalafil 40 mg (AMBITION trial61) or macitentan 10 mg and tadalafil 40 mg (ADUE trial62) has been shown to significantly improve outcomes over monotherapy and is recommended for initial treatment in non-high-risk PAH.

b. Triple Combination Therapy

For high-risk patients or those with an insufficient response to initial oral therapy, triple therapy including a prostacyclin pathway agent is advised. Adding selexipag (0.4–3.2 mg) to oral dual therapy has shown superiority over dual therapy alone.63 In Japan, available parental prostacyclins include intravenous epoprostenol and inhaled, subcutaneous, and intravenous treprostinil. In the era of limited options, ultra high doses of epoprostenol up to 200 ng/kg/min were used. However, in Europe, initial triple therapy using around 20 ng/kg/min has been shown to elicit marked hemodynamic improvements and have a favorable effect on prognosis.64,65

If parental prostacyclin therapy fails to achieve sufficient improvement, listing for lung transplantation should be considered. Treprostinil is less potent than epoprostenol and generally requires 2–3 times the dose to achieve similar effects.66 Some reports suggest that switching from epoprostenol to treprostinil may maintain efficacy while reducing side effects.67 Subcutaneous treprostinil has demonstrated comparable long-term outcomes to epoprostenol,68 although injection site reactions and pain can limit its use.

c. Activin Signaling Inhibitors

Sotatercept, an activin signaling inhibitor, has shown promise in suppressing pulmonary vascular remodeling. A phase III international trial demonstrated significant improvement in the 6-minute walk distance,69 suggesting sotatercept may be an effective add-on therapy for patients not responding adequately to initial combination therapy.

2. Systemic Sclerosis-Associated PAH (Recommendation Table 6)

Recommendation Table 6.

Recommendations and Levels of Evidence for the Diagnosis and Treatment of SSc-PAH

  COR LOE
It is recommended to annually assess the risk of PAH in patients with SSc I B
It is recommended to use the DETECT algorithm to screen for asymptomatic PAH in adult SSc
patients with disease duration >3 years, FVC ≥40%, and %DLCO <60%
I B
It is recommended to perform RHC to exclude PAH in patients with SSc who have unexplained
dyspnea despite non-invasive testing
I C
It should be considered to assess the risk of PAH in SSc patients by combining echocardiography
or pulmonary function tests with BNP or NT-proBNP measurement based on dyspnea evaluation
IIa B
It should be considered to establish an institutional policy for PAH risk assessment in healthcare
facilities treating patients with SSc
IIa C
It may be considered to perform exercise stress echocardiography, CPET or cardiac MRI as
adjuncts to determine the indication for RHC in symptomatic SSc patients
IIb C
It is recommended to treat the underlying disease in SSc-PAH patients according to the latest
guidelines
I A
It is recommended to apply the same treatment algorithm used for IPAH to patients with SSc-PAH I C
It is not recommended to use immunosuppressive therapy for the treatment of SSc-PAH III
No benefit
C

BNP, B-type natriuretic peptide; COR, Class of Recommendation; CPET, cardiopulmonary exercise testing; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; IPAH, idiopathic pulmonary arterial hypertension; LOE, Level of Evidence; MRI, magnetic resonance imaging; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; PAH, pulmonary arterial hypertension; RHC, right heart catheterization; SSc, systemic scleroderma.

This guideline distinguishes between PAH associated with systemic sclerosis (SSc-PAH) and PAH associated with other connective tissue diseases (CTDs; non-SSc CTD-PAH), and describes their respective characteristics. In Western countries, SSc-PAH accounts for over 60% of cases of CTD-PAH,70,71 whereas in East Asia, including Japan, non-SSc CTD-PAH is relatively more prevalent.72,73 This revision of the guideline reflects the observation that immunosuppressive therapy, in addition to vasodilators, may be effective in non-SSc CTD-PAH.

2.1 Diagnosis and Screening

Annual screening is recommended in all patients with systemic sclerosis (SSc), regardless of symptoms. Active screening has been shown to increase the proportion of patients diagnosed in World Health Organization (WHO) Class I/II and improve survival.74,75 Screening accuracy improves when transthoracic echocardiography is combined with pulmonary function tests and biomarkers (BNP/NT-proBNP), helping avoid unnecessary right heart catheterization (RHC) and detect early PAH (mean pulmonary arterial pressure [mPAP] 21–24 mmHg).76–78

The DETECT algorithm targets asymptomatic SSc patients with disease duration >3 years, forced vital capacity ≥40%, and diffusing capacity of the lungs for carbon monoxide (DLCO) <60%, and offers higher sensitivity than transthoracic echocardiography alone.76 Additional tools to support RHC indication include exercise echocardiography, cardiopulmonary exercise testing, and cardiac magnetic resonance imaging.79–83 However, it should be noted that most evidence for these methods was gathered based on the mPAP ≥25 mmHg definition.

2.2 Treatment

Treatment of SSc-PAH follows the principles for I/HPAH. Immunosuppressive therapy, often considered in non-SSc CTD-PAH, is generally ineffective in SSc-PAH and is not recommended.84 In patients with concomitant left heart disease or interstitial lung disease, consider initiating monotherapy with either a phosphodiesterase 5 (PDE5) inhibitor or endothelin receptor antagonist, following the approach for PAH with cardiopulmonary comorbidities.

If pulmonary veno-occlusive disease (PVOD)/pulmonary capillary hemangiomatosis (PCH) is suspected based on %DLCO <50%, hypoxemia, or high-resolution computed tomography (CT) findings (interlobular septal thickening, centrilobular ground-glass opacities, mediastinal lymphadenopathy), pulmonary vasodilator therapy should be administered cautiously with close monitoring of symptoms and gas exchange.

3. Treatment Algorithm for I/HPAH, Drug-Induced PAH, and SSc-PAH (Recommendation Table 7)

Recommendation Table 7.

Recommendations and Levels of Evidence for the Treatment Algorithm in I/HPAH, DPAH, and SSc-PAH

  COR LOE
It is recommended to administer high-dose calcium channel blockers in patients with a positive
acute vasoreactivity test
I A
It should be considered to reassess hemodynamics 3–4 months after initiating high-dose calcium
channel blocker therapy in patients with a positive acute vasoreactivity test, and to consider
further therapeutic interventions if improvement is insufficient
IIa B
It is recommended to perform multimodality assessment, including hemodynamic evaluation, and
risk stratification based on long-term prognostic indicators at the time of diagnosis of IPAH,
HPAH, DPAH or SSc-PAH
I B
It is recommended to initiate combination therapy with an ERA (ambrisentan or macitentan) and
a PDE5 inhibitor (tadalafil) in low- to intermediate-risk patients at the time of diagnosis of IPAH,
HPAH, DPAH or SSc-PAH
I A
It is recommended to initiate triple combination therapy consisting of parenteral prostacyclin
analogs (epoprostenol or treprostinil), an ERA, and a PDE5 inhibitor in high-risk patients at the
time of diagnosis of IPAH, HPAH, DPAH or SSc-PAH
I B
It is recommended to assess treatment response within 3–4 months after initial intervention in
patients with IPAH, HPAH, DPAH or SSc-PAH, and to reassess including hemodynamic
evaluation within 6 months if medications are changed or added
I C
It should be considered to conduct regular multimodality assessments during treatment for IPAH,
HPAH, DPAH or SSc-PAH and to intensify therapy if disease progression is observed
IIa B
It should be considered to comprehensively evaluate severity and intensify appropriate therapeutic
interventions in patients with IPAH, HPAH, DPAH or SSc-PAH who are assessed as intermediate-
or high-risk during follow-up
IIa B
It should be considered to intensify therapy with oral prostacyclin receptor agonists (selexipag) or
inhaled prostacyclin analogs (treprostinil) in patients assessed as intermediate-risk during follow-up
for IPAH, HPAH, DPAH or SSc-PAH
IIa B
It may be considered to switch from a PDE5 inhibitor to a soluble guanylate cyclase (sGC)
stimulator (riociguat) in intermediate-risk patients during follow-up for IPAH, HPAH, DPAH or
SSc-PAH
IIb B
It may be considered to perform triple combination therapy with intravenous or subcutaneous
prostacyclin analogs (epoprostenol or treprostinil), an ERA, and a PDE5 inhibitor in high-risk
patients during follow-up for IPAH, HPAH, DPAH or SSc-PAH
IIb B
It may be considered to intensify treatment by increasing the dose of prostacyclin analogs in
patients with IPAH, HPAH, DPAH or SSc-PAH already receiving intravenous or subcutaneous
therapy who are assessed as intermediate- or high-risk during follow-up
IIb C
It is recommended to refer patients with IPAH, HPAH, DPAH or SSc-PAH already receiving
intravenous or subcutaneous prostacyclin therapy who are classified as intermediate- or high-risk
to a lung transplant center and to consider lung transplantation
I A
It should be considered to add an activin signaling inhibitor in patients with IPAH, HPAH, DPAH
or SSc-PAH who are assessed as intermediate- or high-risk during follow-up, and in high-risk
cases, after carefully evaluating the indication for intravenous or subcutaneous PGI2 therapy
IIa B

COR, Class of Recommendation; DPAH, drug-induced PAH; ERA, endothelin receptor antagonist; HPAH, heritable PAH; iPAH, idiopathic PAH; LOE, Level of Evidence; PAH, pulmonary arterial hypertension; SSc, systemic scleroderma.

3.1 Application of the Algorithm

Most clinical trials for PAH include patients with IPAH, HPAH, drug-induced PAH, and CTD-PAH (predominantly SSc-PAH in Western countries85). Risk stratification studies have similarly focused on typical PAH with pulmonary vascular involvement.86 Therefore, the treatment algorithm based on risk stratification is designed specifically for these patient groups, as shown in Figure 4.47 For risk assessment, a 3strata scheme (low, intermediate, and high risk) is used. Primary risk stratification follows the Japanese Circulation Society (JCS) risk stratification tool (Table 5), but alternative tools, most notably those in the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines, may also be used.7 When a 4strata model is used (e.g., for followup in the 2022 ESC/ERS guidelines), both intermediate–high risk and high risk should be mapped to “high risk” in the 3strata scheme.

Figure 4.

Treatment algorithm for idiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary arterial hypertension (HPAH), drug-induced pulmonary arterial hypertension (DPAH), and systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Ca, calcium; ERA, endothelin receptor antagonist; inh., inhaled; IV, intravenous; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PGI2, prostacyclin; RHC, right heart catheterization; SC, subcutaneous; sGC, soluble guanylate cyclase.

Prior to applying the algorithm, it is essential to evaluate cardiopulmonary comorbidities and determine whether the patient exhibits relevant characteristics.10 Because some patients with typical PAH (excluding SSc) may respond to calcium channel blockers, an acute vasoreactivity test should be performed at the time of initial diagnosis.

3.2 Treatment of PAH With Cardiopulmonary Comorbidities (Recommendation Table 8)

Recommendation Table 8.

Recommendations and Levels of Evidence for the Treatment of PAH With Cardiopulmonary Comorbidities

  COR LOE
It should be considered to initiate therapy with monotherapy rather than combination therapy in
patients with PAH associated with cardiopulmonary diseases
IIa C
It may be considered to intensify PAH treatment in patients receiving monotherapy who are
classified as intermediate- or high-risk and have associated cardiopulmonary diseases
IIb C
It is recommended to optimize the treatment of comorbid underlying diseases in patients with PAH
associated with cardiopulmonary diseases
I C
It is recommended to implement lifestyle modifications in patients with PAH associated with
cardiopulmonary diseases
I C
It is recommended to provide cardiac and respiratory rehabilitation at experienced centers for
patients with PAH associated with cardiopulmonary diseases
I C

COR, Class of Recommendation; LOE, Level of Evidence; PAH, pulmonary arterial hypertension.

The number of PAH patients with comorbid conditions is increasing in clinical practice. In the GRIPHON trial,87 51% of all patients had at least one cardiovascular comorbidity; in the AMBITION trial,88 40% of patients had hypertension, 10% had diabetes, and 4% had coronary artery disease. Although pulmonary vasodilators are effective in these patients, the benefits of early combination therapy, which are seen in typical PAH, may not be as significant. In addition, the incidence of adverse events during treatment is higher. In patients with lung diseases, adverse events such as hypoxemia are more frequent, requiring more frequent follow-up.

Conversely, the GRIPHON and AMBITION trials showed that the reduction in the risk of clinical worsening among patients with comorbidities was similar to that seen in the overall study populations. Moreover, patients with a smoking history and %DLCO <45% have been shown to have a shorter survival time.89 These findings suggest that appropriate treatment intensification remains important.

Based on the above, initial treatment in PAH patients with comorbidities should start with monotherapy. Careful monitoring of treatment tolerability and response is essential, and combination therapy should be considered if monotherapy is insufficient. However, during the course of treatment, it may become evident that PH is driven predominantly by mechanisms other than Group 1 PAH. In such cases, it is appropriate to taper or discontinue PAH-specific treatments and instead focus on treating the underlying disease, such as left heart disease.90 Treatment of the coexisting lung or heart disease should also be provided in parallel (Figure 5).

Figure 5.

Characteristics and treatment of pulmonary arterial hypertension (PAH) with cardiopulmonary comorbidities in idiopathic/heritable PAH (I/HPAH), drug-induced PAH (DPAH), and systemic sclerosis-associated PAH (SSc-PAH). COPD, chronic obstructive pulmonary disease; CT, computed tomography; DLCO, diffusing capacity of the lungs for carbon dioxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HFpEF, heart failure with preserved ejection fraction; ILD, interstitial lung disease; PAWP, pulmonary artery wedge pressure.

3.3 Initial Treatment Algorithm

Initial treatment should be based on risk stratification. In Japan, triple combination therapy is actively used in severe cases, with favorable outcomes.91 Moreover, data from international registries suggest that triple therapy, including parental prostacyclin analogs,65 is effective for high-risk patients and should be promptly initiated after diagnosis.

For patients not classified as high risk, initial combination therapy with an endothelin receptor agonist and a PDE5 inhibitor is recommended. Although both drugs may be started on the same day, sequential initiation over 1–2 weeks is often preferred to ensure tolerability. Tadalafil combined with macitentan (ADUE trial62) or ambrisentan (AMBITION trial) are both supported by evidence and recommended. Sildenafil is typically administered at 20 mg orally 3 times daily;61 although doses up to 80 mg have shown efficacy in the US,92 as of March 2025 such high-dose use was not approved in Japan.

When using parental prostacyclin analogs, it is common practice in Japan to aim for an initial target dose of ≥40 ng/kg/min epoprostenol.93,94 The standard usage of each drug is summarized in Table 6.

3.4 Follow-up Interval and Treatment Intensification

After initiating therapy, hemodynamic reassessment is generally performed after 3–4 months to evaluate treatment response. If treatment is escalated thereafter, follow-up should continue every 3–6 months. Once the patient has reached and maintained a low-risk and stable status, follow-up may include non-invasive risk assessments every 6–12 months, along with annual hemodynamic evaluations, although catheterization intervals may be extended in cases of excellent hemodynamic stability.47

Risk assessment should be repeated during follow-up. In principle, treatment intensification is not required for low-risk patients. However, meta-analyses of the AMBITION, GRIPHON, and SERAPHIN trials show that over 20% of patients categorized as low-risk experience clinical worsening within 3 years.95 Thus, even for low-risk patients, individualized treatment escalation cannot be ruled out.

In Japan, treatment goals include achieving mPAP ≤40 mmHg or pulmonary vascular resistance (PVR) <5 Wood units (based on the REVEAL registry96), because these thresholds are associated with improved right ventricular function and long-term outcomes.97–99 Consequently, treatment intensification aiming for these goals may be widely accepted in the future.

For intermediate-risk patients already on dual oral therapy, additional treatment with oral or inhaled prostacyclin analogs (e.g., selexipag, treprostinil) may be considered. In the GRIPHON study, most patients received background oral therapy, establishing selexipag as a well-supported third-line agent.100 Transitioning from a PDE5 inhibitor to riociguat is also possible based on an open-label randomized controlled trial, although that study was unblinded and used unvalidated endpoints, and thus carries a lower recommendation grade.101 For patients already receiving parental prostacyclin therapy, dose escalation may be warranted; however, optimal target dose data are limited.

In untreated high-risk patients, initiation of parental prostacyclin therapy should be considered. These agents are the only drug class with proven efficacy in WHO Class IV and are expected to exert dose-dependent effects.102,103 Common side effects at high doses include headache, flushing, jaw and limb pain, nausea, and diarrhea, most of which occur early after initiation or dose escalation and often improve over time.104 However, high-dose therapy may also trigger complications such as IgG4-related disease, thyroid dysfunction, and pituitary disorders.105 Thus, treatment should be administered at experienced centers.

3.5 Activin Signaling Inhibitors

Sotatercept, an activin signaling inhibitor, was approved for use and reimbursed in Japan in August 2025. In the STELLAR trial,69 compared with placebo, sotatercept significantly improved the 6-minute walk distance (by 41 m) at 24 weeks (P<0.001). Because more than half the participants were on background triple therapy, sotatercept is expected to be effective as add-on treatment in patients requiring further intensification.106 Therefore, sotatercept is considered a promising fourth-line agent that may be added to the existing 3 pharmacologic pathways (Figure 6). However, adverse effects such as bleeding, worsening telangiectasia, increased hemoglobin, and decreased platelet counts have been reported.69 Continued accumulation of long-term safety data is necessary.

Figure 6.

Treatment pathways for pulmonary hypertension by mechanism of action. BMP, bone morphogenetic protein; BMPR, BMP receptor; Cox, cyclo-oxygenase; eNOS, endothelial nitric oxide synthase; GDFs, growth differentiation factors; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase 5; sGC, soluble guanylate cyclase.

4. PAH Associated With Non-SSc CTDs

Non-SSc CTD-PAH frequently occurs in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease. Treatment should follow the general approach for I/HPAH, including supportive and vasodilator therapies, with immunosuppressive therapy considered at experienced centers.

4.1 Diagnosis

PAH and CTD often develop simultaneously. Therefore, new-onset PAH warrants screening for underlying CTD. Suggestive signs include skin rash, arthritis, cytopenia, nephritis (proteinuria, hematuria), serositis (pleural or pericardial effusion), hypergammaglobulinemia, and prolonged activated partial thromboplastin time. Laboratory testing should include autoantibodies (anti-double-stranded DNA, anti-Smith, anti-U1 ribonucleoprotein particle, anti-Ro/SSA, anti-La/SSB, lupus anticoagulant, anti-cardiolipin, anti-β2 glycoprotein I, Coombs test, antinuclear antibodies) and complement levels (C3, C4, CH50). Diagnosis should be guided by international classification criteria or Japan’s criteria for designated intractable diseases.

Patients may exhibit overlapping features of multiple CTDs (overlap syndrome). If a patient does not meet the criteria for SSc but presents with features such as localized skin sclerosis of the fingers or toes, annual PAH screening should be considered, as with SSc patients.

4.2 Treatment (Recommendation Table 9)

Recommendation Table 9.

Recommendations and Levels of Evidence for the Treatment of Non-SSc CTD-PAH

  COR LOE
It is recommended to treat the underlying disease in patients with non-SSc connective tissue
disease-associated PAH (non-SSc CTD-PAH) according to the latest guidelines
I A
It is recommended to apply the same treatment algorithm as for IPAH to patients with non-SSc
CTD-PAH
I C
It should be considered to perform immunosuppressive therapy combining glucocorticoids and
cyclophosphamide in patients with non-SSc CTD-PAH
IIa C
It may be considered to annually assess the risk of PAH in patients with other connective tissue
diseases that have features of SSc
IIb C

COR, Class of Recommendation; IPAH, idiopathic pulmonary arterial hypertension; LOE, Level of Evidence; PAH, pulmonary arterial hypertension; SSc, systemic scleroderma.

Given the relatively high prevalence of immunosuppressant-responsive cases of non-SSc CTD-PAH in Japan, combination therapy with pulmonary vasodilators and immunosuppressants should be considered based on the treatment algorithm (Figure 7).

Figure 7.

Treatment algorithm for pulmonary arterial hypertension associated with connective tissue diseases other than systemic sclerosis (non-SSc CTD-PAH). Patients with non-SSc CTD-PAH should be referred to an expert center with extensive treatment experience whenever possible, and the risk of pulmonary arterial hypertension (PAH), cardiopulmonary comorbidities, and connective tissue disease (CTD) activity assessed. Treatment should be based on the latest guideline-directed management of the underlying CTD. If CTD disease activity is present or PAH is rapidly progressive, consider immunosuppressive therapy with glucocorticoids plus cyclophosphamide (CYC). In addition, as with other forms of PAH, pulmonary vasodilator monotherapy should be initiated when cardiopulmonary comorbidities are present; if not, pulmonary vasodilators should be selected according to PAH risk assessment. The route of prostacyclin (PGI2) administration (oral, inhaled [inh.], intravenous [IV], or subcutaneous [SC]) should be chosen considering CTD status and infection risk associated with immunosuppressive therapy. Reassessment and treatment adjustment should follow the same principles as for other forms of PAH. If the patient is low risk and hemodynamics have sufficiently improved under immunosuppressive therapy, consider tapering pulmonary vasodilators. ERA, endothelin receptor antagonist; GC, guanylate cyclase; PDE5i, phosphodiesterase 5 inhibitor; sGC, soluble guanylate cyclase.

Standard treatment for CTD includes immunosuppression, comprising glucocorticoids and, depending on severity, methylprednisolone pulse therapy, immunosuppressants, antimalarials, and biologics. PAH is also considered an organ manifestation of CTD with presumed immunopathogenesis. In fact, the efficacy of immunosuppressant therapy, particularly in the early phase, has been demonstrated in numerous case reports, series, and retrospective studies.84,107–112

Retrospective studies in Japan suggest that early combination therapy with glucocorticoids and immunosuppressants significantly improves prognosis in patients with the simultaneous onset of PAH and CTD.111 Predictors of a favorable response include WHO Class I/II, preserved cardiac index, and early-stage PAH.108

Two Japanese guidelines already recommend immunosuppressant therapy for non-SSc CTD-PAH. Specifically:

• immunosuppressive therapy should be performed at centers with experience treating CTD-PAH (Grade 2C; low certainty, weak recommendation)113

• for SLE-associated PAH, early immunosuppressant therapy with glucocorticoids and cyclophosphamide is recommended (evidence level C).114

Although there is no standard immunosuppressive regimen, the most commonly reported approach involves moderate-to-high doses of glucocorticoids combined with cyclophosphamide.84,107–111 Cyclophosphamide is typically administered as intermittent intravenous pulses, 500–1,000 mg per dose, once monthly for 3–10 doses.

Hydroxychloroquine, an antimalarial, is effective in preventing SLE flares and may improve long-term prognosis.114 It should be considered in all SLE patients. However, because of the risk of retinal toxicity, regular ophthalmologic monitoring before and during treatment is required.114–117

5. Portopulmonary Hypertension

5.1 Diagnosis of Portal Hypertension

Direct measurement of portal pressure is invasive; hence, determination of the hepatic venous pressure gradient (HVPG) is commonly used as an indirect method of measurement.118 HVPG is calculated as the difference between wedged hepatic venous pressure and free hepatic venous pressure. An HVPG of 1–5 mmHg is considered normal, HVPG 5–10 mmHg indicates mild portal hypertension, and HVPG ≥10 mmHg is defined as clinically significant portal hypertension.118

Non-invasive surrogate markers such as platelet count, total bile acids, Mac-2 binding protein glycosylation isomer, and autotaxin have been reported to correlate with HVPG.119 Imaging modalities such as abdominal ultrasound, contrast-enhanced CT for detecting portosystemic shunts, endoscopy for esophageal varices, and liver/spleen stiffness measured by ultrasound or magnetic resonance elastography have also shown correlations with HVPG.119 In Western countries, liver stiffness <15 kPa and a platelet count >150,000/μL, as measured by FibroScan, are considered sufficient to exclude portal hypertension.118

5.2 Treatment (Recommendation Table 10)

Recommendation Table 10.

Recommendations and Levels of Evidence for the Treatment of PoPH

  COR LOE
It is recommended to perform echocardiography in patients with liver disease or portal hypertension
who present with symptoms suggestive of PH, such as dyspnea or elevated BNP, and as a
screening before liver transplantation
I C
It is recommended to refer patients with PoPH to specialized centers capable of managing both
PH and liver disease
I C
It should be considered to initiate treatment for PoPH with single-agent pulmonary vasodilator
therapy and to add a second agent if necessary, taking into account the underlying liver disease
and eligibility for liver transplantation
IIa C
It should be considered to individually assess the eligibility for liver transplantation in PoPH
patients if PVR improves to normal or near-normal levels with PAH therapy
IIa C
It is not recommended to administer PAH therapies to patients with portal hypertension who have
elevated pulmonary artery pressure but do not meet PH diagnostic criteria due to high cardiac
output and normal PVR
III
Harm
C
It is not recommended to apply initial combination therapy for PoPH, as evidence supporting its
efficacy is insufficient compared to other forms of PAH
III
Harm
C

BNP, B-type natriuretic peptide; COR, Class of Recommendation; LOE, Level of Evidence; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PoPH, portopulmonary hypertension; PVR, pulmonary vascular resistance.

Patients with portopulmonary hypertension (PoPH) should be referred to specialized centers capable of managing both PH and liver disease. Even in patients with elevated pulmonary artery pressure, if they present with high cardiac output and normal PVR, thus not fulfilling PH criteria, pulmonary vasodilator therapy is not recommended.

5.2.1 General Management of PAH

General treatment measures, such as diuretics, oxygen therapy, and exercise limitation, are similar to those for other types of PAH. Because PoPH patients often have high cardiac output, enhancing diuretic therapy is recommended to prevent pulmonary congestion and right heart failure. However, caution is necessary in patients with ascites, because intravascular plasma volume may be reduced.

5.2.2 Pulmonary Vasodilator Therapy

Several small studies have reported hemodynamic and exercise capacity improvements with sildenafil, bosentan, and ambrisentan in patients with PoPH. Although these studies did not stratify patients according to the severity of liver dysfunction, most participants were classified as Child-Pugh A or B.120–123

The PORTICO trial, a multicenter double-blind placebo-controlled randomized controlled trial using macitentan, is the only such trial targeting PoPH. Among 85 patients with Child-Pugh A or B cirrhosis, those receiving macitentan (10 mg) showed a 35% reduction in PVR compared with placebo (geometric mean ratio 0.65; 95% confidence interval 0.59–0.72; P<0.0001).124

The 2022 ESC/ERS guidelines treat PoPH as a distinct subgroup with a separate treatment algorithm.7 According to the Japanese PAH Registry, 68% of PoPH patients received combination therapy, which improved hemodynamics.125 Initial treatment should start with monotherapy, with stepwise escalation depending on liver disease status and eligibility for liver transplantation. Unlike in other PAH types, there is little evidence supporting initial combination therapy in PoPH.

5.2.3 Role of Liver Transplantation in PoPH

Eligibility for liver transplantation is primarily determined by the severity of liver failure. In PoPH, liver transplantation can be safely performed if mPAP is <35 mmHg or PVR is <250 dyn·s·cm–5. Nonetheless, PH remains a significant risk factor for transplant outcomes.126 Therefore, echocardiographic screening for PH is recommended prior to liver transplantation in patients with portal hypertension. Recent reports suggest that even patients with mPAP ≥35 mmHg and PVR ≥3 Wood units may achieve hemodynamic improvement with preoperative vasodilator therapy, allowing for successful transplantation, with a 6-month post-transplant survival rate of 76% (19/25 patients).127

6. PAH Associated With Adult Congenital Heart Disease

6.1 Diagnosis

Diagnosis of PAH in adult congenital heart disease (ACHD) involves clinical symptoms, history, physical examination, imaging (especially echocardiography), and exercise testing. A comprehensive understanding of the hemodynamics of the underlying congenital heart disease is essential. Definitive diagnosis and treatment planning require RHC to calculate the pulmonary to systemic blood flow ratio (Qp/Qs), using the Fick method when an intracardiac shunt is present. Multimodal assessment using CT, magnetic resonance imaging, and exercise testing is also important.

6.2 Treatment (Recommendation Tables 11–13)

Recommendation Table 11.

Recommendations and Levels of Evidence for Treatment Based on PVR in Patients With Qp/Qs >1.5

  COR LOE
It is recommended to close the shunt in patients with ASD, VSD or PDA when PVR is <3 Wood
units
I C
It should be considered to close the shunt in patients with ASD, VSD or PDA whose PVR is
between 3 and 5 Wood units
IIa C
It may be considered to close the shunt in patients with ASD whose PVR has decreased from >5
Wood units to <5 Wood units following PAH treatment
IIb C
It may be considered to close the shunt in patients with VSD or PDA and PVR >5 Wood units
after careful evaluation at a specialized center
IIb C
It is not recommended to close the shunt in patients with ASD whose PVR remains >5 Wood units
despite PAH treatment
III
Harm
C

ASD, atrial septal defect; COR, Class of Recommendation; LOE, Level of Evidence; PAH, pulmonary arterial hypertension; PDA, patent ductus arteriosus; PVR, pulmonary vascular resistance; VSD, ventricular septal defect.

Recommendation Table 12.

Recommendations and Levels of Evidence for ACHD Risk Assessment

  COR LOE
It is recommended to perform risk assessment in patients who continue to have PAH after shunt
closure
I C
It should be considered to perform risk assessment in patients with Eisenmenger syndrome IIa C

ACHD, adult congenital heart disease; COR, Class of Recommendation; LOE, Level of Evidence; PAH, pulmonary arterial hypertension.

Recommendation Table 13.

Recommendations and Levels of Evidence for the Treatment of ACHD-PAH

  COR LOE
It is recommended to administer an ERA to symptomatic patients with Eisenmenger syndrome to
improve daily exercise capacity
I B
It should be considered to use supplemental oxygen therapy in patients with Eisenmenger
syndrome if it consistently improves arterial oxygen saturation and alleviates symptoms
IIa C
It should be considered to administer iron supplementation in patients with iron deficiency IIa C
It should be considered to use ERA, PDE5 inhibitors, riociguat, prostacyclin analogs, and
prostacyclin receptor agonists in patients with ACHD, including Eisenmenger syndrome
IIa C
It should be considered to initiate oral combination therapy with approved PAH drugs in low- to
intermediate-risk patients with PAH after ACHD surgery, and to consider initial therapy including
intravenous or subcutaneous prostacyclin analogs in high-risk patients
IIa C
It should be considered to intensify treatment with combination therapy in patients with ACHD,
including Eisenmenger syndrome, who do not achieve treatment goals
IIa C
It may be considered to administer oral anticoagulants in patients with Eisenmenger syndrome
and pulmonary artery thrombosis if there is no significant hemoptysis
IIb C
It is not recommended to allow pregnancy in women with Eisenmenger syndrome III
Harm
C
It is not recommended to perform regular phlebotomy for polycythemia in patients with
Eisenmenger syndrome
III
Harm
C

ACHD, adult congenital heart disease; COR, Class of Recommendation; ERA, endothelin receptor antagonist; LOE, Level of Evidence; PAH, pulmonary arterial hypertension.

Outcomes for ACHD-PAH have improved markedly due to advances in PAH-targeted therapies, surgical and transcatheter interventions, and multidisciplinary care centered on ACHD specialists.128–131 Multidisciplinary support, including patient education, rehabilitation, and psychosocial services, is essential.132

Patients with left-to-right shunts and no significant PVR elevation may be candidates for surgical or transcatheter closure.133,134 In simple ACHD-PAH, closure recommendations have been based on Qp/Qs and PVR values. Traditionally, patients with high PVR were contraindicated for closure. However, recent reports from Japan suggest that in patients with severe PAH, if PVR improves with vasodilators, shunt closure may further benefit PAH.134–136

This strategy, namely “treat and repair”, is gaining clinical traction, particularly in atrial septal defect-related PAH, where transcatheter closure without cardiopulmonary bypass is possible.134,136,137 Similar outcomes have been reported in ventricular septal defect-related PAH.135 Whether to close the defect completely or leave a fenestration remains to be investigated, but this approach may improve prognosis and calls for long-term evaluation.

7. Drug- and Toxin-Induced PAH (Recommendation Table 14)

Recommendation Table 14.

Recommendations and Levels of Evidence for the Treatment of Drug- and Toxin-Induced PAH

  COR LOE
It is recommended to discontinue the suspected causative drug as promptly as
possible when drug- or toxin-induced PAH is suspected
I C
It should be considered to administer pulmonary vasodilators according to the
IPAH treatment algorithm, in addition to discontinuing the causative drug, if
hemodynamic impairment is severe in drug- or toxin-induced PAH
IIa C

COR, Class of Recommendation; IPAH, idiopathic pulmonary arterial hypertension; LOE, Level of Evidence; PAH, pulmonary arterial hypertension.

Several drugs and toxins have been identified as risk factors for PAH. Since the 6th World Symposium on Pulmonary Hypertension (2018),6 agents are classified based on evidence as having either a “definite association” (supported by outbreak data, epidemiological case-control studies, and multicenter trials) or a “possible association” (supported by multiple case series or mechanistic similarity). It is important to ask patients whether they are taking any agents listed in the 7th World Symposium on Pulmonary Hypertension classification (Table 7).10

Table 7.

Drugs and Toxins Associated With Drug-Induced PAH

Agents definitely associated with PAH Agents possibly associated with PAH
Aminorex
Benfluorex
Dasatinib
Dexfenfluramine, fenfluramine
Methamphetamine
Toxic rapeseed oil
Mitomycin-C
Carfilzomib
Alkylating agents
Amphetamines
Bosutinib
Cocaine
Diazoxide
Direct-acting antiviral agents for HCV (e.g., sofosbuvir)
Indirubin (Chinese herb Qing-Dai)
Interferon-α and interferon-β
Leflunomide
L-tryptophan
Phenylpropanolamine
Ponatinib
Organic solvents
St. John’s wort B
evacizumab
Bortezomib

“Definitely associated”=multiple case series or pharmacovigilance signals. “Possibly associated”=case reports, early signals or biologic plausibility. HCV, hepatitis C virus; PAH, pulmonary arterial hypertension. (Adapted from Kovacs G, et al., 2024 with modifications.10) ©Kovacs G, et al. 2024. CC BY-NC 4.0.

8. HIV-Associated PAH (Recommendation Table 15)

Recommendation Table 15.

Recommendations and Levels of Evidence for the Treatment of HIV-Associated PAH

  COR LOE
It is recommended to administer antiretroviral therapy (HAART) in patients with HIV-associated PAH I A
It should be considered to start PAH-specific therapy as monotherapy in HIV-associated
PAH, with attention to drug interactions, and to consider combination therapy if the
treatment response is insufficient
IIa C

COR, Class of Recommendation; HIV, human immunodeficiency virus; LOE, Level of Evidence; PAH, pulmonary arterial hypertension.

8.1 Diagnosis

HIV-PAH presents similarly to IPAH. Routine PH screening in asymptomatic HIV patients is not recommended. However, unexplained dyspnea warrants evaluation with BNP/NT-proBNP and echocardiography. HIV-PAH is more common in men and in intravenous drug users.138,139 Evaluation should include consideration of liver diseases (e.g., hepatitis B/C) and exposure to other PAH risk factors. Due to advances in antiretroviral therapy and PAH treatments, outcomes for HIV-PAH are improving, although early diagnosis remains crucial.139

8.2 Treatment Strategy

Despite being based on retrospective studies, highly active antiretroviral therapy (HAART) improves functional status and survival in HIV-PAH, and is recommended regardless of viral load or CD4+ count.7,140,141 When combining PAH drugs with protease inhibitors (which inhibit cytochrome P450 3A4), blood concentrations may increase, heightening the risk of adverse effects. Drug–drug interactions are common in HIV treatment; PAH drugs should be initiated cautiously and at low doses.

HIV-PAH treatment regimens mirror those used in IPAH, with adjustments for interactions with HAART. If monotherapy is insufficient based on risk stratification, combination therapy should be considered.7

Among first-generation PAH drugs, bosentan has shown efficacy in small short-term open-label trials.142 Long-term benefits have also been reported.143 Sildenafil has been reported as effective in a few cases.144,145 Epoprostenol has demonstrated significant improvements in WHO functional class, exercise capacity, hemodynamics, and survival.138 Future studies are needed to confirm the efficacy and safety of newer drug combinations in this population.

9. PAH With Features of PVOD/PCH (Recommendation Table 16)

Recommendation Table 16.

Recommendations and Levels of Evidence for the Diagnosis and Treatment of PVOD/PCH

  COR LOE
It is recommended to perform a comprehensive clinical diagnosis of PVOD or PCH by integrating
clinical findings, imaging findings, physiological tests, and genetic testing
I B
It is recommended to consider lung transplantation once the diagnosis of PVOD or PCH is
confirmed
I C
It may be considered to administer pulmonary vasodilators under careful monitoring in patients
with PVOD or PCH
IIb C
It is not recommended to perform lung biopsy for definitive diagnosis of PVOD or PCH due to the
high associated risks
III
No benefit
C

COR, Class of Recommendation; LOE, Level of Evidence; PCH, pulmonary capillary hemangiomatosis; PVOD, pulmonary veno-occlusive disease.

PVOD and PCH are rare forms of PH due to distal pulmonary vascular lesions, often also involving pulmonary arteries. They are thus considered part of the PAH spectrum. Mutations in EIF2AK4 have been identified in association with these conditions.146–148

Clinical signs suggestive of PVOD/PCH include severe hypoxemia, reduced DLCO, and high-resolution CT findings such as interlobular septal thickening, centrilobular ground-glass opacities/nodules, and mediastinal lymphadenopathy.147–149

Pulmonary vasodilators may cause pulmonary edema in these patients, necessitating caution. Although a definitive diagnosis requires histology, an early clinical diagnosis is essential due to poor prognosis, and lung transplantation should be considered.

9.1 Clinical Diagnosis

Given the risks of lung biopsy, diagnosis should be based on clinical findings (Table 8).150 Key clues include resting and exertional desaturation and severely reduced %DLCO (<50%) despite normal spirometry.

Table 8.

Diagnostic Criteria for PVOD/PCH

Clinical diagnostic criteria
Main criteria
 1. Hemodynamic criteria
  Must meet PAH diagnostic criteria on right heart catheterization and meet the following:
  • Mean pulmonary artery pressure (mPAP) ≥20 mmHg
  • Pulmonary vascular resistance (PVR) ≥2 Wood units
  • Pulmonary artery wedge pressure (PAWP) ≤15 mmHg
 2. CT findings suggestive of PVOD/PCH
  Typical triple sign on high-resolution CT (HRCT):
  • Centrilobular ground-glass opacities
  • Interlobular septal thickening
  • Mediastinal lymph node enlargement
 3. Pulmonary edema after vasodilator therapy or lung biopsy
  Pulmonary edema triggered by oxygen, diuretics or PAH vasodilators
  Pulmonary edema or hemorrhage after lung biopsy
Auxiliary criteria
 1. Severe resting hypoxemia: PaO2 ≤70 mmHg
 2. Severely reduced diffusing capacity: DLCO ≤55%
 3. Decreased pulmonary perfusion on scintigraphy (normal lung ventilation or mismatched pattern)
Supportive findings
 Hemosiderin-laden macrophages in bronchoalveolar lavage
 More common in:
 • Males
 • Smokers
Pathological diagnostic findings
PVOD
 Obstruction predominantly involving pulmonary venules (especially the septal venules)
 Variable degree of luminal narrowing (typically 30–90%)
 Intimal fibrosis observed
PCH
 Proliferation of capillary channels throughout the alveolar septa and/or small pulmonary veins
 Some cases show findings overlapping with PVOD, and may also include features of secondary remodeling of pulmonary veins
Differential diagnosis
 Important to distinguish from:
 • IPAH/HPAH/drug-induced PAH
 • PAH associated with CTD, portal hypertension, CHD, HIV
 • CTEPH
 • Interstitial lung disease and other pulmonary parenchymal diseases
Definite Diagnosis
 All 3 main criteria + pathological finding
Clinical diagnosis (when pathology is not available)
 Main criteria 1 and 2 + ≥2 of the 3 auxiliary criteria
Suspected PVOD/PCH
 Main criteria 1 and 2 + at least 1 of the 3 auxiliary criteria

CHD, congenital heart disease; CTD, connective tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; DLCO, diffusing capacity for carbon monoxide; HPAH, heritable pulmonary arterial hypertension; HIV, human immunodeficiency virus; IPAH, idiopathic, pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PCH, pulmonary capillary hemangiomatosis; PVOD, pulmonary veno-occlusive disease. (Source: Prepared based on the Research Group on Intractable Respiratory Diseases and Pulmonary Hypertension, Ministry of Health, Labour and Welfare, Japan, 2024.150)

Chest X-ray may show ground-glass opacities and Kerley B lines. High-resolution CT findings include subpleural interlobular septal thickening, centrilobular ground-glass opacities, and mediastinal lymphadenopathy.151 Ventilation/perfusion scans may reveal subsegmental perfusion defects (especially in upper lobes). RHC shows precapillary PH with normal pulmonary arterial wedge pressure.152 Vasoreactivity testing is contraindicated due to the risk of pulmonary edema.152 Bronchoalveolar lavage may reveal hemosiderin-laden macrophages.153 Diagnosis should be guided by clinical criteria.150

9.2 Treatment

The only definitive treatment for PVOD/PCH is lung transplantation. Referral to experienced centers and early transplant listing are advised. No pharmacological therapies have proven effective; vasodilators carry the risk of pulmonary edema. Low-dose epoprostenol has been used cautiously as a bridge to transplant.154,155 Imatinib has shown limited off-label benefit in small case series (as of March 2025, not approved).156

10. Lung Transplantation

10.1 General Indications

The Japanese criteria for lung and heart–lung transplant recipients were first published in 1997 and updated in 2015. In 2023, HIV antibody positivity was removed as an exclusion criterion due to advances in HIV treatment.157 The current criteria include general indications (Table 9),157 eligible diseases, and exclusion criteria (Table 10).157 Transplantation is indicated for patients with progressive lung disease unresponsive to optimal medical therapy and with no other life-saving options. Generally, candidates should be aged under 55 years for bilateral lung transplants and under 60 years for single-lung transplants.

Table 9.

General Eligibility Criteria for Lung Transplant Recipients

General indications
1. Patients with progressive chronic lung disease that does not respond to treatment, and for whom no other
effective life-saving therapy exists besides lung transplantation
2. Patients who are judged clinically to have a limited life expectancy without transplantation
3. As a general rule, the recipient fs age should be younger than 55 years for bilateral lung transplantation, and
younger than 60 years for single lung transplantation
4. The recipient must be mentally stable, recognize the necessity of transplantation, and demonstrate a positive
and cooperative attitude toward treatment. In addition, it should be expected that the family and surrounding
support system will provide sufficient cooperation.
The recipient must be able to understand the need for regular postoperative follow-up examinations and
immunosuppressive therapy, and be psychologically and physically capable of tolerating them

(Adapted from the Council of Lung Transplantation-Related Academic Societies, 2023.157)

Table 10.

Exclusion Criteria for Lung Transplant Candidates

Exclusion CRITERIA
1. Presence of active infectious lesions outside the lungs
2. Presence of advanced, irreversible dysfunction of other vital organs
 • Malignant disease
 • Bone marrow disorders
 • Coronary artery disease
 • Severe thoracic deformity
 • Neuromuscular disease
 • Liver disease (T-Bil >2.5 mg/dL)
 • Renal disease (Cr >1.5 mg/dL, Ccr <50 mL/min)
3. Severely deteriorated nutritional status
4. Recent history of smoking
5. Extreme obesity
6. Inability to undergo rehabilitation or lack of potential to perform rehabilitation
7. Presence of significant psychosocial impairment
8. Alcohol or drug dependence
9. Inability to obtain understanding and cooperation from the patient and family
10. Various hemorrhagic disorders and coagulation abnormalities without effective treatment options
11. Presence of extensive adhesions or scarring in the thoracic cavity

Ccr, creatinine clearance; Cr, creatinine; T-Bil, total bilirubin. (Adapted from the Council of Lung Transplantation-Related Academic Societies, 2023.157)

In Japan, the average wait time for brain-dead lung transplantation is long: 525 days for actively listed patients and 1,008 days when including temporarily inactive patients.158 Timely listing is critical. As of the end of 2022, 1,036 lung transplants had been performed in Japan (excluding heart–lung transplants), of which 158 (15.3%) were for PAH (mostly bilateral).159

10.2 Indications in PAH

The International Society for Heart and Lung Transplantation published guidelines in 1998 and revised them in 2006, 2014,160 and 2021.161 Each version of these guidelines defines the timing for referral to transplant centers and listing on transplant waitlists. The 2021 update of the guidelines reflects recent advances in PAH risk stratification. Two widely used models are REVEAL 2.0162 and the 2015 ESC/ERS model.163

IV. Group 2 Pulmonary Hypertension Due to Left Heart Disease

1. Definition

Pulmonary hypertension (PH) caused by elevated pulmonary venous pressure due to left heart disease (LHD) is classified as Group 2 PH (PH-LHD), which is the most common subtype of PH.7 PH-LHD is further categorized according to the underlying condition as isolated post-capillary PH (IpcPH) or combined post- and precapillary PH (CpcPH), defined as follows:

• IpcPH: mean pulmonary arterial pressure (mPAP) >20 mmHg, pulmonary arterial wedge pressure (PAWP) >15 mmHg, and pulmonary vascular resistance (PVR) ≤2 Wood units

• CpcPH: mPAP >20 mmHg, PAWP >15 mmHg, and PVR >2 Wood units.

Previously, the diastolic pressure gradient (DPG; calculated as dPAP minus PAWP) was used to differentiate between IpcPH and CpcPH (DPG <7 for IpcPH DPG ≥7 for CpcPH), but it is no longer used because it is not considered predictive of prognosis.164

2. Diagnosis

In heart failure with preserved ejection fraction (HFpEF), PAWP may fall below 15 mmHg with treatment, and persistent PH may be misclassified as precapillary PH. Therefore, caution is necessary. Scoring systems such as HFA-PEFF and H2 FPEF may help identify HFpEF as the underlying cause of PH.165–167 If LHD is suspected (Table 11)164 and PH is moderate to severe and differentiation from chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension is required, or if advanced heart failure warrants transplant evaluation, right heart catheterization should be considered.164 Accurate hemodynamic assessment requires optimal treatment of the underlying LHD and a stable condition prior to right heart catheterization.7

Table 11.

Pretest Probability of Left Heart Disease (LHD)

Finding High probability Intermediate probability Low probability
Age >70 years 60–70 years <60 years
Risk factors (obesity,
hypertension, impaired
glucose tolerance,
metabolic syndrome)
≥2 factors 1–2 factors 0 factors
History of cardiovascular
disease
Yes No No
Atrial fibrillation Present Paroxysmal None
Signs of pulmonary
congestion
Yes No No
ECG Left bundle branch block or
LV hypertrophy
Mild LV hypertrophy Normal or isolated
LA enlargement
Echocardiography Left atrial enlargement,
LV diastolic dysfunction grade ≥2
Left atrial enlargement,
LV diastolic dysfunction grade <2
Normal or mild LV enlargement;
E/e′ <13
CPET ↑ V̇E/V̇CO2 slope, ↓ Peak V̇O2,
evidence of ventilatory inefficiency
↑ V̇E/V̇CO2 slope, ↓ peak V̇O2
(exercise pulmonary
hypertension possible)
High peak V̇O2, ↑ V̇E/V̇CO2 slope
only or exercise hypoxemia alone
Cardiac MRI LA strain reduction / increased LA/LV
ratio / elevated RV mass index
Possible LA changes No evidence of LHD

CPET, cardiopulmonary exercise testing; LA, left atrial; LHD, left heart disease; LV, left ventricular; MRI, magnetic resonance imaging; RV, right ventricular. (Adapted from: Vachiéry JL, et al. 2019; ESC/ERS 2019 Clinical Practice Guidelines.164) ©ERS 2019. CC BY-NC 4.0.

3. Treatment

3.1 Treatment of Underlying Disease (Recommendation Table 17)

Recommendation Table 17.

Recommendations and Levels of Evidence for the Management of PH-LHD

  COR LOE
It is recommended to perform RHC as needed to determine the treatment strategy in heart failure
patients suspected of having PH
I C
It is recommended to fully treat the LHD that causes heart failure before evaluating PH when
PH-LHD is suspected
I A
It is recommended to treat the underlying left heart disease responsible for PH-LHD I C
It is not recommended to use pulmonary vasodilators for the treatment of pulmonary hypertension
due to PH-LHD
III
No benefit
A

COR, Class of Recommendation; LHD, left heart disease; LOE, Level of Evidence; PH, pulmonary hypertension; RHC, right heart catheterization.

To correct PH-LHD, the most important step is to treat the underlying LHD appropriately to reduce pulmonary venous pressure. Therefore, in LHD patients in whom PH is suspected, optimization of the underlying disease should precede PH evaluation. If left ventricular dysfunction is suspected, heart failure treatment should follow the 2025 Revised Heart Failure Management Guidelines.168

3.2 Pulmonary Vasodilator Therapy for PH-LHD (Recommendation Table 18)

Recommendation Table 18.

Recommendations and Levels of Evidence for the Treatment of PH-LHD

  COR LOE
It is recommended to optimize the treatment of the underlying disease before considering the
evaluation of PH in patients with LHD
I A
It is recommended to treat the underlying LHD responsible for PH-LHD I C
It may be considered to individualize treatment in patients with LHD and combined pre- and post-
capillary PH (CpcPH) who have a severe precapillary component (typically PVR >5 Wood units)
IIb B
It is not recommended to administer epoprostenol for the purpose of improving prognosis in
patients with PH-LHD
III
No benefit
C
It is not recommended to administer bosentan for the purpose of improving prognosis in patients
with PH-LHD
III
No benefit
C

COR, Class of Recommendation; LHD, left heart disease; LOE, Level of Evidence; PH, pulmonary hypertension; PVR, pulmonary vascular resistance.

Several trials have evaluated the efficacy of pulmonary vasodilators in heart failure with reduced ejection fraction (HFrEF). Although prostacyclin and endothelin pathway agents have shown improvement in hemodynamics, New York Heart Association functional class, and the 6-minute walk distance, no survival benefit has been demonstrated.169,170 Evidence on phosphodiesterase 5 inhibitors is mixed.171 In the LEPHT trial of riociguat, modest improvements were observed in hemodynamics and activities of daily living, but the primary endpoint (change in mPAP) was not significantly improved.172 The BADDHY trial evaluating bosentan in HFpEF with PH found no benefit in exercise tolerance.173

In the MELODY-1 trial targeting CpcPH (with 73% of patients having HFpEF), macitentan increased fluid retention.174 Across all trials of endothelin receptor antagonists, early adverse events, such as fluid retention, have been reported, and there is no evidence supporting their efficacy.

In the RELAX trial of sildenafil, no improvement in the primary outcome (exercise tolerance) was observed.175 However, in studies focused on CpcPH patients, sildenafil improved 6-minute walk distance, pulmonary hemodynamics, and right ventricular function.176 In the study of Guazzi et al., patients with high PVR and impaired right ventricular function showed improvements in PAWP, PVR, and right ventricular function.177 The DYNAMIC trial of riociguat showed improvement in cardiac output at 26 weeks, but not in exercise capacity or quality of life.178

The REDUCE LAP-HF II trial evaluating atrial shunt devices in HFpEF showed no overall efficacy.179 However, improvements in PVR, pulmonary artery elastance, and compliance were observed in a subset of patients.

Pulmonary artery denervation has shown benefit in PAH180 and one report suggested that, in CpcPH, pulmonary artery denervation led to improved PVR and exercise tolerance compared with sildenafil.181

In PH due to valvular heart disease, surgical or transcatheter valve repair is the first-line treatment and leads to hemodynamic improvement.182 However, persistent PH after valve correction is associated with poor prognosis.183,184 Functional mitral regurgitation occurs in both HFrEF and HFpEF. According to the 2020 Revised Valvular Heart Disease Treatment Guidelines,185 intervention for severe mitral regurgitation associated with heart failure symptoms is recommended.182 In aortic stenosis, preoperative PH is associated with worse long-term outcomes.186–191 Even moderate postoperative PH correlates with poor outcomes. In these patients, sildenafil worsened outcomes compared with placebo.186–192

In summary, aggressive use of pulmonary vasodilators is not recommended for PH-LHD. However, in LHD patients with a significant precapillary component (generally PVR >5 Wood units), individualized therapy may be considered at the discretion of specialists. Pulmonary vasodilators should be avoided in IpcPH.

V. Group 3 Pulmonary Hypertension Associated With Lung Diseases and/or Hypoxia

1. Diagnostic Approach and Definition of Severe Pulmonary Hypertension in Group 3 Pulmonary Hypertension

In Group 3 pulmonary hypertension (PH), a pulmonary vascular phenotype is recognized, characterized by mild obstructive or restrictive ventilatory impairment and limited parenchymal abnormalities on chest computed tomography, with a predominant pulmonary vascular component. The distinction between this phenotype and pulmonary arterial hypertension (PAH) with coexisting lung disease is often unclear.193–195 Clinical features and prognosis are reported to be similar between Group 3 PH treated with vasodilators and PAH with lung disease.89

Group 3 PH and PAH can be differentiated by the extent of ventilatory impairment (forced vital capacity <70% or forced expiratory volume in 1 second <60%) and parenchymal abnormalities. In Group 3 PH, exercise limitation primarily results from ventilatory dysfunction, and the reduction in the diffusing capacity of the lungs for carbon monoxide (DLCO) parallels the degree of ventilatory impairment, whereas in PAH, DLCO is disproportionately low, reflecting circulatory limitation.194

Echocardiography is the initial screening tool, but it is often infeasible or inaccurate in advanced lung disease.196,197 Right heart catheterization (RHC) is essential for definitive diagnosis and is recommended when lung transplantation or lung volume reduction surgery is considered, when PAH or chronic thromboembolic pulmonary hypertension is suspected, or when additional hemodynamic data are needed for phenotyping or treatment planning.7,194,198 Hemodynamic assessment should be performed when a patient is clinically stable, because severe PH may appear transiently during exacerbations due to hypoxemia.7,199 Traditionally, severe Group 3 PH has been defined as a mean pulmonary arterial pressure (mPAP) ≥35 mmHg, or mPAP ≥25 mmHg with a low cardiac index (<2.5 or <2 L/min/m2).194,200 Recent registry data in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) indicate that pulmonary vascular resistance (PVR) >5 Wood units predicts poor prognosis regardless of mPAP, and this threshold is now recommended in the European Society of Cardiology/European Respiratory Society guidelines.7,199,201

2. PH Associated With ILD

2.1 Diagnosis

When worsening dyspnea, decreased SpO2, or reduced exercise tolerance are observed without clear progression of ILD, the coexistence of PH should be suspected.202 RHC is necessary for diagnosing PH, although echocardiography is often used for screening. However, in a study of 374 patients with severe lung disease awaiting lung transplantation, 48% of patients were misdiagnosed with PH using echocardiography. Discrepancies were also noted between estimated right ventricular pressures and those measured by RHC.196

Combining B-type natriuretic peptide, DLCO, and echocardiography for screening has been reported to improve the diagnostic accuracy for ILD-PH and may help identify patients with ILD who require RHC.203

2.2 Treatment

2.2.1 Treatment of ILD

Treatment for ILD includes corticosteroids and immunosuppressive agents. More recently, antifibrotic drugs have been used for idiopathic pulmonary fibrosis (IPF) and progressive fibrosing ILD.204 In addition to pharmacologic therapy, appropriate pulmonary rehabilitation and initiation of long-term oxygen therapy (LTOT) are important. When PH is present in ILD with chronic respiratory failure, LTOT is often initiated due to suspected hypoxic pulmonary vasoconstriction. However, there is no conclusive evidence that LTOT improves prognosis. If PH persists despite adequate ILD treatment, pulmonary vasodilator therapy may be considered depending on the severity of PH.

2.2.2 Systemic Pulmonary Vasodilator Therapy

Several studies have evaluated pulmonary vasodilators for ILD-PH, with some small studies showing potential improvements in pulmonary hemodynamics.205,206 However, a randomized controlled trial of bosentan in idiopathic interstitial pneumonia-associated PH showed no improvement in PVR, World Health Organization (WHO) functional class, or symptoms.207 In the COMPERA registry, phosphodiesterase 5 (PDE5) inhibitors also did not improve exercise tolerance.208 Nevertheless, in treatment responders, defined as those with post-treatment improvement in PVR or WHO functional class, survival was better, especially in connective tissue disease ILD-PH, suggesting possible responsiveness in this subgroup.200,208,209 PDE5 inhibitors are often used in ILD-PH because they cause less ventilation–perfusion mismatch.210 However, supporting evidence for improvements in prognosis or clinical parameters remains limited.211,212 Combination with antifibrotic agents has not demonstrated significant benefits in terms of quality of life (QOL) or disease progression.213,214

Ambrisentan and riociguat are not recommended for IPF or idiopathic interstitial pneumonia-associated PH due to findings of serious adverse events, increased mortality, and lack of clinical benefit.215–217 Overall, the effectiveness of pulmonary vasodilators for ILD-PH remains unclear, and a meta-analysis showed no superiority in terms of 6-minute walk distance (6MWD), respiratory function, or severe adverse events.218

2.2.3 Inhaled Treprostinil for ILD-PH

In 2021, the results of a randomized controlled trial evaluating inhaled treprostinil for ILD-PH were published.219 Treprostinil resulted in a significant improvement in the primary endpoint (i.e., 6MWD after 16 weeks) of 31.12 m (95% confidence interval 16.85–45.39 m; P<0.001). In addition, a reduction in clinical worsening was observed in the treprostinil arm. Inhaled treprostinil was particularly effective in patients with severe disease (baseline 6MWD ≤350 m, %DLCO <40%, or PVR ≥4 Wood units).

Furthermore, inhaled treprostinil has been reported to slow the decline in forced vital capacity in ILD-PH, suggesting it may be beneficial as a treatment for the underlying ILD.220

In Japan, as of September 2024, the indication for inhaled treprostinil was expanded to include ILD-PH. Further investigations are needed to determine the long-term efficacy of inhaled treprostinil and its impact on prognosis.

2.2.4 Effect of Pulmonary Vasodilators According to PH Severity

Several studies have examined the impact of PH severity on the effectiveness of pulmonary vasodilators in ILD-PH. These studies include reports showing acute hemodynamic improvement with sildenafil in IPF-PH,210 retrospective cohort studies demonstrating the efficacy of PDE5 inhibitors in Group 3 PH,211 and improvements in pulmonary hemodynamics, exercise capacity, and QOL with subcutaneous or intravenous treprostinil in IPF-PH.205 All these studies were conducted in patients with severe PH (mPAP ≥35 mmHg, or mPAP ≥25 mmHg with cardiac index <2.0 L/min/m2). Moreover, inhaled treprostinil showed significant efficacy only in patients with PVR ≥4 Wood units; its effect was attenuated in patients with PVR <4.221 No studies have demonstrated the benefit of pulmonary vasodilator therapy in patients with ILD-associated mild PH. Thus, pulmonary vasodilator therapy in ILD-PH should primarily be considered in patients with severe PH.

3. PH Associated With COPD and Emphysema (Recommendation Table 19)

Recommendation Table 19.

Recommendations and Levels of Evidence for the Diagnosis and Treatment of PH Associated With Lung Disease

  COR LOE
It is recommended to interpret echocardiographic findings together with arterial blood gas analysis,
pulmonary function tests including DLCO, and CT imaging when PH associated with lung
disease is suspected
I C
It is recommended to appropriately treat underlying conditions such as hypoxemia, sleep-
disordered breathing, and alveolar hypoventilation when PH associated with lung disease is
suspected
I C
It is recommended to consult with or refer to a specialist when severe PH associated with lung
disease is suspected or when there is uncertainty regarding treatment for PH
I C
It is recommended to consider lung transplantation in patients with severe PH associated with
lung disease
I C
It is recommended to perform RHC when it is judged to assist in treatment decision-making for
patients with lung disease suspected of having PH
I C
It is recommended to individualize treatment, including PAH therapies, for patients with severe
PH associated with lung disease
I C
It should be considered to use PDE5 inhibitors when administering pulmonary vasodilators to
patients with PH associated with lung disease
IIa C
It is not recommended to use PAH therapies for non-severe PH associated with lung disease III
No benefit
C
ILD-PH
It is recommended to individualize treatment, including PAH therapies, for patients with severe
ILD-PH
I C
It may be considered to administer inhaled treprostinil in patients with ILD-PH IIb B
It is not recommended to use ambrisentan in patients with PH associated with idiopathic
pulmonary fibrosis
III
Harm
B
It is not recommended to use riociguat in patients with PH associated with idiopathic interstitial
pneumonias
III
Harm
B
It is not recommended to use PAH therapies for non-severe ILD-PH III
No benefit
C
COPD-PH
If PaO2 ≤60 mmHg, long-term oxygen therapy should be administered I A
It is recommended to individualize treatment, including PAH therapies, for patients with severe
COPD-PH
I C
It is not recommended to use PAH therapies for non-severe COPD-PH III
No benefit
C
It is not recommended to use inhaled treprostinil in patients with COPD-PH III
Harm
B
PH associated with hypoventilation
It should be considered to initiate NPPV therapy IIa B
It may be considered to initiate home oxygen therapy in patients with severe respiratory failure
(PaO2 ≤55 mmHg) who cannot tolerate CPAP or NPPV therapy
IIb C
PH associated with sleep apnea
It should be considered to initiate CPAP therapy in patients with sleep-disordered breathing who
meet the eligibility criteria
IIa B
It should be considered to initiate NPPV therapy in patients with severe nocturnal hypoventilation IIa B
It may be considered to provide weight reduction counseling for obese patients IIb C

COR, Class of Recommendation; CPAP, continuous positive airway pressure; CT, computed tomography; DLCO, diffusing capacity for carbon monoxide; ILD, interstitial lung disease; LOE, Level of Evidence; NPPV, non-invasive positive pressure ventilation; PaO2, arterial partial pressure of oxygen; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase type 5; PH, pulmonary hypertension; RHC, right heart catheterization.

3.1 Diagnosis

Echocardiography is typically the first imaging modality used for non-invasive diagnosis of COPD-PH. However, in advanced COPD, hyperinflated lungs often hinder adequate visualization, reducing diagnostic accuracy.196,197 In severe COPD-PH, plasma BNP or N-terminal pro B-type natriuretic peptide levels may be elevated, but sensitivity is low for detecting moderate disease.222 RHC is considered the gold standard for diagnosing COPD-PH and is recommended when its findings would significantly impact therapeutic decision-making.7,194,198

3.2 Treatment

COPD management, including treatment of the underlying disease, oxygen therapy, and respiratory rehabilitation, should follow current guidelines.194,223

3.3 Long-term Oxygen Therapy

According to the Nocturnal Oxygen Therapy Trial group in the US, in patients with COPD and PaO2 ≤55 mmHg or PaO2 ≤59 mmHg with edema, cor pulmonale, or polycythemia, 24-h oxygen therapy significantly improved prognosis and PVR compared with nighttime-only oxygen therapy.224

Similarly, the UK Medical Research Council (MRC) working party reported that more than 15 h of oxygen therapy improved prognosis compared with no oxygen therapy in COPD patients with PaO2 40–60 mmHg and accompanying hypercapnia or heart failure.225 The use of LTOT for 15 h daily suppressed mPAP elevation, and extending therapy to over 18 h slightly reduced mPAP.226

However, for COPD patients with resting SpO2 of 89–93%, 24-h LTOT over 1–6 years did not improve mortality or delay hospitalization (as shown by the LTOT Research Group).227 Thus, patients without resting PaO2 ≤60 mmHg may derive limited benefit from LTOT. Nonetheless, even when PaO2 is high, those with elevated PAP or a low cardiac index may have reduced PvO2 (a marker of tissue oxygenation), which should be taken into consideration.228

3.4 Pulmonary Vasodilators

The indication for PAH-specific drugs in COPD-PH is not established. In severe COPD-PH (mPAP 39 mmHg, PVR 7 Wood units), sildenafil was reported to improve pulmonary hemodynamics, the BODE index, and QOL measures (e.g., Modified MRC and 36-Item Short Form Health Survey [SF-36]).229 However, in mild COPD-PH (mPAP 32 mmHg, PVR 4.2 Wood units), it did not improve 6MWD or hemodynamics.230

In the PERFECT trial involving 136 COPD-PH patients (mPAP 42 mmHg, PVR 7.2 Wood units), inhaled treprostinil did not improve the primary endpoint (6MWD), and fatigue, dyspnea, and serious adverse events were more common in the treatment group, leading to early trial termination.231 Inhaled treprostinil is not recommended for COPD-PH. Meta-analyses to date have shown that although pulmonary vasodilators improve hemodynamics, they offer limited benefit in 6MWD.223,232–237

Caution is needed due to the risk that relieving hypoxic vasoconstriction with vasodilators may worsen ventilation–perfusion mismatch.223 Registries show that approximately 30% of patients with severe PH exhibit an improvement in functional class or PVR, and responders have improved survival.223,238

For patients with suspected severe COPD-PH or when there is uncertainty in management, consultation with specialists in lung disease and PH (or referral to an expert center) is recommended.7,194,223

VI. Group 4 Chronic Thromboembolic Pulmonary Hypertension

1. Diagnosis and Treatment Algorithm, Chronic Thromboembolic Pulmonary Hypertension Team

1.1 Diagnostic Algorithm

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that should be suspected in all patients with pulmonary hypertension (PH) at the time of diagnosis, and tests should be conducted to confirm or rule out the disease. Risk factors for CTEPH239 include a history of acute pulmonary embolism (PE), intravenous devices (pacemaker, long-term central venous line, ventriculoatrial shunt), inflammatory bowel disease, essential thrombocythemia, polycythemia vera, splenectomy, antiphospholipid syndrome, high-dose thyroid hormone replacement therapy, and cancer. In patients with a history of acute PE, CTEPH should be suspected if: at the time of PE diagnosis, computed tomography pulmonary angiography (CTPA) shows organized mural thrombi with a morphology clearly different from acute thrombi;240 after 3 months of adequate anticoagulation therapy, echocardiography findings remain highly suggestive of PH;7 or the patient experiences persistent dyspnea and exercise limitation during the clinical course241 (Figure 8;7 Table 122,242,243). In the 2022 European Society of Cardiology/European Resiratory Society guidelines,7 the CTEPH diagnostic algorithm mandates that patients suspected of having PH on echocardiography undergo blood tests, electrocardiography, chest X-ray, arterial blood gas analysis, pulmonary function tests, and high-resolution chest computed tomography (CT) to exclude lung disease and left heart disease. After these are excluded, a ventilation–perfusion (V/Q) scan should be performed to exclude CTEPH. V/Q scans are highly sensitive and specific for detecting CTEPH and are particularly useful tests. However, because of issues such as isotope shortages and the need for large, specialized equipment, V/Q scans cannot be performed at every institution. In recent years, there have been reports on diagnostic modalities for CTEPH-related perfusion defects using iodine mapping CT, dual-energy CT, magnetic resonance imaging, cone-beam CT, and analysis for dynamic chest radiography. However, as of March 2025, no prospective study has been performed, and these modalities have not yet been established. If a V/Q scan indicates suspicion of CTEPH, confirming PH by right heart catheterization and demonstrating organized thrombi in the pulmonary arteries by pulmonary angiography or CTPA establishes a diagnosis of CTEPH. Differential diagnoses of CTEPH include pulmonary artery sarcoma or malignant tumors (e.g., renal carcinoma, uterine carcinoma, metastatic germ cell tumors), arteritis, peripheral pulmonic stenosis, parasitic infection (hydatid cyst), and foreign body embolism, all of which can cause pulmonary artery narrowing or occlusion. In addition, there is a condition of chronic thromboembolic pulmonary disease (CTEPD) without PH, in which unresolved pulmonary clots lead to residual perfusion defects without meeting the hemodynamic definition of PH. Especially in symptomatic patients, CTEPD without PH should be diagnosed and treated similarly to CTEPH. (See Chapter 1, Section 6 on transition to chronic conditions [post-thrombotic syndrome and CTEPD].)

Figure 8.

Diagnostic and treatment algorithm for chronic thromboembolic pulmonary hypertension (CTEPH; cases where CTEPH should be suspected). * In cases where CTPA cannot determine whether CTEPH is present. BPA, balloon pulmonary angioplasty; CPET, cardiopulmonary exercise test; DSA, digital subtraction angiography; MDT, multidisciplinary team; PH, pulmonary hypertension; RHC, right heart catheterization; V/Q, ventilation–perfusion. (Source: Prepared based on Humbert M, et al.7)

Table 12.

Risk Factors for Chronic Thromboembolic Pulmonary Hypertension

History of acute pulmonary
thromboembolism (PE)
Presence of organized thrombus in the pulmonary arteries on CTPA at diagnosis,
showing morphology different from acute thrombus
Persistent PH strongly suspected on echocardiography despite ≥3 months of
adequate anticoagulation therapy
Persistent dyspnea or exercise intolerance during the clinical course after PE
Intravascular devices (pacemaker leads, long-term central venous catheters, ventriculoatrial shunts)
Inflammatory bowel disease
Essential thrombocythemia, polycythemia vera
History of splenectomy
Antiphospholipid antibody syndrome
High-dose thyroid hormone replacement therapy
Active malignancy

CTEPH should be considered in all patients with PH at diagnosis, and these risk factors should be evaluated. CTPA, computed tomography pulmonary angiography; PH, pulmonary hypertension. (Source: Prepared based on Konstantinides SV, et al. 2020;2 Delcroix M, et al. 2021;242 Bonderman D, et al. 2009.243)

1.2 CTEPH Treatment Algorithm

Until around 2010, pulmonary endarterectomy (PEA) was the treatment of choice for CTEPH, and treatment algorithms primarily focused on determining surgical operability. PEA performed under deep hypothermic circulatory arrest can potentially normalize pulmonary hemodynamics (~65% reduction in pulmonary vascular resistance [PVR]) and restore exercise tolerance. However, in the past decade, balloon pulmonary angioplasty (BPA) and medical therapies have advanced, dramatically changing CTEPH treatment. Therefore, a multimodal treatment approach needs to be considered.

The treatment algorithm requires a multidisciplinary approach that combines PEA, BPA, and a pulmonary vasodilator, targeting proximal, peripheral, and microvascular disease components, respectively. The latest CTEPH treatment algorithm (Figure 9) reflects this comprehensive approach. All CTEPH patients should receive lifelong anticoagulation. Historically, vitamin K antagonists were used, but in recent years evidence has been reported supporting the use of direct oral anticoagulants (DOACs) as an alternative.244–248 In a randomized controlled trial (RCT) comparing continued warfarin vs. switching to edoxaban, edoxaban was non-inferior in terms of change in PVR at 1 year.244 Anticoagulation is essential to prevent recurrent thrombosis and should be continued lifelong, even after PH improves following any intervention (e.g., PEA, BPA). In addition, general management for CTEPH includes considering oxygen therapy in the case of hypoxemia and using diuretics or inotropic agents if right heart failure is present.

Figure 9.

Therapeutic algorithm for chronic thromboembolic pulmonary hypertension (CTEPH). *1 Surgical eligibility should be determined comprehensively, considering lesion location, age, and overall condition. *2 In some cases, preoperative medical therapy before pulmonary endarterectomy (PEA) should be considered. *3 In certain cases, a combination of PEA and balloon pulmonary angioplasty (BPA) may be considered. *4 In some cases, invasive treatment may be difficult due to the patient’s overall condition. DOAC, direct oral anticoagulant; MDT, multidisciplinary team; PH, pulmonary hypertension.

Ideally, patients with CTEPH should be managed at specialized CTEPH/BPA centers by a multidisciplinary team. The CTEPH team ideally includes an experienced PEA surgeon, PH specialist, BPA interventionist, and a radiologist trained in CTEPH imaging, although not all centers can staff every specialty. However, especially for assessment of surgical candidacy, it is recommended to consult with experienced centers, either in person or online, with referral as appropriate.

In formulating a treatment strategy, mechanical interventions targeting the organized thrombi should be considered first. Thus, whether the lesions are surgically accessible should be evaluated first. If organized thrombi are located in proximal pulmonary arteries, the patient is considered suitable for PEA. If the lesions are peripheral (organized thrombi confined to segmental and subsegmental branches), the disease is considered more suitable for BPA. Surgical candidacy is determined based on lesion location and the patient’s condition, including age and any comorbidities.249,250 If the patient is deemed a surgical candidate, PEA is recommended, but BPA may be considered after weighing the risks and benefits. In the case of mixed lesions, where one lung has surgically accessible proximal disease and the other has peripheral disease, BPA alone or a hybrid approach of combined BPA and PEA can be considered. To reduce the risks of PEA, performing BPA or administering pulmonary vasodilators beforehand can also be considered. For patients who are not candidates for PEA, a combination of pulmonary vasodilator therapy (riociguat, selexipag) and BPA is recommended. Notably, there is evidence that starting a pulmonary vasodilator before BPA may reduce BPA-related serious adverse events; therefore, in patients with PVR ≥4 Wood units, initiating medical therapy prior to BPA should be considered.251 Studies have found that if, after PEA, a patient’s mean pulmonary arterial pressure (mPAP) is ≥38 mmHg and PVR is ≥5 Wood units, long-term survival is worse. Therefore, in patients with residual or recurrent PH and persistent symptoms after PEA, a combination of BPA and pulmonary vasodilator therapy (riociguat, selexipag) is recommended.249,252,253 If a patient’s condition does not improve even with such a multimodal approach, adding other pulmonary vasodilators (besides riociguat and selexipag) can be considered.

CTEPD without PH also requires lifelong anticoagulation therapy. Because pulmonary vasodilators are not approved for CTEPD without PH, patients with symptomatic CTEPD without PH should be considered for PEA or BPA.254,255

2. BPA (Recommendation Table 20)

Recommendation Table 20.

Recommendations and Levels of Evidence for Diagnosis and Treatment of CTEPH

  COR LOE
It is recommended to perform ventilation/perfusion (V/Q) lung scintigraphy to diagnose or exclude
CTEPH
I C
It is recommended to perform contrast-enhanced CT for the diagnosis of CTEPH and the
assessment of lesion location
I C
It is recommended to perform PAG and RHC for the diagnosis of CTEPH I C
It should be considered to use auxiliary imaging modalities such as iodine-mapping CT, dual-
energy CT, MRI or dynamic chest X-ray imaging for diagnosis
IIa C
It is recommended to administer lifelong anticoagulation therapy with vitamin K antagonists for
patients with CTEPH
I C
It should be considered to use DOACs as an alternative to lifelong vitamin K antagonist therapy
in patients with CTEPH
IIa B
It is recommended that treatment strategies for CTEPH be discussed by a multidisciplinary team
including PEA and BPA specialists at a CTEPH/BPA specialized center
I C
It is recommended that patients with CTEPH continue to be followed at CTEPH/BPA specialized
centers even after initiation of PEA, BPA or pharmacological therapy
I C
It is recommended to perform PEA under deep hypothermic circulatory arrest in patients with
CTEPH who are eligible for surgery
I C
It is recommended to perform BPA in patients with CTEPH who are not candidates for surgery I A
It is recommended to administer pulmonary vasodilators (riociguat or selexipag) in patients with
CTEPH who are not candidates for surgery
I A
It is recommended to perform BPA for peripheral-type CTEPH or for residual/recurrent PH after
PEA
I A
It is recommended to administer pulmonary vasodilators (riociguat or selexipag) for residual or
recurrent PH after PEA
I A
It should be considered to administer oxygen therapy to patients with CTEPH presenting with
hypoxemia
IIa C
It should be considered to perform hybrid therapy combining BPA and PEA in patients with
mixed-type CTEPH
IIa C
It should be considered to evaluate the risks and benefits by a multidisciplinary team including
PEA and BPA specialists at a CTEPH/BPA specialized center and consider BPA even in patients
with CTEPH eligible for surgery
IIa C
It should be considered to initiate pulmonary vasodilator therapy before performing BPA IIa B
It should be considered to perform BPA in symptomatic patients with CTEPD without PH IIa C
It should be considered that BPA be performed by BPA-certified operators at CTEPH/BPA
specialized centers
IIa C
It may be considered to administer pulmonary vasodilators other than riociguat and selexipag for
CTEPH cases refractory to multidisciplinary approaches
IIb B
It may be considered to administer diuretics and inotropic agents for patients with CTEPH
complicated by right heart failure
IIb C
It may be considered to perform BPA prior to PEA to reduce surgical risk IIb C
It may be considered to administer pulmonary vasodilators (riociguat or selexipag) before PEA in
patients with CTEPH eligible for surgery
IIb C
It is recommended to perform PEA under deep hypothermic circulatory arrest for surgically
accessible CTEPH
I C
It should be considered to perform PEA under deep hypothermic circulatory arrest for surgically
accessible CTEPD without PH
IIa C

BPA, balloon pulmonary angioplasty; COR, Class of Recommendation; CT, computed tomography; CTEPD, chronic thromboembolic pulmonary disease; CTEPH, chronic thromboembolic pulmonary hypertension; DOAC, direct oral anticoagulant; LOE, Level of Evidence; MRI, magnetic resonance imaging; PAG, pulmonary angiography; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; RHC, right heart catheterization.

2.1 Indications for BPA

Because the efficacy and safety of BPA have been established, BPA should be considered for all CTEPH patients who have symptoms and are not candidates for PEA. BPA can be considered regardless of symptom severity; even patients who are asymptomatic at rest but have symptoms with exercise may be candidates for BPA.7 CTEPH patients who are not eligible for PEA include: (i) those whose disease consists of lesions in locations that are surgically inaccessible; and (ii) those with poor surgical tolerance due to factors like advanced age or frailty, as well as patients with residual PH after PEA in whom repeat surgery is deemed difficult. Reports from Japan have shown that BPA is effective and safe even in elderly256,257 and frail258 CTEPH patients. In the current guidelines, both categories (i) and (ii) described above are equally recommended indications for BPA. Moreover, even in patients who have technically accessible lesions for surgery but who are judged to have inadequate surgical tolerance (due to age, frailty, or comorbidities), the efficacy and safety of BPA has been shown to be comparable to that in patients with distal lesions.259 Therefore, in deciding between BPA and PEA, in addition to the anatomical surgical accessibility of thrombi, a patient’s age and overall condition should be taken into consideration.

It should be noted that in order to safely handle potentially life-threatening complications of BPA, earlier statements in 2014 specified detailed criteria for operators and institutions performing BPA. However, now that the safety of BPA is established when it is performed by operators with knowledge of its complications and countermeasures, these strict requirements have become less critical. Reasonable criteria for defining a BPA center are the presence of a Japanese Circulation Society–certified BPA operator or instructor and the availability of a multidisciplinary CTEPH team with a collaborative relationship with an experienced PEA center.

2.2 Imaging and Selective Pulmonary Angiography

Selective pulmonary angiography can reveal lesions such as webs, bands, pouches, irregular vessel walls, and chronic total occlusions (see Chapter 5, Section 4.12). Based on the appearance of lesions on pulmonary angiography, Kawakami et al.260 categorized BPA target lesions into 5 types: Type A, ring-like stenotic lesions; Type B, webs; Type C, subtotal occlusion; Type D, total occlusion; and Type E, tortuous lesions. Using this lesion classification, the success rate of BPA was high for Type A and B lesions (98.6–100%), whereas Type D lesions had the lowest success rate (∼52%). Complications were reported to be more frequent with Type C and E lesions. These findings support initiating BPA on lesions with a lower complication risk.

Moreover, findings from selective pulmonary angiography can be used to evaluate the effectiveness of BPA treatment. A pulmonary flow grade has been proposed to assess perfusion from the pulmonary arteries through to the pulmonary veins on angiograms: Grade 0, a lesion where the pulmonary artery does not opacify; Grade 1, the pulmonary artery is visible but blood flow distal to the stenosis is slow; Grade 2, the pulmonary artery is opacified but only part of the pulmonary veins are opacified; and Grade 3, both the pulmonary artery and pulmonary veins are opacified.261 If BPA achieves Grade 3 perfusion, it is considered to have yielded the maximum effect. Inami et al. reported achieving Grade 3 perfusion in 69.7% of treated lesions.261 Other imaging modalities are also considered useful, including optical coherence tomography,262 optical frequency domain imaging,263 intravascular ultrasound,264 and magnetic resonance imaging. However, caution is required with optical coherence tomography because the pressure injection of contrast into the distal pulmonary arteries can cause vessel injury.265

2.3 BPA Procedure

The pulmonary artery tree is divided into 19 segmental branches on each side, and when including subsegmental branches, a considerable number of lesions can be present. For this reason, BPA treatment is usually completed over multiple sessions. The number of sessions needed varies among patients, but is approximately 4–5.265–270

2.3.1 Selection of Target Lesions

In PEA, organized thrombi are removed together with a layer of intima as a single piece, so the morphology of individual lesions has little influence on treatment candidacy or outcomes. In BPA, the morphology of each lesion is related to treatment feasibility, efficacy, and complication risk.260,271 Various nomenclatures exist for lesion morphology, but the classification proposed by Kawakami et al.260 is widely recognized (Figure 10). In the initial BPA session, especially when pulmonary artery pressure is high, treatment is primarily directed at lesions such as webs or ring-like stenoses. After pulmonary pressure has decreased following initial treatments, lesions that carry relatively higher risk can be addressed in later sessions. In recent years, evidence has shown that treating all lesions, including subtotal and total occlusion lesions, to achieve complete revascularization leads to better improvement in hemodynamics and symptoms, suggesting that any lesion can be considered a treatment target.272,273 Accordingly, devices and techniques from coronary and peripheral vascular interventions have increasingly been applied to BPA.274–277 It should be noted that tortuous lesions have the highest complication rates, and therefore require utmost caution during BPA.

Figure 10.

Characteristic morphologies of pulmonary artery lesions targeted for balloon pulmonary angioplasty treatment: (A) ring-like stenotic lesion; (B) web lesion; (C) subtotal occlusion; (D) total occlusion; and (E) tortuous lesion.

2.3.2 Incidence and Management of Intraoperative Complications

The incidence of complications with BPA, including minor complications, is higher than for coronary interventions. Most intraoperative complications are thought to be pulmonary hemorrhage resulting from guidewire perforation or balloon overdilation. Occasionally, the tip of the guiding catheter may dissect the pulmonary artery, but the incidence of pulmonary artery dissection is low and, in most cases, it heals spontaneously without specific treatment.260,267

Pulmonary hemorrhage that becomes clinically evident (such as presenting with hemoptysis) occurs in 5–15% of BPA sessions. However, small bleeding events that are not clinically apparent but can be detected on post-procedural chest X-ray or CT occur at even higher rates.260,267,269,271,278 The occurrence of procedure-related pulmonary hemorrhage is influenced by factors such as lesion morphology, the tip load of the guidewire, and the operator’s skill. Whether a bleed manifests clinically (e.g., as hemoptysis) also depends on the pulmonary artery pressure and the perfusion pressure beyond the dilated lesion.270,275,279 Therefore, when pulmonary artery pressure is high, it is advisable to avoid high-risk lesions or techniques and to focus treatment on webs, ring-like stenoses, and similar lower-risk lesions.260,271 It has also been shown that performing BPA in the setting of remarkably high pulmonary artery pressure increases the risk of reperfusion pulmonary edema, underscoring the importance of choosing an appropriate treatment strategy based on the patient’s condition. Measures that have been implemented include using a pressure wire to measure the mean distal pressure and ensuring that after dilation it does not exceed 35 mmHg, as well as adopting a staged BPA approach starting with small balloons.270,275,280 In addition, administering oxygen or inhaled nitric oxide during BPA to lower pulmonary artery pressure may help reduce complications.281,282 In the RACE cross-over trial (which compared riociguat to BPA and cross-over in an extended period), patients pretreated with riociguat had a lower incidence of serious complications during BPA.251 To prevent complications like pulmonary hemorrhage from becoming life-threatening, early recognition and management are crucial. Bleeding is sometimes difficult to visualize on angiography, so it is essential to continuously monitor not only angiographic signs (e.g., the guidewire’s position) but also the patient’s symptoms (e.g., coughing) during the procedure. If pulmonary hemorrhage occurs, the key is to promptly stop the bleeding: wedge the catheter into the involved branch or inflate a balloon in the proximal vessel to occlude blood flow and achieve hemostasis. In most cases, these maneuvers will control the bleeding. If vessel injury is severe and the bleeding cannot be stopped with these methods, embolization with a gelatin sponge or coils is effective.

2.3.3 Determining Endpoints

Because BPA treatment is completed over multiple sessions, it is necessary to consider both the overall treatment endpoint for the patient and the endpoint for each session. The patient-level endpoint is influenced by many factors, including hemodynamics (mPAP, PVR), symptoms, age, risk of complications, renal function, the patient’s preferences, and the patient’s access to a BPA center. In the absence of specific contraindications, complete revascularization (i.e., complete dilatation of all treatable pulmonary artery lesions) leads to greater improvements in postoperative World Health Organization (WHO) functional class, oxygenation, exercise tolerance, and other outcomes.273 The endpoint for each BPA session should be determined by considering both patient-related factors (lesion morphology, PH severity, renal function) and non-patient factors (radiation exposure, contrast volume, procedure time). Unlike coronary intervention, BPA involves the treatment of many branches, so there is no absolute criterion for when to end a session. Prolonged procedures beyond the operator’s concentration may increase the risk of complications. Thus, centers may consider establishing their own rules for ending a session, such as a maximum fluoroscopy time, radiation dose, or contrast volume. In addition, as noted above, if a large number of pulmonary segments were dilated to their maximum size while baseline mPAP remains high, the risk of serious complications can increase. In an initial BPA session for a patient with extremely high mPAP, a promising strategy is to limit treatment to only a few lesions (e.g., a few webs or ring-like stenoses in lower lobe regions with high flow) and to use a balloon size approximately 50% of the target vessel’s diameter, rather than dilating to full size in that first session.

2.4 Pre- and Postoperative Management

2.4.1 Preoperative Management

a. Anticoagulation Therapy

A survey of anticoagulation practices in Japan revealed diverse approaches: some centers continue oral anticoagulation up to the BPA session and concurrently administer intravenous heparin during the procedure, whereas others switch from oral anticoagulants to heparin infusion prior to the procedure. There is not yet a standardized anticoagulation protocol for the peri-BPA period. Nonetheless, all reports indicate that some form of anticoagulation is maintained during the BPA procedure. Because bleeding complications related to the procedure (mainly pulmonary vascular injuries) are the most common intraoperative complications,271,282 each institution should prepare protocols in advance for how to handle bleeding complications during BPA, tailored to their own setting.

b. Pulmonary Vasodilators and Inotropic Agents

The most common complication after BPA is lung injury (reperfusion pulmonary edema), which is caused by procedure-related factors (primarily guidewire perforation or balloon-induced vessel trauma).271,279,283 However, the progression to severe respiratory/circulatory failure due to bleeding is associated with the severity of the patient’s hemodynamic status at the time of BPA.261,279,284 Therefore, improving hemodynamics with medical therapy before the BPA may help prevent BPA-related severe respiratory failure. In a subanalysis of the RACE trial, patients who received riociguat before BPA had fewer complications during BPA than those who underwent BPA alone.251 The 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines give a Class IIa recommendation to initiate riociguat prior to BPA.7 In addition, because the severity of hemodynamic impairment correlates with the severity of post-BPA complications, dobutamine infusion is empirically administered in patients with a low cardiac output,266,284 and the protocol of the Japanese MR BPA study also incorporated this approach.285

2.4.2 Intraoperative Management

As discussed in Section 3.3.4,271,279 lung injury is the most frequent perioperative complication and arises from procedure-related causes. Completely eliminating procedure-related complications is challenging, but if overt signs such as hemoptysis or blood sputum appear during the procedure, it is critical to achieve hemostasis before finishing the session. Leaving the catheterization laboratory without confirming hemostasis can lead to worsening respiratory failure due to ongoing hemorrhage, and thus must be avoided.

2.4.3 Postoperative Management

a. Lung Injury

Lung injury is the leading cause of respiratory failure after BPA. In a Japanese registry published in 2017,267 lung injury was observed in 17.8% of 308 patients, with mechanical ventilation required in 5.5% and extracorporeal membrane oxygenation required in 2.9%. Hemoptysis occurred in 14.0% of patients, which is higher than the incidence of evident lung injury on chest X-ray, suggesting that some bleeding events occur without overt lung opacities. Consequently, the reported incidence of lung injury varies depending on the diagnostic criteria and imaging used. Two recent RCTs, namely the Japanese MR BPA trial and the French RACE trial, reported on the incidence of lung injury after BPA. In the MR BPA trial,285 lung injury (defined by CT findings, regardless of hypoxemia) occurred in 8 of 31 patients (26%), with 1 (3%) patient requiring non-invasive positive airway pressure ventilation. In the French RACE trial, lung injury with hypoxemia confirmed on chest X-ray was observed in 15% of patients. Furthermore, in RACE, the appearance of serious adverse events (including lung injury) was predicted by mPAP >45 mmHg and performing BPA without concomitant riociguat. As noted above, to reduce the risk of BPA-related lung injury, it may be beneficial to improve hemodynamics with medications before BPA, minimize procedure-related complications, and to tailor the target lesions to the severity of PH and lesion morphology, for example using a staged BPA approach280 or guiding BPA with distal pressure measurements (pressure wire-guided BPA).275 Rarely, a transient pulmonary edema can develop in lung fields outside the treated areas (delayed pulmonary edema). The mechanism is unclear but, like lung injury, it has been reported to correlate with the severity of the hemodynamic impairment. If severe respiratory failure occurs due to lung injury or delayed pulmonary edema, supportive care with nasal high-flow oxygen, non-invasive positive airway pressure ventilation, mechanical ventilation, or extracorporeal membrane oxygenation should be used as appropriate to maintain adequate oxygenation.

b. Other Complications

Other common catheter-related complications include access site complications (vessel injury, hematoma, arteriovenous fistula), contrast reactions, and contrast-induced nephropathy. In patients with renal dysfunction, it is necessary to limit the contrast volume during BPA. However, one report noted that an increase in mixed venous oxygen saturation (SvO2) ≥25% after BPA compared with before may improve renal function.286

2.5 BPA Outcomes

The outcomes of BPA were first reported in 2001 by a group in San Diego in 18 CTEPH patients who were not surgical candidates. In that study, mPAP improved by 9 mmHg, but one patient died of right heart failure (mortality 5.6%).287 For approximately a decade thereafter, publications on BPA were mostly case reports, until Mizoguchi et al., from Okayama Medical Center, reported in 2012 that, in 68 patients, mPAP improved by 21 mmHg and mortality was 1.5%. In the subsequent approximate 10 years, many BPA outcome studies have been published, mainly from Japan, and more recently reports from outside Japan have increased with the wider adoption of BPA.288,289

In Japan, numerous PH specialty centers have reported BPA results. A multicenter registry of 308 patients who underwent BPA at expert centers from 2004 to 2013 showed that mPAP improved from a mean (±SD) of 43.2±11.0 to 24.3±6.4 mmHg, and PVR improved from 853.7±450.7 to 359.5±222.6 dyn·s·cm–5 (a 58% reduction in PVR), with a 30-day mortality of 2.6%.267 In recent data from Japanese high-volume BPA centers, post-BPA mPAP is around 20 mmHg, which is nearly normal. However, the mean pre-BPA mPAP in those reports was also below 40 mmHg, indicating that, compared with earlier registries, BPA is now being performed in patients with less severe hemodynamics.290–292

Many earlier reports included patients on pulmonary vasodilators before and/or after BPA. The outcomes of BPA alone in treatment-naïve patients were demonstrated in the MR BPA trial from Japan, an RCT comparing BPA to riociguat. The primary endpoint in the MR BPA trial was the change in mPAP from baseline to 12 months. In the BPA group (n=32), mPAP decreased from 38.1±7.9 to 21.4±4.7 mmHg (−16.3 mmHg), whereas in the riociguat group (n=29) mPAP decreased from 37.5±8.5 to 31.5±7.8 mmHg (−7.0 mmHg). These results confirmed the superior hemodynamic improvement with BPA. In that trial, BPA-related complications occurred in 17 of 147 sessions (12%).285 There have been a few reports on medium- and long-term outcomes after BPA. In the 308-patient registry, mPAP after completing BPA was 24.3±6.4 mmHg; approximately 1.2 years later it was 22.5±5.4 mmHg.267 In a study following 170 patients for a median of 2.8 years after BPA, hemodynamics (mPAP, PVR) remained almost normal at the short-term (0.5–1.5 years), mid-term (1.5–3.5 years), and long-term (>3.5 years) follow-up.293

The excellent results of BPA have contributed to improved long-term survival. Approximately 40 years ago, when no effective treatments beyond anticoagulation existed, the 5-year survival was only approximately 10% among patients with mPAP ≥50 mmHg.294 Even after PEA was introduced, although outcomes improved for those who underwent surgery, the prognosis of patients who were inoperable remained poor. In the 2010–15 prospective international CTEPH registry, the 3-year survival rate was 89% among patients who underwent PEA, compared with 70% among those who did not.295

In contrast, in the Japanese BPA multicenter registry, the 1- and 3-year survival rates after BPA were 96.8% and 94.5%, respectively, which is comparable to post-PEA outcomes.267 In recent years in Japan, many inoperable patients have undergone BPA or received medical therapy, and prognosis has improved along with the dissemination of BPA.247,291

BPA can dramatically improve hemodynamics, and near-normalization of mPAP and PVR has often become achievable in recent years. However, the effects of BPA on oxygenation and lung function are limited. In the MR BPA trial, in treatment-naïve patients, PaO2 improved from 63.6±9.2 to 73.2±7.3 mmHg and the proportion of patients on long-term oxygen therapy decreased from 58% to 23%, but full normalization of oxygenation was not achieved.285 Similarly, other reports indicate that even when BPA almost normalizes hemodynamics, only approximately half of patients can discontinue home oxygen therapy.291,293

BPA was largely developed in Japan, but with accumulating evidence it has now spread worldwide and earned a Class I recommendation in the 2022 ESC/ERS guidelines. BPA outcomes differ by country, with PVR reduction rates ranging from 30% to 60%. Some of this variation may be due to patient population differences, but countries with high-volume PEA centers have fewer BPA cases and tend to report less dramatic BPA outcomes,269,296 suggesting that procedural experience plays a significant role. Notably, in the RCTs of BPA vs. riociguat conducted in Japan and France, the reduction in PVR in treatment-naïve CTEPH was ∼59.6% and ∼59.7%, respectively, almost identical.251,285

3. Surgical Treatment

3.1 Pulmonary Endarterectomy

PEA is a surgical treatment in which, under deep hypothermic circulatory arrest, an endarterectomy is performed to remove organized thrombi along with the inner layer of the pulmonary artery wall in both lungs. PEA is an effective therapy for CTEPH with lesions that are surgically accessible, and it produces immediate and marked improvements in pulmonary hemodynamics, symptoms, and exercise capacity after surgery. In an international registry, PVR decreased from 736 to 248 dyn·s·cm–5 (median), the proportion of patients with WHO Class I/II improved from 25% preoperatively to 90% postoperatively, and the 6-minute walk distance (6MWD) increased from 362 to 459 m (median).297

In Japan, the annual number of PEA surgeries from 2012 to 2021was 50–70 per year, remaining unchanged over that period298,299 (Figure 11). A 2011 Japanese registry study found that only 13.9% of CTEPH patients underwent PEA, compared with 56.8% in the 2007–09 international registry.297,300 In a 2015–16 international registry, among all CTEPH patients, only 25% in Japan were judged operable, compared with 72% in Europe and 69% in the US.301

Figure 11.

Number of pulmonary endarterectomies (PEAs) and 30-day/in-hospital mortality rates in Japan from 2012 to 2021. (Source: Prepared based on Yoshimura N, et al.298 and the Ministry of Health, Labour and Welfare.299)

3.2 Indications

Indications for surgery are determined by factors including the team’s experience, the surgical accessibility of the lesions, the relationship between PH severity and lesion location/extent, and the presence of comorbidities.7,250 Pulmonary angiography and CT can underestimate the extent of disease, so evaluation of surgical accessibility by an experienced PEA surgeon is crucial.302 Although a high preoperative PVR is associated with increased risk of perioperative mortality, such patients should not be excluded from surgery, because the improvements in pulmonary circulation with PEA can be substantial.303 Lesions at the segmental branch level overlap with areas treatable by BPA, but segmental lesions on the proximal side are considered surgically accessible. Some PEA experts consider distal segmental lesions to be accessible.302,304 Furthermore, even in patients without PH (CTEPD without PH), PEA can be contemplated if the patient is symptomatic and has surgically accessible thrombotic lesions.255

3.3 Pulmonary Artery Lesion Location (Morphology)

Two classifications are commonly used: the Jamieson classification and the University of California, San Diego (UCSD) classification. The Jamieson classification categorizes the morphology of surgical specimens: Types I and II are central-type disease, and Types III and IV are peripheral-type disease.305 The UCSD classification is based on the location of the predominant lesions: Levels I and II are central, and Levels III and IV are peripheral.306

The PEA procedure is performed under general anesthesia via a median sternotomy, using cardiopulmonary bypass and deep hypothermic circulatory arrest (core temperature lowered to <20℃) as needed. The surgeon establishes a dissection plane in the media just beneath the intima in the main pulmonary arteries, and then removes the thrombotic intima specimen extending to the subsegmental branch level. The deep hypothermic circulatory arrest technique is used to provide a bloodless surgical field during the endarterectomy.250,305

3.4 PEA Outcomes

3.4.1 Early Outcomes

PEA outcomes depend on the experience of the surgeon and the multidisciplinary team. At centers performing ≥100 PEA procedures annually, the 30-day in-hospital mortality rate is approximately 2–3%.250,307–309

An international registry study found that centers performing ≥50 PEA procedures per year had lower hospital and 1-year mortality rates than centers performing <10 PEA procedures per year (hospital mortality 4.7% vs. 7.4%, respectively; 1-year mortality 7% vs. 11.1%, respectively).297 In Japan, the 30-day (in-hospital) mortality for PEA was 3.65% (4.75% including in-hospital deaths) in the 10-year period from 2012 to 2021, and this improved to 2.6% (4.5% including in-hospital deaths) in the more recent 5-year period from 2017 to 2021298 (Figure 11).

Reported risk factors for in-hospital mortality include high preoperative PVR, WHO Class IV, right heart failure, and high postoperative PVR.250,297,310,311 There is no evidence that preoperative pulmonary vasodilator therapy improves surgical outcomes; some reports have even suggested that prolonging time to surgery (to treat medically) was associated with higher early and long-term mortality.249,295 In the case of mixed-type disease (one lung with central disease and the contralateral lung with distal disease), a strategy has been reported in which BPA is performed on the peripheral lesions before surgery to reduce surgical risk, followed by PEA for the central lesions.312

Complications specific to PEA include pulmonary (airway) hemorrhage, reperfusion pulmonary edema, and residual PH, and are the main causes of in-hospital death.297 In addition, deep hypothermic circulatory arrest carries a risk of neurological complications.313–315

3.4.2 Late Outcomes

In an international registry, 1- and 3-year survival rates after PEA were 93% and 89%, respectively, significantly better than the 88% and 70%, respectively, observed in the non-operated patient group.295 Single-center studies have reported 5- and 10-year survival rates of approximately 79–82% and 75–79%, respectively. Identified risk factors for late mortality include residual PH after PEA and preoperative WHO Class IV.249,295 Cannon et al. reported that mPAP ≥38 mmHg and PVR ≥425 dyn·s·cm–5 after PEA were risk factors for long-term all-cause mortality.249

Ishida et al. studied patients who survived beyond 30 days after PEA in the era of multimodal treatment, comparing patients with and without residual PH immediately after PEA. Those patients with residual PH were treated with pulmonary vasodilators and/or BPA. The authors found that residual PH immediately after PEA did not affect CTEPH-related mortality.316 This supports a multimodal approach to managing residual PH after PEA.

4. Medical Treatment

4.1 Pulmonary Vasodilator Therapy in CTEPH

4.1.1 Background and Rationale for Use of Oral Therapies

CTEPH is caused by organized thrombi that physically narrow and occlude pulmonary arteries, but the pathology of CTEPH involves a pulmonary arteriopathy (microvasculopathy) similar to that in pulmonary arterial hypertension (PAH).317 Therefore, it has been hypothesized that pulmonary vasodilators used for PAH could also be effective in CTEPH. The microvasculopathy in CTEPH cannot be addressed by PEA or BPA. Accordingly, researchers have investigated medical therapy in patients who are inoperable or who have residual PH after PEA. These efforts demonstrated the efficacy and safety of PAH therapies in CTEPH, and, in Japan, the soluble guanylate cyclase stimulator riociguat318 and the prostacyclin receptor agonist selexipag318 have been approved for CTEPH. These medications are indicated for patients who are inoperable or who have residual or recurrent PH after PEA. There is currently no evidence on initial combination oral therapy (e.g., riociguat plus selexipag) in CTEPH, and the results of future studies are awaited. Moreover, if interventions like BPA or PEA normalize the pulmonary hemodynamics, the clinical value of continuing PAH medications is unclear due to a lack of evidence, and further research is needed.

4.1.2 Riociguat

The CHEST-1 trial was an RCT of riociguat that showed a significant improvement in the 6MWD in both inoperable CTEPH (70% of patients) and in patients with persistent/recurrent CTEPH after PEA (30% of patients).318 This improvement was correlated with a significant reduction in PVR and improvements in right ventricular function parameters.316 The improvement in 6MWD was sustained at 2 years in 98% of patients who enrolled in the long-term extension (CHEST-2).319 As a result, riociguat became the first pulmonary vasodilator approved for CTEPH in patients who are not candidates for PEA or who have residual PH after PEA. In addition, in the MR BPA trial (an RCT in Japan comparing BPA to riociguat),285 although BPA yielded a greater decrease in mPAP, riociguat produced a significant increase in cardiac output. This effect was also observed in the RACE trial (an RCT in France evaluating BPA vs. riociguat in terms of PVR reduction). Furthermore, a subanalysis of RACE showed that initiating riociguat before BPA reduced the incidence of serious BPA-related adverse events, which provides a rationale for recommending riociguat pretreatment.7

4.1.3 Selexipag

In a phase II trial in Japanese patients, selexipag did not show a significant improvement in the primary endpoint (PVR), but there was a trend towards improved pulmonary hemodynamics.320 Therefore, a phase III trial in Japanese CTEPH patients was conducted,252 which demonstrated that the primary endpoint (change in PVR from baseline) improved significantly with selexipag vs. placebo, leading to the listing of selexipag in Japan for CTEPH in 2021.

4.2 Anticoagulation Therapy in CTEPH

In the treatment of CTEPH, anticoagulation is the most fundamental pharmacotherapy, and it must be continued lifelong. The 2022 ESC/ERS guidelines recommend warfarin (Class I, Level C) as the anticoagulant for CTEPH,7 but no prospective studies have demonstrated whether anticoagulation improves prognosis or prevents CTEPH progression.

DOACs are used as first-line therapy for acute PE and for the secondary prevention of venous thromboembolism, and, in real-world practice, many patients who develop CTEPH after PE are maintained on DOACs. However, experience with the use of DOACs specifically in CTEPH is limited, and their efficacy and safety have not been confirmed.

In a retrospective multicenter study from the UK of CTEPH patients after PEA, the recurrence rate of venous thromboembolism was higher among those on DOACs than among those on warfarin (4.6% vs. 0.8% per patient-year, respectively), but the incidence of major bleeding (0.7% per patient-year in both groups) and 5-year survival (90% vs. 92%, respectively) were similar between the 2 groups. Because VTE recurrences were particularly common within 6 months after surgery in that study, caution may be warranted when using DOACs in the early postoperative period.245 Results from a registry study in Turkey suggest that DOACs may carry a lower risk of major bleeding.321

In the international post-marketing prospective EXPERT registry of CTEPH patients on riociguat, the incidence of major thrombotic events was 1.6% (17 events/1,068 patient-years) in the vitamin K antagonist (including warfarin) group vs. 2.9% (8 events/276 patient-years) in the DOACs group, which was not a statistically significant difference but suggested a possible increase in thrombotic events with DOACs.246 Conversely, data from the Japanese CTEPH AC registry showed that DOACs did not increase the risk of worsening CTEPH compared with warfarin and tended to reduce the incidence of clinically relevant bleeding events.247

Japanese investigators conducted the world’s first head-to-head RCT directly comparing warfarin and a DOAC in CTEPH patients, known as the KABUKI trial.244 In that trial, edoxaban was shown to be non-inferior to warfarin for the primary endpoint (the ratio of PVR change after 48 weeks of treatment). The incidence of clinically important bleeding during the 48-week treatment period was 1 in 37 patients (2.7%) in the edoxaban group and 2 in 37 patients (5.4%) in the warfarin group, with no symptomatic venous thromboembolism or deaths recorded in either group. Based on this evidence, edoxaban is considered an effective and safe anticoagulant therapy comparable to warfarin in CTEPH patients after revascularization therapy (PEA or BPA). In the future, it is expected that the use of DOACs in CTEPH will increase worldwide. It will be important to promptly establish large registries of CTEPH patients on warfarin and DOACs, and to conduct comparative registry studies and prospective RCTs (with warfarin as the control) to further evaluate the efficacy and safety of DOACs in CTEPH.

5. Peripheral Pulmonary Stenosis and Vasculitis (Recommendation Table 21)

Recommendation Table 21.

Recommendations and Levels of Evidence for Treatment of Non-CTEPH PH Group 4

  COR LOE
It should be considered to differentiate other group 4 diseases besides CTEPH when imaging
shows ventilation–perfusion mismatch in patients with PH
IIa C
It should be considered to administer immunosuppressive therapy in patients with PH during
active vasculitis
IIa C
It may be considered to combine catheter-based therapy with pulmonary vasodilators for patients
with peripheral pulmonary artery stenosis (PPS)
IIb C

COR, Class of Recommendation; CTEPH, chronic thromboembolic pulmonary hypertension; LOE, Level of Evidence; PH, pulmonary hypertension.

5.1 Peripheral Pulmonary Stenosis

Peripheral pulmonary stenosis (PPS) is characterized by multiple stenoses in the intrapulmonary arteries. Most pediatric cases of PPS are associated with congenital syndromes such as congenital rubella syndrome, Williams syndrome, or Noonan syndrome, or with structural cardiac anomalies such as ventricular septal defect. PPS is also known to occur in association with moyamoya disease, and a relationship with RNF213, the susceptibility gene for moyamoya disease, has been reported.322,323

Sporadic adult-onset PPS without other congenital disorders has been described.324–327 In a Japanese study, 84% of patients had CTEPH-like wedge-shaped perfusion defects on V/Q scans. Pulmonary angiography showed stenosis in segmental arteries (93%), subsegmental arteries (82%), and tortuosity (43%)324 (Figure 12A). Of 20 Japanese patients diagnosed with adult-onset PPS, 80% carried RNF213 mutations, most being homozygous mutations.327

Figure 12.

Imaging findings of (A) pulmonary artery sarcoma, (B) peripheral pulmonary artery stenosis (PPS), and (C) Takayasu arteritis. (A) Computed tomography image of primary pulmonary artery sarcoma originating in the left pulmonary artery, extending into the right pulmonary artery. (B) Right pulmonary angiogram showing PPS with segmental and subsegmental stenoses. (C) Right pulmonary angiogram showing Takayasu arteritis with main pulmonary artery dilation and occlusion of the right lower lobe branch.

No standardized treatment exists for PPS. Japanese reports show that although pulmonary vasodilators alone improve hemodynamics, greater benefit is achieved with catheter intervention. Several studies have reported improved hemodynamics and symptoms after catheter therapy in adult-onset PPS. However, compared with CTEPH, the response to balloon angioplasty is limited due to incomplete lesion dilation and restenosis.327

5.2 Pulmonary Hypertension Associated With Vasculitis

Takayasu arteritis is a granulomatous vasculitis of unknown cause that primarily affects the aorta and its major branches and is more prevalent in Asian women.328 Isolated pulmonary artery involvement is rare, but approximately 8.3% of patients with Takayasu arteritis have pulmonary artery lesions, including dilation of the main pulmonary artery, stenosis or occlusion of the right or left pulmonary arteries, and thrombotic lesions329,330 (Figure 12B). PH in Takayasu arteritis is a prognostic factor and occurs in 61.7% of patients with pulmonary artery lesions.329,330

Evaluation of disease activity is critical and requires collaboration with rheumatologists. Diagnostic tools include digital subtraction angiography, magnetic resonance angiography, CTPA, positron emission tomography CT, and V/Q scans. CTPA and pulmonary angiography typically show no organized thrombi, unlike CTEPH. Differential diagnosis via V/Q scans alone is challenging.

Reported 1-, 3-, and 5-year survival rates for patients with Takayasu arteritis and PH are 94.0%, 83.2%, and 77.2%, respectively.331 Treatment options for Takayasu arteritis-related PH include percutaneous pulmonary angioplasty and pulmonary vasodilators.332 Immunosuppressive therapy should be considered in patients with active vasculitis.333

VII. Pulmonary Hypertension in Children

1. Idiopathic/Heritable Pulmonary Arterial Hypertension in Children

1.1 Pulmonary Hypertension in Children

The annual incidence of pediatric pulmonary hypertension (PH) has been reported to be 64 per 1,000,000 population.334 The majority of pediatric pulmonary arterial hypertension (PAH) represents transient PH (e.g., increased pulmonary blood flow due to a reparable lefttoright shunt), followed by idiopathic/heritable PAH (I/HPAH) and PAH associated with congenital heart disease. Developmental lung disorders such as bronchopulmonary dysplasia and congenital diaphragmatic hernia account for 34–49% of cases.335–337 Genetic developmental lung disorders, including alveolar capillary dysplasia and TBX4 variant-related lung disease, are also categorized within this group.338 Another feature of pediatric PH is a high proportion of chromosomal abnormalities, such as trisomy 21.338 The annual incidence of pediatric I/HPAH is reported to be 0.48–0.7 per 1,000,000 population, and the prevalence is 2.1–2.2 per 1,000,000 population.334,339,340 According to the Japanese Society of Pediatric Cardiology and Cardiac Surgery survey on heart disease with onset in childhood,341 the number of cases of pediatric I/HPAH in Japan in recent years has been 24–43 per year, suggesting an incidence of approximately 1–2 per 1,000,000 population. The femaletomale ratio is relatively low in children (0.9–1.6) compared with that in adults (1.7–4.1).70,334,342–348

1.2 HPAH in Children

As in adults, pathogenic variants are identified in 20–30% of sporadic cases of pediatric PAH and in 70–80% of familial cases.42,349 Although BMPR2 variants are the most frequent, a characteristic of pediatric PAH is the higher frequency of variants in ACVRL1334 and TBX4.350–352 TBX4 is a gene involved in lung and skeletal development,353 and its carrier frequency is the second most common after that of BMPR2.349 Although cases cluster in infancy and early childhood, TBX4 variants have also been identified in adult PAH and in Group 3 PH (developmental lung disorders).354 Variants in BMPR2 and ACVRL1 have been reported as prognostic factors even in children.355 Genetic counseling and genetic testing are recommended for pediatric PH patients and their families.356

1.3 Diagnosis and Risk Assessment

1.3.1 Diagnosis

Common symptoms of pediatric I/HPAH include exertional dyspnea (44–66%) and easy fatigability (25–55%), whereas syncope is observed in 18–36% of patients.336,347,348 Because the symptoms are nonspecific,70,342,343,357 there is a tendency towards delayed diagnosis,336,347 and prior to the diagnosis of PAH, patients are sometimes diagnosed with conditions such as asthma or epilepsy.358 In Japan, approximately onethird of I/HPAH cases are detected through school electrocardiographic screening; many of these patients are relatively asymptomatic and are in World Health Organization (WHO) Class I or II, but it should be noted that they are not necessarily mild cases.348 Compared with adults, pediatric I/HPAH is characterized by higher PAP but a preserved cardiac index, lower right atrial pressure, and relatively preserved exercise tolerance; in addition, marked dyspnea or syncope tends to occur with excessive exertion.359,360

1.3.2 Severity Assessment

Key variables for evaluating severity and prognosis in pediatric I/HPAH are presented in Table 13.361–363 Based on these variables, patients are categorized into low and highrisk groups, and the treatment strategy is determined (Figure 13).362 It is recommended that treatment be selected with the goal of achieving and maintaining a lowrisk profile as evidence of adequate therapeutic effect. Serum B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide levels,364–366 as well as serum uric acid levels,367 are used for to assess severity and evaluate treatment response.

Table 13.

Key Indicators for Assessing Severity and Prognosis in Pediatric PAH

Low risk Category High risk
None Right heart failure Present
None Disease progression Present
None Syncope Present
Normal Growth/development Impaired
I or II WHO functional class III or IV
Mild elevation BNP/NT-proBNP Marked elevation (>1,200 pg/mL)
Mild RV/RA dilation
Normal RV systolic function
Indicators:
 • RV/LV end-systolic ratio <1
 • TAPSE normal (z-score > −2)
 • S/D ratio <1.0 (TR jet)
 • No pericardial effusion
Echocardiographic findings Severe RV/RA dilation
Reduced RV systolic function
Indicators:
 • RV/LV end-systolic ratio >1.5
 • APSE decreased (z-score <−3)
 • S/D ratio >1.4 (TR jet)
 • Pericardial effusion present
CI >3.0 L/min/m2
mRAP <10 mmHg
mPAP/mSAP <0.5
SvO2 >65%
Acute vasoreactivity: positive
Cardiac catheterization CI <2.5 L/min/m2
RAP >15 mmHg
mPAP/mSAP >0.75
SvO2 <65%
PVRI >15 Wood units/m2

Patients without high-risk features are considered low risk. BNP, B-type natriuretic peptide; CI, cardiac index; LV, left ventricular; mPAP, mean pulmonary artery pressure; mRAP, mean RAP; mSAP, mean systemic arterial pressure; mean NT-proBNP, N-terminal pro-BNP; PAH, pulmonary arterial hypertension; PVRI, pulmonary vascular resistance index; RA, right atrium; RAP, right atrial pressure; RV, right ventricular; S/D, systolic/diastolic; SvO2, mixed venous oxygen saturation; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation. (Source: Prepared based on: Abman SH, et al. 2015;361 Hansmann G, et al. 2019;362 and Haarman MG, et al. 2019.363)

Figure 13.

Therapeutic algorithm for pediatric idiopathic/heritable pulmonary arterial hypertension (PAH). *1 Phosphodiesterase 5 inhibitor (PDE5i) + endothelin receptor antagonist (ERA). *2 Oral/inhaled (inh.) prostacyclin (PGI2) + PDE5i + ERA. *3 Intravenous/subcutaneous (IV/SC) PGI2 + PDE5i + ERA. Ca, calcium; PH, pulmonary hypertension; RHC, right heart catheterization. (Source: Prepared based on Hansmann G, et al. 2019.362)

1.4 Treatment Guidance

A pediatric I/HPAH treatment algorithm reflecting current practice in Japan is shown in Figure 13, and recommendations for pulmonary vasodilators for pediatric I/HPAH are presented in Recommendation Table 22.368–395 General management and supportive therapy for pediatric I/HPAH are summarized in RecommendationTables 23 and 24. For PAH with longterm response to calcium channel blockers,29,30 the Sitbon criteria are used to interpret results of acute vasoreactivity testing (AVT): a positive response is defined as a decrease in mean pulmonary arterial pressure of ≥10 mmHg to an absolute value <40 mmHg, with cardiac output unchanged or increased.396,397 Although AVT-positive cases are reported to be more frequent in pediatric IPAH than in adults,398 when calcium channel blocker therapy is initiated, it is recommended to that hemodynamic improvement is confirmed after 3–4 months; if no improvement is observed, a transition to a treatment strategy using PAHspecific agents for AVTnegative PAH is recommended (Figure 13).

Recommendation Table 22.

Recommendations and Levels of Evidence for Pharmacologic Therapy in Pediatric PAH369–395

  COR LOE
PDE5 inhibitors
Sildenafil IIa B
Tadalafil IIa B
ERAs
Bosentan IIa C
Ambrisentan IIa C
Macitentan IIa C
PGI2 pathway agents (analogs/receptor agonists)
Epoprostenol (IV) I B
Treprostinil (IV) IIa C
Treprostinil (SC) IIb C
Treprostinil (Inhaled) IIb C
Iloprost (Inhaled) IIa C
Selexipag (Oral) IIb C
Beraprost (Oral) IIb C
sGC stimulator
Riociguat (Oral) IIb C
Surgical/catheter-based interventions
Atrial septostomy IIa C
Potts shunt IIb C

COR, Class of Recommendation; ERA, endothelin receptor antagonist; IV, intravenous; LOE, Level of Evidence; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase type 5; PGI2, prostacyclin; SC, subcutaneous; sGC, soluble guanylate cyclase.

Recommendation Table 23.

Recommendations and Levels of Evidence for the General Management of Pediatric PAH

  COR LOE
It is recommended to provide counseling on the significant maternal and fetal risks of pregnancy
and appropriate contraception to adolescent girls with IPAH/HPAH
I C
It is recommended that pediatric IPAH/HPAH patients (including suspected cases) undergo
comprehensive evaluation and treatment by a multidisciplinary team at a specialized center
I C
It is recommended that surgeries or invasive procedures requiring sedation or general anesthesia
in pediatric IPAH/HPAH patients be performed under the care of physicians specialized in
pediatric cardiac anesthesia and intensive care, with appropriate monitoring
I C
It is recommended to avoid dehydration and to provide appropriate fluid supplementation when
necessary
I C
It is recommended to administer all indicated vaccinations that are not contraindicated to prevent
exacerbations from preventable infections
I C
It is not recommended to engage in competitive sports or intense isometric exercise III
Harm
C
It is not recommended for patients who are not stable and adequately treated to travel by airplane III
Harm
C

COR, Class of Recommendation; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; LOE, Level of Evidence.

Recommendation Table 24.

Recommendations and Levels of Evidence for Supportive Therapy in Pediatric PAH

  COR LOE
It should be considered carefully administering diuretics in severe cases where adequate cardiac
output is dependent on preload
I C
It should be considered to administer continuous oxygen therapy when PaO2 <60 mmHg or SpO2
<92%
IIa C
It should be considered to administer oxygen during high-altitude stays or airplane travel in
patients with pulmonary hypertension
IIa C
It may be considered to administer diuretics to pediatric IPAH/HPAH patients presenting with
right heart failure
IIb C
It may be considered to administer anticoagulant therapy (e.g., warfarin) to pediatric IPAH/HPAH
patients
IIb C
It may be considered to carefully evaluate the use of anticoagulants in infants and young children
prone to bleeding complications, and to use antiplatelet agents (e.g., aspirin) as an alternative
IIb C
It is not recommended to administer anticoagulant therapy in patients with HPAH complicated by
hereditary hemorrhagic telangiectasia (ALK-1 mutation)
III
Harm
C

COR, Class of Recommendation; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; LOE, Level of Evidence; PaO2, arterial partial oxygen pressure; SpO2, percutaneous oxygen saturation.

In lowrisk patients, oral or inhaled pulmonary vasculartargeted therapies are used; in highrisk patients, initial multidrug combination therapy including continuous intravenous epoprostenol should be instituted. It has been reported that highdose sildenafil (>3 mg/kg/day) may be associated with a potential increase in mortality risk,399 and therefore dosing requires caution. In patients refractory to maximum medical therapy, palliative balloon atrial septostomy, Potts shunt, or lung transplantation are indicated.370

2. PH in the Neonatal Period

Physiological PH that exists immediately after birth decreases stepwise over time, with pulmonary arterial pressure becoming normal by around 3 months of age. Pathological PH occurring in the neonatal period includes persistent PH of the newborn (PPHN), PH associated with bronchopulmonary dysplasia/newborn chronic lung disease, and PH associated with congenital diaphragmatic hernia.

2.1 Symptoms and Diagnosis of PPHN

In PPHN, marked hypoxemia is present, with a difference in oxygen saturation between the upper and lower extremities (oxygen saturation in the lower extremities being ≥5–10% lower than in the upper extremities). Echocardiography is essential for the assessment of cardiovascular structure, cardiac function, and hemodynamics; in severe PPHN, righttoleft (or bidirectional) shunting is observed at both the ductus arteriosus and the foramen ovale. In the differential diagnosis, it is important to consider coexisting cyanotic congenital heart disease and to be alert for alveolar capillary dysplasia.

2.2 PH-Specific Therapy for PPHN

Inhaled nitric oxide (iNO) reduces the incidence of death or initiation of extracorporeal membrane oxygenation in term infants.400 Typical dosing is 5–20 ppm iNO, and therapy is often initiated at a dose of 20 ppm. Doses of iNO exceeding 20 ppm increase the risk of methemoglobinemia and other adverse effects. The use of iNO to prevent PH in preterm infants with respiratory failure is not recommended.401 Regarding iNO weaning, if oxygenation improves, the dose can usually be reduced relatively quickly to 5 ppm iNO, and therapy is often discontinued within 5 days. If rebound PH occurs upon discontinuation, measures such as tapering to 1 ppm iNO before cessation should be considered.

The efficacy of phosphodiesterase 5 inhibitors in the pathophysiology of PPHN has been suggested, and a dose of sildenafil 0.5–1.0 mg/kg administered enterally every 6 h is used.402 A metaanalysis of 3 randomized controlled trials including a total of 77 neonates with PPHN suggested that sildenafil improves oxygenation and may reduce mortality.403

In patients with right ventricular dysfunction, maintenance of ductal patency with prostaglandin (PG) E1 should be considered to reduce right ventricular afterload; however, oxygen saturation in the lower body will decrease.

Although the use of other PHtargeted therapies for PPHN (endothelin receptor antagonists and prostacyclin [PGI2] analogs) is a potential option, many uncertainties remain regarding longterm outcomes.

VIII. Treatment of Pulmonary Embolism

1. Treatment Strategy According to the Severity of Acute Pulmonary Embolism

In recent years, treatment strategies based on detailed severity classifications, combining hemodynamic parameters, imaging findings, biomarkers, and clinical scoring systems such as the Pulmonary Embolism Severity Index (PESI) and Simplified PESI (sPESI), as recommended by the European Society of Cardiology (ESC) guidelines, have become widely accepted.2 A flowchart outlining the treatment strategies for acute pulmonary embolism (PE) according to severity is shown in Figure 14.2

Figure 14.

Treatment strategies for acute pulmonary embolism (PE) by severity. *1 When considering outpatient treatment, appropriate treatment for residual deep vein thrombosis should be performed, and sufficient attention should be paid to the risk of PE recurrence. *2 Evaluation should be performed using transthoracic echocardiography or computed tomography (CT) pulmonary angiography. *3 Thrombolytic therapy should be considered, and surgical or catheter-based thrombectomy should be considered depending on availability in the facility and the patient’s condition. sPESI, Simplified Pulmonary Embolism Severity Index; VA-ECMO, veno-arterial extracorporeal membrane oxygenation. (Source: Prepared based on Konstantinides SV, et al. 2020.2)

In cases of cardiac arrest, immediate consideration should be given to the introduction of veno-arterial extracorporeal membrane oxygenation (VA-ECMO). For high-risk patients in shock, in addition to anticoagulation therapy, reperfusion therapies such as thrombolytic therapy, surgical embolectomy, or catheter-directed treatments should be considered. For intermediate-risk patients who present with both right ventricular (RV) dysfunction and elevated cardiac biomarkers (intermediate–high risk), anticoagulation should be initiated along with close hemodynamic monitoring. If hemodynamic deterioration occurs, reperfusion therapy should be considered. For patients at intermediate–low risk, hospitalization and initiation of anticoagulation therapy should be considered. Conversely, for low-risk patients identified using clinical risk scores such as sPESI and without evidence of RV dysfunction, anticoagulation therapy can be initiated with consideration of early discharge or outpatient treatment.

2. Outpatient Treatment for Acute PE

Traditionally, acute PE has been managed with careful inpatient treatment. However, the widespread availability of direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban has enabled treatment with oral medication from the acute phase, allowing not only for early discharge but also for outpatient treatment. Therefore, identifying appropriate candidates for outpatient care using acute-phase risk scores is important.

The Hestia score, developed with a focus on selecting patients for outpatient treatment, includes both patient clinical background and social factors conducive to outpatient care. Its utility has been demonstrated in several studies.404,405

Although the PESI/sPESI scores were originally designed to stratify 30-day mortality risk, they are now also used to assess eligibility for outpatient treatment. In a randomized controlled trial (RCT) of 344 low-risk patients identified by the PESI score, those assigned to inpatient vs. outpatient treatment had the same 90-day mortality rate of 0.6%, suggesting outpatient management is feasible for properly selected patients.406

In a Japanese cohort, the 30-day mortality rate in patients with an sPESI score of 0 was 0.5%, significantly lower than in those with a score ≥1.407 These findings support extrapolating Western data to Japanese patients for outpatient treatment.

Recent studies have also examined outpatient treatment using DOACs. Among 525 low-risk PE patients who were hemodynamically stable, had no RV dysfunction, and no serious comorbidities, outpatient treatment with rivaroxaban resulted in no PE-related deaths and only 3 (0.6%) cases of symptomatic or fatal recurrent PE at 3 months.408

Although criteria for patient selection remain under discussion, outpatient treatment using DOACs may be a reasonable option for patients with a low-risk profile, favorable social circumstances, and no significant comorbidities. The 2019 ESC guidelines state that outpatient treatment can be considered for patients judged to be at low risk based on clinical scores and without RV dysfunction, provided they have appropriate social support.2

In such cases, appropriate evaluation of residual deep vein thrombosis (DVT) and careful attention to recurrence risk are necessary. Recently, incidental or mild PE has been increasingly identified in cancer patients. Although cancer contributes 1 point to the sPESI score, making cancer patients them formally ineligible for a “low-risk” status, some recent studies suggest that outpatient care may still be feasible for cancer patients without additional sPESI factors.409

3. Respiratory and Circulatory Management of High-Risk PE (Recommendation Table 25)

Recommendation Table 25.

Recommendations and Levels of Evidence for Cardiorespiratory Management of High-Risk Pulmonary Embolism

  COR LOE
Oxygen therapy, including HFNC, is recommended when PaO2 is ≤60 mmHg or SpO2 is ≤90%;
if oxygenation does not improve, mechanical ventilation with a tidal volume of 6 mL/kg should be
performed
I C
In cases where cardiopulmonary resuscitation is difficult or where respiratory and circulatory
failure cannot be stabilized even with drug therapy, the introduction of V-A ECMO should be
considered
IIa C
Administration of norepinephrine should be considered for patients with decreased cardiac output
and hypotension
IIa B
For patients with decreased cardiac output and normotension, administration of dobutamine
should be considered
IIa C
Volume loading in hypotensive patients with right ventricular failure may be considered with
caution to avoid overload
IIb C

COR, Class of Recommendation; LOE, Level of Evidence; PaO2, arterial partial oxygen pressure; SpO2, percutaneous oxygen saturation; V-A ECMO, veno-arterial extracorporeal membrane oxygenation.

Acute PE is fundamentally a form of acute respiratory and circulatory failure. In massive PE, the mortality rate within the first hour is extremely high.410 In severe cases, respiratory and circulatory management, diagnosis, and treatment must proceed simultaneously.

3.1 Circulatory Management

Circulatory failure in acute PE is primarily due to mechanical obstruction of the pulmonary vascular bed and pulmonary vasoconstriction caused by hypoxia and chemical mediators, leading to increased pulmonary vascular resistance (PVR), pulmonary hypertension, and increased RV afterload. Clinically, this manifests as elevated pulmonary arterial pressure, elevated RV and right atrial pressures, reduced RV output (RV failure), reduced left ventricular (LV) output, systemic hypotension, and shock.

3.2 Volume Loading

There is no strong evidence supporting volume loading in PE. Some experimental models show conflicting results.411,412 Goldhaber reported that volume loading of the RV could impair LV filling via ventricular interdependence and further reduce cardiac output.413 The 2019 ESC guidelines suggest that in patients with low central venous pressure, a cautious fluid challenge (≤500 mL) may improve cardiac output.414

3.3 Pharmacologic Therapy

Vasopressors with sympathomimetic effects (norepinephrine, dopamine, dobutamine) and phosphodiesterase 3 inhibitors with positive inotropic and vasodilatory properties can be used. Norepinephrine improves systemic hemodynamics without affecting PVR by enhancing ventricular contractility and coronary perfusion.412 In an RCT comparing norepinephrine to dopamine in shock, norepinephrine was associated with fewer arrhythmias and lower 28-day mortality in PE patients.415

In small studies, dobutamine reportedly improved cardiac index by 35% and reduced PVR.416 Although some patients show a drop in PaO2 due to ventilation–perfusion mismatch, overall oxygen delivery improves with increased cardiac output.417 Milrinone, a phosphodiesterase 3 inhibitor, has shown favorable pulmonary vasodilation without worsening oxygenation in canine models of PE and may be more selective than dopamine or dobutamine.418 Current practice generally favors dobutamine for RV failure without hypotension and norepinephrine when hypotension is present.

3.4 Inhaled Nitric Oxide

Inhaled nitric oxide (NO) selectively dilates pulmonary arteries without significantly affecting systemic vascular resistance, theoretically improving ventilation–perfusion mismatch in acute PE. Some case reports show improved pulmonary artery pressure and PVR with NO inhalation,419,420 but evidence regarding clinical efficacy and safety remains insufficient.421 In Japan, inhaled NO is covered by medical insurance only during perioperative cardiac care.

3.5 Mechanical Circulatory Support

Mechanical support should be considered in patients presenting with cardiac arrest, those who fail to stabilize with oxygen therapy and medication, and those with progressive hypoxemia or hypotension. VA-ECMO can rapidly stabilize respiratory and circulatory function and serve as a bridge to definitive therapy.2 After extracorporeal membrane oxygenation (ECMO) initiation, transesophageal echocardiography or contrast computed tomography should be performed to confirm thrombi near the main pulmonary arteries, and surgical embolectomy should be considered.

According to data from the Japanese Society for Cardiovascular Surgery (2008–14), among 355 patients undergoing surgical embolectomy, 94 received ECMO, and the 30-day mortality rate in this group was 24.5%.422 Other studies show high survival rates in PE patients with ECMO support during cardiogenic shock or arrest.423 However, a meta-analysis up to 2020 did not show definitive survival benefits.424 The optimal method of reperfusion in cases where VA-ECMO is initiated remains unclear.425–427 Key predictors of survival with ECMO include age under 60 years and receiving surgical embolectomy.428 Conversely, cardiac arrest before ECMO initiation was associated with poorer outcomes. Care must be taken to prevent thrombus obstruction of ECMO drainage cannulas if thrombi remain in the right atrium or inferior vena cava (IVC).429 The 2020 Japan Resuscitation Council guidelines suggest considering ECMO-assisted cardiopulmonary resuscitation when conventional resuscitation fails and appropriate indications are present.430

4. Thrombolytic Therapy for PE (Recommendation Table 26)

Recommendation Table 26.

Recommendations and Levels of Evidence for Thrombolytic Therapy of PE

  COR LOE
Thrombolytic therapy is recommended for patients with acute PE who are in shock or
hemodynamically unstable due to prolonged hypotension
I B
For patients with acute PE who have normal blood pressure but have both right ventricular
dysfunction and positive cardiac biomarkers, anticoagulation therapy with parenteral drugs
is the first choice, and signs of hemodynamic deterioration should not be overlooked. It will
be managed under constant monitoring. Thrombolytic therapy should be considered if
signs of hemodynamic deterioration are observed
IIa B

COR, Class of Recommendation; LOE, Level of Evidence; PE, pulmonary embolism.

Thrombolytic therapy can dissolve thrombi and promptly improve the pulmonary circulation more effectively than anticoagulation alone with unfractionated heparin.431 In Japan, monteplase (a recombinant tissue plasminogen activator) is the only thrombolytic agent covered by medical insurance for the treatment of acute PE. Thrombolytic therapy shows its greatest efficacy when administered within 48 h of symptom onset, although it may still be beneficial in cases with symptoms lasting 6–14 days.432 Although thrombolytic therapy clearly provides rapid thrombus resolution and hemodynamic improvement, RCTs have not demonstrated a significant survival benefit.

A meta-analysis of 16 RCTs involving PE patients (10% low risk, 71% intermediate risk, 1% high risk, 18% unclassified) reported that thrombolytic therapy was associated with a reduction in all-cause mortality (odds ratio [OR] 0.53; 95% confidence interval [CI] 0.32–0.88; P=0.01) but also with a significantly increased risk of major bleeding (OR 2.73; 95% CI 1.91–3.91; P<0.01).433 However, most of these studies did not target high-risk patients. Thus, it remains unclear whether anticoagulation alone is sufficient in severe cases.

Jerjes-Sanchez et al. demonstrated in the only RCT of acute PE with shock that all 4 patients who received thrombolytic therapy survived, whereas all 4 in the heparin-only group died within 1–3 h.434

Right ventricular dysfunction at onset is considered an important prognostic factor in acute PE. The PEITHO trial, a multicenter double-blind RCT conducted in 2014, evaluated thrombolytic therapy (tenecteplase + heparin) vs. anticoagulation alone (placebo+heparin) in 1,005 normotensive patients with RV dysfunction and myocardial injury (elevated troponin).435 The combined endpoint of death or hemodynamic deterioration within 7 days occurred less frequently in the thrombolysis than anticoagulation alone group (2.6% vs. 5.6%; P=0.015), but there was no difference in all-cause mortality (1.2% vs. 1.8%, respectively; P=0.42). Major extracranial bleeding (6.3% vs. 1.2%) and stroke, including intracranial hemorrhage (2.4% vs. 0.2%), were significantly more common in the thrombolysis group, offsetting the efficacy benefit.

Based on these results, routine thrombolytic therapy is not recommended for hemodynamically stable PE patients with RV dysfunction. However, it may be considered in younger patients at low risk of bleeding or in cases of hemodynamic worsening despite anticoagulation.

Bleeding is the major complication of thrombolytic therapy. Post-marketing surveillance of monteplase in Japan of 1,241 patients reported major bleeding in 8.1% and intracranial hemorrhage in 1.7%.436 There are absolute and relative contraindications to thrombolytic therapy due to bleeding risks (Table 14).2 Many relative contraindications overlap with PE risk factors, requiring careful consideration. When thrombolytic therapy is contraindicated, surgical or catheter-directed embolectomy or placement of an IVC filter should be considered as alternative strategies.

Table 14.

Contraindications to Thrombolytic Therapy

Absolute contraindications
 • History of hemorrhagic stroke or stroke of unknown origin
 • Ischemic stroke within the previous 6 months
 • Malignant neoplasm of the central nervous system
 • Major trauma, major surgery or head injury within the previous 3 weeks
 • Bleeding diathesis
 • Active bleeding
Relative contraindications
 • Transient ischemic attack within the previous 6 months
 • Current oral anticoagulation
 • Pregnancy or within the first postpartum week
 • Non-compressible vascular puncture sites
 • Traumatic resuscitation
 • Refractory hypertension (systolic BP >180 mmHg)
 • Advanced liver disease
 • Infective endocarditis
 • Active peptic ulcer

BP, blood pressure. (Excerpted from Konstantinides, et al.2) ©The European Society of Cardiology 2019. All rights reserved.

There is no clear consensus regarding the need for concurrent heparin during thrombolytic therapy, because its effect on efficacy or bleeding risk remains inconclusive.

Recent studies have explored half-dose thrombolysis. In small RCTs comparing half-dose thrombolysis to full-dose therapy or anticoagulation alone, half-dose thrombolysis showed comparable efficacy and safety.437,438 However, a meta-analysis of 4 observational studies and 9 RCTs indicated that full-dose thrombolysis carried a higher risk of bleeding than low-dose thrombolysis (OR 1.48; 95% CI 1.00–2.19), and that systemic low-dose thrombolysis resulted in a 5-fold increase in bleeding compared with anticoagulation alone (relative risk [RR] 5.08; 95% CI 1.39–18.6).439

Whether thrombolytic therapy influences long-term outcomes such as functional capacity, symptom persistence, or the development of chronic thromboembolic pulmonary hypertension in high- or intermediate-risk PE remains uncertain. One small RCT suggested that thrombolysis may improve functional capacity at 3 months.440 In the PEITHO trial, 33% of patients had mild symptoms (mainly dyspnea) at long-term follow-up (∼41.6 months),441 but persistent or newly developed pulmonary hypertension on echocardiography was rare in both treatment arms (tenecteplase: 85%; placebo: 96%).

5. Anticoagulation Therapy for PE (Recommendation Table 27)

Recommendation Table 27.

Recommendations and Levels of Evidence for Anticoagulation Therapy in Acute PE

  COR LOE
For acute treatment of acute PE, parenteral anticoagulants such as heparin are initiated *1 and
are administered in combination with the oral anticoagulant warfarin. Parenteral anticoagulants
are continued until the effect of warfarin reaches the therapeutic range
I B
The therapeutic range of warfarin should be adjusted to maintain a PT-INR of 1.5–2.5 IIa C
DOACs are administered as acute treatment for hemodynamically stable acute PE. Edoxaban is
initiated after appropriate initial treatment. Rivaroxaban and apixaban are administered at a
maintenance dose after a certain period of initial intensive therapy at a high dose
I A
For PE provoked by major transient risk factors or minor transient risk factors (without additional
risk factors for recurrence), anticoagulation therapy for 3 months should be considered
IIa B
For PE provoked by minor transient risk factors (with additional risk factors for recurrence), if the
bleeding risk is not high, extended anticoagulant therapy *2 beyond 3 months should be considered
IIa C
For unprovoked PE, if the bleeding risk is not high, extended anticoagulant therapy *2 should be
considered
IIa C
For PE provoked by persistent risk factors, extended anticoagulant therapy *2 should be considered IIa B
For PE in patients with active cancer, extended anticoagulant therapy should be considered
unless the cancer is cured, while paying attention to bleeding complications
IIa B
When anticoagulant therapy for acute PE is extended beyond 3 months, the risks and benefits
should be carefully considered periodically
I C

*1 The treatment target for unfractionated heparin is an APTT of 1.5–2.5 times the control value. *2 When extended treatment with DOACs is performed, low-dose DOACs should also be considered, taking into account the risks of thrombosis and bleeding (note that this is not covered by health insurance in Japan). APTT, activated partial thromboplastin time; COR, Class of Recommendation; DOAC, direct oral anticoagulant; LOE, Level of Evidence; PE, pulmonary embolism; PT-INR, prothrombin time-international normalized ratio.

5.1 Historical Background in Japan

In Japan, the only standard anticoagulation therapy for venous thromboembolism (VTE) had been unfractionated heparin as an injectable agent and warfarin as an oral anticoagulant. In contrast, low-molecular-weight heparin (LMWH), which does not require dose adjustment, has long been available as the first-line injectable anticoagulant in Western countries. However, in Japan, LMWH is still not covered by health insurance for the treatment or secondary prevention of VTE, except in some perioperative prophylactic settings in orthopedic and abdominal surgery. Fondaparinux, an indirect synthetic Factor Xa inhibitor administered subcutaneously, became available in Japan in 2011. Following this, direct oral Factor Xa inhibitors, namely edoxaban, rivaroxaban, and apixaban, became available from 2014 onwards.

5.2 Secondary Prevention and Anticoagulation in the Chronic Phase

Once the acute phase resolves, the next step is to consider anticoagulation therapy for secondary prevention of VTE recurrence. Because anticoagulants carry a bleeding risk, the therapy should be reserved for patients whose risk of recurrence outweighs the bleeding risk. These risks may change over time, so it is essential to re-evaluate them regularly and weigh the risks and benefits of continuing or discontinuing anticoagulation therapy. Furthermore, in assessing these risks and benefits, the specific clinical weight and consequences of recurrence or bleeding events should also be considered.

5.3 Evidence on the Optimal Duration of Anticoagulation

Historically, numerous RCTs have been conducted to determine the optimal duration of warfarin therapy.442–446 These studies yielded several insights: (i) all patients should receive at least 3 months of anticoagulation; (ii) whether the treatment duration is 3–6 months or longer (12–24 months), the risk of recurrence after discontinuation is similar; and (iii) extending anticoagulation beyond 3 months significantly reduces the risk of recurrence, but this benefit may be offset by an increased bleeding risk.

More recently, RCTs on DOACs, believed to have a lower bleeding risk than warfarin, have also been reported, including the EINSTEIN Extension trial,447 EINSTEIN Choice trial,448 and the AMPLIFY Extension trial.449 In the EINSTEIN Extension trial,447 of the 1,196 patients with first-time DVT who had completed 6–12 months of anticoagulation, those randomized to an additional 6–12 months of rivaroxaban (20 mg/day) had a significantly lower recurrence rate than those on placebo (1.3% vs. 7.1%; hazard ration [HR] 0.18). However, major or clinically relevant bleeding occurred more frequently in the rivaroxaban than placebo group (6.0% vs. 1.2%). In the EINSTEIN Choice trial,448 a double-blind RCT with 3,365 symptomatic VTE patients who had completed 6–12 months of anticoagulation, those given rivaroxaban 10 or 20 mg daily for an additional 12 months had significantly lower recurrence rates than those given aspirin 100 mg daily (1.2% and 1.5% vs. 4.4%, respectively; HR 0.26 [10 mg rivaroxaban] and 0.34 [20 mg rivaroxaban]), with comparable bleeding risks. In the AMPLIFY Extension trial,449 among 2,486 patients with a first episode of VTE, 12 additional months of apixaban 2.5 or 5 mg twice daily reduced all-cause mortality and symptomatic VTE recurrence vs. placebo (3.8% and 4.2% vs. 11.6%, respectively; HR 0.33 [2.5 mg apixaban] and 0.36 [5 mg apixaban]). There were no significant differences in major or clinically relevant bleeding.

5.4 Perspectives From International Guidelines on the Duration of Anticoagulation

Clinical trials to date have shown that extending anticoagulation therapy beyond 3 months significantly reduces the risk of VTE recurrence, although it slightly increases bleeding risk. However, because DOACs are associated with a potentially lower bleeding risk, recent international guidelines recommend prolonged anticoagulation for patients not considered to have a low recurrence risk.2,3

Low-dose rivaroxaban (10 mg) and apixaban (2.5 mg twice daily) have demonstrated efficacy in preventing recurrent VTE while maintaining a favorable bleeding profile. As a result, extended treatment with low-dose anticoagulants is recommended for non-cancer patients with VTE.2,3

However, such low-dose regimens are not yet covered by insurance in Japan, and clinical evidence specific to the Japanese population remains limited.450,451 Given that Japanese and other Asian populations may have a higher bleeding risk than Western populations, the appropriateness of low-dose extended therapy may, in fact, be greater in Japan, warranting further investigation.

5.5 Aspirin as an Alternative Therapy

Aspirin has antiplatelet effects and is inferior to anticoagulants in preventing recurrent VTE, but it carries a lower bleeding risk and has shown utility for primary VTE prevention in orthopedic postoperative settings. In 2 RCTs in which aspirin was administered after the completion of standard anticoagulation therapy in patients with unprovoked VTE, the recurrence risk was reduced by approximately 30–35%.452,453

Although aspirin was less effective than anticoagulants (less than half as effective), the increased bleeding risk was minimal. Thus, although anticoagulation remains the first-line therapy for secondary prevention, aspirin may be considered as an alternative in patients who refuse or cannot tolerate anticoagulants.2

6. Risk of VTE Recurrence and Duration of Therapy

6.1 Basic Risk Estimation of VTE Recurrence

Estimating the risk of recurrence after discontinuing anticoagulation is essential for determining the appropriate treatment duration. Studies have shown that clinical features at the time of VTE onset significantly influence the risk of recurrence.454,455 An initial step involves categorizing the event based on provoking factors: transient major provoking factors (e.g., surgery) are associated with very low recurrence risk once removed; persistent provoking factors (e.g., active cancer) carry a high recurrence risk. Unprovoked VTE falls between these extremes and is considered to have a moderate risk. Many guidelines now classify VTE patients into 5 groups based on recurrence risk. Although classification criteria and estimated risk vary slightly across sources, a representative classification is presented in Table 15.

Table 15.

Classification of VTE Recurrence Risk Based on Provoking Factors and Recommended Duration of Anticoagulation Therapy

Classification by provoking
factors at the time of VTE onset
Estimated
recurrent risk
Examples Recommendation
for PE
Recommendation
for proximal DVT
VTE provoked
by transient
risk factors
Major transient
risk factor
Low risk • Major surgery requiring general
anesthesia (operation time ≥30 min)
• Staying in hospital bed due to
acute illness
• Trauma involving fractures
• Cesarean section
3 months (I, B) 3 months (IIa, B)
Minor transient
risk factor
Low risk –
Intermediate risk
• Minor surgery under general
anesthesia (operation time <30 min)
• Hormone therapy
• Pregnancy and delivery
• Staying in bed outside of a hospital
• Traveling (seating) for long periods
of time
Without additional
factors *1 : 3 months
(IIa, B)
With additional
factors *1 : Extended
duration (IIa, C)
3 months (IIa, B)
Unprovoked
VTE
  Intermediate risk   Extended duration
(IIa, B)
Extended duration
(IIb, C)
VTE provoked
by persistent
risk factors
Non-malignant
persistent risk
factor
Intermediate–high
risk
• Active collagen disease
• Ulcerative colitis
• Antiphospholipid syndrome
Extended duration
(IIa, B)
Extended duration
(IIa, B)
Active cancer High risk   Extended duration
(as long as cancer
is active) (IIa, B)
Extended duration
(as long as cancer
is active) (IIa, B)

*1 Additional recurrence risk factors to consider (Section 6.2):

 • Age and sex

 • Obesity

 • Thrombus location (PE > proximal DVT > distal DVT)

 • Recurrent VTE

 • Inherited thrombophilia (congenital coagulation factor abnormalities)

 • Residual thrombosis; D-dimer after discontinuation of anticoagulation

Recommended duration of anticoagulation therapy is “when the risk of bleeding is not high” (recommendation class and evidence level). When implementing extended duration with DOACs, low-dose DOACs should also be considered, taking into account the risk of thrombosis and bleeding (note that this is not approved for insurance coverage in Japan). DOAC, direct oral anticoagulant; DVT, deep venous thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.

6.2 Additional Risk Factors to Consider for Recurrence

In addition to classification based on the presence or absence of provoking factors, various additional risk factors are considered to be involved in the risk of VTE recurrence. Representative factors include: age, sex, and obesity; thrombus location (PE or DVT); whether the event is an initial onset or a recurrence; and the presence of congenital thrombophilia. Furthermore, residual thrombus during the course of treatment and D-dimer levels after cessation of anticoagulation therapy may also influence the risk of recurrence. Several risk scoring systems that incorporate these additional factors and multiple other elements to predict VTE recurrence have been reported;456 however, few have gained widespread use at present. Considerations regarding these additional factors are detailed below.

• Age and sex: The evidence is inconsistent; some studies suggest higher risk in older adults and males, whereas others do not457–462

• Obesity: A known risk factor for VTE, but its role in recurrence remains unclear. Notably, obesity is less common in the Japanese population463

• Thrombus location: Generally, recurrence risk is higher for PE > proximal DVT > distal DVT.464,465 Japanese data suggest recurrence risk is similar between PE and DVT, but recurrence often involves the same site or condition466

• Recurrent VTE: Patients with a history of VTE have a higher risk of future recurrence, particularly if the prior event was not associated with a transient major risk factor467

• Residual thrombus or elevated D-dimer after treatment: These may indicate increased recurrence risk;468 however, due to the frequent occurrence of mildly elevated D-dimer levels in elderly patients, international guidelines do not actively incorporate this factor

6.3 Determining the Duration of Therapy for PE Based on Recurrence Risk

Evidence regarding the optimal duration of anticoagulation for PE in Japan is limited, and guidance is based primarily on international studies. Current international guidelines classify patients into 5 risk groups and recommend treatment durations accordingly2,3,469,470 (Table 15). For VTE caused by a transient major risk factor, 3-month anticoagulation is generally sufficient. For VTE due to a transient minor risk factor, recommendations vary, with some suggesting 3 months is adequate2,469 and others favoring longer durations depending on recurrence risk.3,470 Given the lower thrombosis risk and higher bleeding risk among Japanese patients, a limited duration (3 months) of anticoagulation therapy may be sufficient in the absence of additional risk factors. In PE patients with higher clinical severity, extended anticoagulation may be more strongly considered. Japanese data show that VTE due to minor transient risk factors has a significantly higher recurrence rate after discontinuation of anticoagulation than VTE due to major transient factors.471 According to international guidelines, unprovoked VTE, VTE with persistent non-cancer-related provoking factors, and VTE associated with active cancer are all considered to carry at least a moderate risk of recurrence. For these conditions, anticoagulation therapy longer than 3 months is recommended, with the aim of indefinite continuation. Japanese data have similarly shown that in patient groups with at least moderate recurrence risk, including unprovoked VTE, the recurrence risk after discontinuation of anticoagulation therapy was comparable to that reported in Western countries.471 From the standpoint of recurrence risk alone, continued anticoagulation therapy for as long as possible is recommended for patients with PE, in accordance with Western guidelines.

6.4 Bleeding Risks Associated With Anticoagulation

Anticoagulants carry a risk of bleeding. During warfarin therapy, the annual risk of major bleeding is slightly under 3%.472 In contrast, meta-analyses of phase III trials have shown that DOACs reduce the risk of major bleeding by approximately 40% compared with warfarin.473 In East Asian populations, including Japanese patients, edoxaban therapy showed a 1.6% rate of major bleeding and a 9.9% rate of clinically relevant bleeding.474 Observational studies during the warfarin era reported a 5.2% rate of major bleeding at 1 year, suggesting that real-world bleeding risks may be higher than in clinical trials.451,475

The bleeding risk is especially high during the first month of therapy. Known risk factors include advanced age, prior bleeding, anemia, active cancer, prior stroke, chronic kidney disease, liver dysfunction, and concomitant antiplatelet therapy. Several bleeding risk scores have been developed. The VTE-BLEED score has been externally validated in Japanese populations and shown moderate utility, although it performs poorly in cancer patients.476 Japanese data during the warfarin era identified active cancer (HR 3.06), prior major bleeding (HR 2.38), anemia (HR 1.75), thrombocytopenia (HR 2.11), and advanced age (HR 1.64) as independent risk factors for major bleeding.475

6.5 Treatment Duration Considering Both Recurrence and Bleeding Risks

Although no universally accepted strategy exists for determining the duration of anticoagulation therapy, many guidelines suggest evaluating recurrence and bleeding risks together. Based on the aforementioned recurrence risk, it has also been proposed that the duration of anticoagulation therapy should be determined with additional consideration of the bleeding risk (Figure 15).477 Because both can fluctuate over time, periodic reassessment is essential. It is also important to consider that the clinical consequences of PE and DVT differ, which may influence decisions regarding the duration of anticoagulation therapy.

Figure 15.

Method for determining the duration of anticoagulation therapy based on the risk of recurrence and bleeding. VTE, venous thromboembolism. (Adapted from Yamashita Y, et al. 2022.477)

©2021 Japanese College of Cardiology. Published by Elsevier Ltd., with permission from Elsevier.

6.6 Anticoagulation Therapy During Pregnancy

Warfarin crosses the placenta and is associated with embryopathy when used between Weeks 6–12 of gestation, and with central nervous system abnormalities or fetal bleeding when used later in pregnancy. Therefore, warfarin should be avoided during pregnancy. Among the DOACs, only rivaroxaban is explicitly contraindicated in pregnancy according to the package insert in Japan. For the other DOACs, the instructions for use state they should only be used when the therapeutic benefits are deemed to outweigh the risks. However, because the impact on the fetus and long-term outcomes in infants remain unknown, DOAC use during pregnancy is not currently recommended.478 Heparin, which has minimal placental transfer and no teratogenicity, is considered the only anticoagulant safe for long-term use during pregnancy. In Japan, LMWH is not covered by medical insurance, so unfractionated heparin is used via subcutaneous injection or continuous intravenous infusion during the perinatal period.

6.7 Anticoagulation Therapy During Breastfeeding

Warfarin has minimal transfer into breast milk and can be safely used during the lactation period. In contrast, all DOACs are known to transfer into breast milk, and breastfeeding should generally be avoided while they are being used. That said, pharmacologic studies suggest that rivaroxaban transfers into breast milk in only small amounts.479 Moreover, a report on pharmacokinetics in a neonate breastfed by a mother taking rivaroxaban indicated that safe management was possible, suggesting that rivaroxaban may be a potential option under careful consideration.480

7. Catheter-Directed Therapy for Acute VTE

Catheter-directed treatment for acute PE is broadly divided into 2 categories: with and without thrombolytic agents481,482 (Recommendation Table 28; Table 16). When used with thrombolytics, the catheter tip is placed within the pulmonary arterial thrombus, and the thrombolytic drug is administered directly into the clot. Compared with systemic administration via peripheral veins, this approach aims to achieve effective thrombolysis with smaller doses. It can be used in patients at high risk of bleeding but is contraindicated in those with active bleeding, especially intracranial hemorrhage.

Recommendation Table 28.

Recommendations and Levels of Evidence for Catheter-Directed Therapy for Acute VTE

  COR LOE
Catheter thrombectomy without thrombolytic agents by skilled operators and at specialized
centers should be considered for high-risk acute PE with contraindications to systemic
thrombolysis or anticoagulation
IIa C
Catheter thrombectomy without thrombolytic agents by skilled operators and at specialized
centers may be considered for intermediate-risk acute PE with contraindication to anticoagulation
IIb C
Catheter thrombectomy without thrombolytic agents by skilled operators and at specialized
centers should be considered for high-risk acute PE in whom systemic thrombolysis is
contraindicated or ineffective, or anticoagulation is contraindicated
IIa C
For patients with critical iliac DVT with arterial ischemia, catheter thrombectomy should be
performed
I C
For patients in the early stage of iliac DVT with severe symptoms, catheter thrombectomy can be
considered
IIa C
For patients with severe post-thrombotic syndrome who do not improve sufficiently with
compression therapy and anticoagulant therapy, catheter-based treatment should be considered
IIa C

COR, Class of Recommendation; DVT, deep vein thrombosis; LOE, Level of Evidence; PE, pulmonary embolism; VTE, venous thromboembolism.

Table 16.

Catheter-Based Treatment for Acute PE

Catheter-based treatment using thrombolytic drugs
Catheter-directed thrombolysis Thrombolytic drug administration to the localized pulmonary artery
thrombus using various catheters
Catheter-based treatment without thrombolytic drugs
Mechanical thrombectomy
Aspiration thrombectomy
Thrombotomy
FlowTriever® (Inari Medical, Irvine, CA, USA) (Not approved in Japan)
Indigo® (Penumbra, Alameda, CA, USA) (Not approved in Japan)
Pigtail catheters, balloon catheters

PE, pulmonary embolism.

Catheter-directed therapies without thrombolytics allow removal of pulmonary artery thrombi without increasing bleeding complications and are less invasive than surgical embolectomy, making them suitable for high-risk patients with active bleeding. Catheter-directed thrombolytic therapies include catheter-directed thrombolysis (CDT), delivery of thrombolytics to the thrombus site via a catheter, rheolytic thrombectomy (e.g., AngioJet®; whereby thrombolytics soften the thrombus and the Venturi effect assists aspiration), and ultrasound-assisted thrombolysis (USAT; e.g., EkoSonicTM; whereby ultrasound waves enhance thrombolysis).

In an RCT comparing CDT with systemic thrombolysis, no difference in thrombolytic efficacy was found unless the catheter penetrated the thrombus and the agent was administered directly into the thrombus.483 In one study, USAT significantly improved the RV to LV ratio at 24 h in 59 PE patients with right heart strain compared with heparin alone.484 However, in another study of 81 patients with submassive PE, no significant difference in thrombus reduction (Miller score at 48 h) was found between CDT and USAT.485

Recently, catheter therapies without thrombolytics have shown favorable outcomes with fewer bleeding complications in intermediate- to high-risk PE patients.486–488 These therapies include the INARI FlowTriever® system, a large-bore flexible aspiration catheter with a thrombus removal disc and blood recovery system, and the Penumbra Indigo® system, a medium-bore flexible catheter with a continuous, sustained suction pressure mechanism. These devices are not yet approved in Japan, and manual aspiration using guiding catheters remains the standard. Reported complications include bleeding at the puncture site, pulmonary hemorrhage, arrhythmia, hemolysis, hemoglobinuria, acute renal failure, right heart injury, and pulmonary artery injury.

The FLARE study using the INARI FlowTriever® showed a 25.1% improvement in the RV/LV ratio at 48 h in 106 intermediate-risk PE patients, with a major bleeding rate of 1%.488 The interim results of the FLASH study reported similar improvements (22.1% decrease in the RV/LV ratio) with a 1.2% major bleeding rate and a 0.4% 30-day mortality rate in 250 high- and intermediate-risk patients.487 In the EXTRACT-PE registry, the use of the Penumbra Indigo® system in 119 intermediate-risk PE patients significantly improved the RV/LV ratio at 48 h, with a low rate of major complications.488

However, none of these catheter interventions has been validated through large RCTs against anticoagulation or systemic thrombolysis. As of March 2025, early approval applications have been submitted to the Japanese Government by related academic societies in Japan for unapproved catheter thrombectomy devices.

8. Surgical Embolectomy for PE (Recommendation Table 29)

Recommendation Table 29.

Recommendations and Levels of Evidence for Surgical Treatment of Acute PE

  COR LOE
Pulmonary artery thrombectomy (using cardiopulmonary bypass) is performed in high-risk PE
cases where a thrombus is present in the central pulmonary artery (pulmonary trunk, main
pulmonary artery), in cases where thrombolytic therapy is contraindicated, in cases where
thrombolytic therapy is unsuccessful, in cases where percutaneous extracorporeal circulation is
initiated or in cases where hemodynamic maintenance is difficult with the administration of
vasopressors
I C
Pulmonary artery thrombectomy (using cardiopulmonary bypass) should be considered for
high-risk or intermediate-high risk PE patients with thrombus in the central pulmonary artery
(pulmonary trunk, main pulmonary artery) who are at high risk of bleeding with continuous
anticoagulation therapy
IIa C
Pulmonary artery thrombectomy (using cardiopulmonary bypass) should be considered in cases
of intermediate–high-risk PE in which a thrombus is present in the central pulmonary artery
(pulmonary trunk, main pulmonary artery), in cases in which thrombolytic therapy is
contraindicated, in cases in which thrombolytic therapy is unsuccessful, in cases in which
hemodynamics, respiratory status or right ventricular function worsen or in cases in which the
predicted mortality rate is judged to be high
IIa C

COR, Class of Recommendation; LOE, Level of Evidence; PE, pulmonary embolism.

High-risk PE carries a very high in-hospital mortality rate (25–65%).489,490 Therefore, invasive treatments, including thrombolytic therapy and surgical interventions, may be required in addition to anticoagulation. Surgery is indicated in patients for whom thrombolytic therapy is contraindicated due to bleeding risk, as well as those who do not respond to catheter-directed or thrombolytic therapies. Surgical pulmonary embolectomy has the advantage of rapidly reducing RV pressure overload and improving hemodynamics immediately after the procedure. It is especially useful in patients who cannot maintain circulatory stability with vasopressor support. In patients with free-floating thrombi in the right atrium or ventricle, which carry a 29% mortality risk, surgery should be considered due to the potential for sudden hemodynamic collapse.491

Although intermediate-risk PE generally has a low in-hospital mortality rate and is not routinely an indication for surgery, intermediate- to high-risk patients with worsening hemodynamics, respiratory failure, or right heart dysfunction under anticoagulation or thrombolytic therapy may be considered surgical candidates. There are subgroups of intermediate- to high-risk PE patients with higher mortality, and severity scores such as PESI may assist with surgical decision-making.492 For acute decompensation of chronic thromboembolic pulmonary hypertension (acute-on-chronic PE), pulmonary endarterectomy under deep hypothermic circulatory arrest is required, and simple surgical embolectomy is not appropriate.

Reported 30-day mortality rates range from 2.3% to 19%, with rates of 0–23.7% for massive PE and 0–11.4% for submassive PE.492–496 Preoperative cardiopulmonary resuscitation is significantly associated with higher mortality.497,498 The mortality rate for patients who failed thrombolytic therapy was 27%, compared with 3.6% for those who underwent surgery alone.499 Massive PE is associated with more postoperative complications than submassive PE.494 A meta-analysis showed that 33% of patients with acute PE required prolonged mechanical ventilation, 14% developed respiratory failure, and 13% developed pneumonia.500 VA-ECMO was used in 16% of patients.500 Re-exploration for bleeding was required in 8.4% of patients, and was more common in patients who had received preoperative thrombolysis.494

9. IVC Filters

The fundamental principle in the prevention and treatment of acute PE is anticoagulation. IVC filters are medical devices used to supplement anticoagulant therapy.501,502 Regarding the indications for IVC filter placement in patients who can receive anticoagulation (i.e., relative indications), the PREPIC trial, which used permanent IVC filters, demonstrated a short-term benefit in preventing PE (4.8% vs. 1.1%).503 However, this benefit was offset by a higher rate of DVT recurrence in the medium term (20.8% vs. 11.6%). A follow-up after 8 years yielded similar results.504 In the PREPIC2 trial, which used retrievable filters (ALN filters), the filters were removed after 3 months.505 The incidence of PE at 3 and 6 months was 3.0% and 3.5% in the filter group, respectively, compared with 1.5% and 2.0%, respectively, in the non-filter group. There were no significant differences in mortality. Based on these findings, the 10th edition of the American College of Chest Physicians guidelines (2016) recommends against IVC filter use in patients with acute VTE who can receive anticoagulation.506 However, in proximal DVT, where recurrence could be fatal, expert placement may be considered.

Common reasons for inadequate or unsuccessful anticoagulation include poor adherence, subtherapeutic anticoagulant levels, drug interactions, incorrect dosing, or anatomical abnormalities underlying VTE.507 Most of these factors may be corrected. However, in patients with worsening or recurrent PE despite adequate anticoagulation, IVC filter placement is considered a Class IIa recommendation (Recommendation Table 30).

Recommendation Table 30.

Recommendations and Levels of Evidence for IVC Filter Placement in VTE

  COR LOE
IVC filter is recommended for patients with VTE who cannot be anticoagulated (however, only if
the distal DVT extends to the proximal portion)
IIa C
IVC filter should be removed as soon as it is no longer necessary I C
IVC filter should be considered in patients with exacerbation or recurrence of PE during adequate
anticoagulation therapy
IIa C
Patients who can be anticoagulated but have the potential for fatal PE due to re-embolization of
residual thrombus should be considered for IVC filter placement
IIa C
Routine IVC filter placement is not recommended even in patients with VTE who can be
anticoagulated
III
No benefit
A
For patients undergoing advanced intervention for acute PE or DVT, IVC filter should be
considered only in patients who are at risk of further worsening of PE
IIa C
Prophylactic IVC filter placement is not recommended in trauma patients or those undergoing
major surgery without acute VTE
III
No benefit
B
If the IVC filter is not removed, the patient should be monitored for further follow-up I C

COR, Class of Recommendation; DVT, deep vein thrombosis; IVC, inferior vena cava; LOE, Level of Evidence; VTE, venous thromboembolism.

Analysis of US national inpatient data showed that among unstable patients undergoing thrombolysis (those in shock or on mechanical ventilation), in-hospital mortality was significantly lower in the filter than non-filter group (7.6% vs. 18%).508 The mortality benefit was especially notable in patients aged 80 years and older (RR 0.35).509 In a Japanese cohort study, patients receiving thrombolysis had a significantly reduced risk of in-hospital death when a filter was used (RR 0.51).510 Thus, in patients undergoing intensive treatment such as thrombolysis or catheter-directed therapy for acute PE or DVT, IVC filter placement may be considered to prevent worsening PE. A systematic review in the UK concluded that IVC filters have similar utility in pregnant as in non-pregnant patients.511

Regarding prophylactic filter use in severely injured trauma patients without confirmed VTE, RCTs have shown no difference in PE incidence between those with and without filters.512 Similarly, US inpatient data revealed a higher incidence of PE in trauma patients with fractures who received filters (14.7%) than in those who did not (0.5%).506 This aligns with previous studies indicating that delayed or interrupted pharmacologic prophylaxis for ≥5 days after trauma increases the risk of VTE (DVT, PE).513 Therefore, in trauma patients without a confirmed diagnosis of VTE, routine IVC filter placement for primary prevention is not recommended (Class III recommendation).

Considering the complications of IVC filters, they should be removed promptly once they are no longer needed.

IX. Treatment of Deep Vein Thrombosis

1. Anticoagulation Therapy for Deep Vein Thrombosis

1.1 Proximal Deep Vein Thrombosis

Because patients with deep vein thrombosis (DVT) have a high recurrence rate of DVT rather than pulmonary embolism (PE),466 the clinical significance of recurrence must be considered when evaluating whether to extend anticoagulation beyond 3 months.

• For proximal DVT with a transient major risk factor, the recurrence rate is low once the factor is removed, and a 3-month duration of anticoagulation is considered appropriate.

• For transient minor risk factors, the recurrence rate falls between that of unprovoked and major transient factor-induced DVT.471 However, because the clinical severity of DVT is considered lower than that of PE, a 3-month duration of anticoagulation is still generally recommended.

• For unprovoked proximal DVT or DVT associated with persistent risk factors, long-term low-dose direct oral anticoagulant (DOAC) therapy is recommended if the patient has a low bleeding risk (Recommendation Table 31; Table 15).

Recommendation Table 31.

Recommendations and Levels of Evidence for Anticoagulation Therapy for DVT

  COR LOE
Treatment for proximal DVT: Initial (0–7 days) to long-term treatment (8 days–3 months)
As acute treatment for central DVT, parenteral anticoagulants such as heparin should be started *1
and combined with warfarin, and parenteral anticoagulants should be continued until the effect of
warfarin reaches the therapeutic range
I B
The therapeutic range of warfarin is suggested to be adjusted to achieve a PT-INR of 1.5–2.5 IIa C
For proximal DVT, DOACs should be administered as acute therapy. Edoxaban should be
initiated after appropriate initial parental therapy. Reveroxaban and apixaban are continued at
maintenance doses after a period of initial therapy with higher doses
I A
For all patients with proximal DVT, anticoagulant therapy should be administered for at least 3
months unless there is a contraindication to anticoagulants or unsustainable bleeding
I A
Treatment of proximal DVT: Extended anticoagulant therapy (>3 months) to prevent recurrence
≥3 months of anticoagulation should be considered for the treatment and prevention of recurrence
of proximal DVT due to transient major factors and transient minor factors (with no additional risk
factors for recurrence to consider)
IIa B
≥3 months of anticoagulation should be considered for treatment and prevention of recurrence of
proximal DVT with no triggers (unprovoked proximal DVT), if the patient is at high risk of bleeding
IIa B
Prolonged anticoagulation with low-dose DOACs is suggested for treatment and long-term
anticoagulation for prevention of recurrence of proximal DVT with no triggers (unprovoked
proximal DVT), if the patient is not at high risk of bleeding *2
IIb C
Long-term anticoagulation, if possible, is suggested for the treatment and prevention of recurrence
of proximal DVT due to persistent risk factors
IIa B
Anticoagulation for active cancer patients with proximal DVT should be considered to continued
with care of bleeding complications, as long as the cancer remains active
IIa B
Long-term anticoagulation is recommended for patients with recurrent proximal DVT, if possible I B
When anticoagulation of proximal DVT is extended beyond 3 months, risks and benefits should
be thoroughly reviewed on a regular basis
I C
For extended treatment of proximal DVT in patients other than those at high risk of recurrence,
such as those with active cancer, low-dose DOACs should be considered *2
IIa A
Aspirin may be considered to prevent recurrence following discontinuation of anticoagulation for
unprovoked DVT, when extended anticoagulation therapy is not desired or not possible
IIb B
Treatment of distal DVT
Distal DVT should not be uniformly anticoagulated, especially distal chronic DVT I B
Distal DVT is treated with physical therapy and observation for proximal progression I C
When anticoagulation is administered for distal DVT, duration of anticoagulation is recommended
up to 3 months (see other recommendations regarding distal DVT in patients with active cancer)
I B
Anticoagulation, with attention to bleeding complications, should be considered for asymptomatic
distal DVT complicated by active cancer
IIb B
When anticoagulation of distal DVT complicated by active cancer is extended beyond 3 months,
risks and benefits should be thoroughly reviewed on a regular basis
I C

*1 The treatment target for unfractionated heparin is to achieve an APTT of 1.5–2.5 times the control value. *2 Low-dose DOACs are not covered by health insurance in Japan. APTT, activated partial thromboplastin time; COR, Class of Recommendation; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; LOE, Level of Evidence; PT-INR, prothrombin time-international normalized ratio.

It should be noted that, as of March 2025, low-dose DOACs are not covered by insurance in Japan, and the bleeding risk associated with standard-dose DOACs is comparable to that of warfarin.471,514

1.2 Distal DVT

Patients with distal DVT were excluded from major DOAC randomized controlled trials (RCTs), and therefore, the evidence base is limited.447,515–517 Both international and Japanese guidelines refrain from recommending uniform anticoagulation for distal DVT.469,506,518–520 Two RCTs have assessed low-molecular-weight heparin and compression therapy for symptomatic distal DVT without cancer. Although initial exploratory studies showed benefit, later trials showed no efficacy for anticoagulation and increased bleeding risk.521,522

In symptomatic distal DVT, if no proximal propagation is observed within 2 weeks, further extension is unlikely.518,523 In Japan, asymptomatic distal DVT generally has a favorable natural course,524 with better outcomes than symptomatic DVT.

In Japanese clinical practice, screening is commonly conducted for safety purposes, and nearly half of all cases of detected distal DVT are asymptomatic.525 Recent screening among cancer patients showed a 5.9% prevalence of venous thromboembolism (VTE), with 99.7% of patients being asymptomatic and 78.8% having distal DVT.526 In the screening of DVT in a general healthy population, the detection rate for distal DVT was 4.3%.527 In contrast, symptomatic PE is rare (3.1 cases per 10,000 perioperative patients),528 and hospital data indicate 124.2 PE cases per 100,000 inpatients.529 Despite the screening of DVT being performed in only a limited number of hospitals, the overall incidence of PE remains low, suggesting that not all distal DVTs pose significant risk.

For patients with distal DVT considered at low risk of recurrence, only follow-up ultrasonography at 7–14 days is recommended. Anticoagulation should be reserved for patients with proximal propagation or high-risk features.506,518,519

Features of high-risk distal DVT include: symptomatic presentation not detected by screening; large, fresh thrombi near the popliteal vein; active cancer; a history of VTE; and perioperative status or hospitalization.518 Considering the risks of bleeding and healthcare costs, routine anticoagulation for all cases of distal DVT should be avoided. Instead, the following approach is recommended:

1. Monitor with ultrasonography at 7–14 days without anticoagulation.

2. Administer anticoagulation only to patients with high recurrence risk.

For asymptomatic distal DVT detected by screening or incidental imaging, follow-up with ultrasonography and physical therapy is more appropriate. In contrast, anticoagulation may be considered in patients with symptoms, a history of VTE, large thrombi, those undergoing orthopedic or cancer surgery, or those receiving chemotherapy.530 Given the low recurrence rate of distal DVT, a 3-month treatment period is generally appropriate.464,531,532

2. Catheter-Directed Therapy for Acute DVT and Post-Thrombotic Syndrome (Recommendation Table 28)

2.1 Acute DVT

For extensive iliofemoral DVT in the acute phase, catheter-directed therapies include catheter-directed thrombolysis (CDT) as used for PE;533 percutaneous mechanical thrombectomy, which involves thrombus fragmentation and aspiration without thrombolytics; and pharmacomechanical CDT (PCDT), which is a combination of CDT and percutaneous mechanical thrombectomy.534

RCTs have assessed the efficacy of these therapies. The CaVenT trial compared CDT with conventional anticoagulation in patients with iliofemoral DVT and found superior vein patency at 6 months and a lower rate of post-thrombotic syndrome (PTS) at 24 months.535 The difference in PTS incidence was even greater at 5 years.536

The ATTRACT trial, comparing PCDT to anticoagulation in 692 patients with proximal DVT, showed no difference in overall PTS or VTE recurrence, but PCDT reduced the incidence of severe PTS537 Although PCDT increased major bleeding, subgroup analysis of iliofemoral DVT showed that PCDT alleviated early leg pain and swelling, reduced PTS severity, and improved quality of life.538

In the CAVA trial, involving 184 patients with iliofemoral DVT, PTS incidence and quality of life at 1 year were comparable between ultrasound-assisted CDT and anticoagulation alone.539

Based on these RCTs, Western guidelines (e.g., American College of Chest Physicians, European Society of Cardiology) recommend anticoagulation as the primary treatment for DVT.3,469,470 Endovascular treatment should be considered for young patients at low bleeding risk with severely symptomatic iliofemoral DVT or phlegmasia cerulea dolens.

During CDT, unfractionated heparin is administered to prevent thrombus extension and recurrence. Placement of an inferior vena cava filter during CDT may help prevent PE from embolized thrombi but does not improve long-term outcomes.540,541 If an inferior vena cava filter is applied, retrievable filters are recommended, and removal should be attempted once the embolic risk diminishes.542

For residual stenosis after thrombolysis (e.g., May–Thurner syndrome), balloon angioplasty or stenting can help maintain venous outflow, reduce recurrence, and improve outcomes.543,544 However, high rates of in-stent restenosis have also been reported.545

In Japan, urokinase had been the only thrombolytic agent approved for DVT, but its supply was suspended during the COVID-19 pandemic due to loss of urine collection for production. This led to the approval of 2 large-bore thrombectomy devices that do not require thrombolytics: Indigo® (Penumbra) and ClotTriever® (Inari Medical). Early results have been favorable, but no comparative data with anticoagulation are available, and the indication for these devices as of March 2025 remains limited to selected severe cases.546–548 In particular, phlegmasia cerulea dolens accompanied by arterial ischemia, although rare, carries a risk of limb amputation. Surgical venous thrombectomy has conventionally been the mainstay of treatment; however, thrombectomy devices that enable early reperfusion with less invasiveness are expected to be useful.549 According to the appropriate use criteria for thrombectomy devices in Japan,482 patient indications include severe DVT involving acute-phase symptoms such as iliac vein obstruction accompanied by arterial ischemia (e.g., phlegmasia cerulea dolens, phlegmasia alba dolens, or venous gangrene) or DVT that causes persistent pain despite adequate conservative therapy (e.g., anticoagulation, limb elevation, or compression therapy) and significantly impairs daily activities (defined as a Revised Venous Clinical Severity Score pain score of 3, or a pain score of 2 combined with a Villalta score of ≥15).

2.2 Post-Thrombotic Syndrome

PTS refers to a condition where chronic venous stasis symptoms and findings appear due to residual thrombus after DVT or regurgitation caused by valve destruction, ultimately presenting as refractory venous leg ulcers. Although many cases of PTS improve with lifestyle guidance and compression therapy, such as elastic stockings, some patients experience recurrent venous leg ulcers or persistent pain. Catheter-directed treatments, including venous stenting, have demonstrated efficacy for these PTS patients.550–552 However, there are no RCTs comparing catheter-directed treatments to conservative therapy, and they should be reserved for severe cases where conservative therapy has failed. Treatment must follow appropriate use criteria of venous stents.482

3. Surgical Thrombectomy for DVT (Recommendation Table 32)

Recommendation Table 32.

Recommendation and Level of Evidence for Surgical Treatment of DVT

  COR LOE
For severe acute DVT accompanied by arterial ischemia, surgical venous thrombectomy
should be considered
IIa C

COR, Class of Recommendation; DVT, deep vein thrombosis; LOE, Level of Evidence.

Most cases of DVT are treated with anticoagulation alone. However, in severe cases, endovascular therapies may be introduced, and surgical thrombectomy combined with endovascular intervention is performed in select patients.553 Surgical thrombectomy is indicated only for severe cases such as phlegmasia cerulea dolens, venous gangrene, and acute DVT with severe, persistent pain. Among patients with phlegmasia cerulea dolens, surgery is preferred in more severe cases because endovascular thrombolysis cannot deliver immediate relief.549,554 Surgery also suitable for patients with contraindications to anticoagulation or thrombolysis due to high bleeding risk. Although surgical thrombectomy may help prevent PTS even in patients with mild DVT, the procedure is highly invasive.555,556

In cases not limited to phlegmasia cerulea dolens, hybrid surgical thrombectomy with endovascular therapy resulted in a patency rate of 70–80% and a PTS incidence of 10–20%.557 Some reports indicate a lower PTS rate following surgery compared with anticoagulation alone.556 On analysis reported in 2008 amputation and mortality rates of 22% in phlegmasia cerulea dolens.549 However, a more recent series of 15 patients reported no major amputations or deaths following surgical venous thrombectomy.554

4. Physical Therapy for DVT (Recommendation Table 33)

Recommendation Table 33.

Recommendations and Levels of Evidence for Physical Therapy for DVT

  COR LOE
If anticoagulant therapy is administered as the initial treatment for DVT, early mobilization and
walking should be considered rather than bed rest
IIa B
In patients with DVT without PE, outpatient treatment should be considered if their general
condition, lower limb symptoms, home environment, and hospital environment are suitable
IIa A
Compression therapy should be considered to improve acute symptoms of DVT IIa C
Compression therapy should be considered for patients with proximal DVT to prevent PTS IIa A
Patients with severe PTS, such as venous ulcers, should wear elastic bandages and compression
stockings
I A
To prevent the recurrence of venous ulcers due to chronic venous insufficiency, compression
therapy using elastic stockings should be considered
IIa B

COR, Class of Recommendation; DVT, deep vein thrombosis; LOE, Level of Evidence; PE, pulmonary embolism; PTS, post-thrombotic syndrome.

4.1 Bed Rest and Mobilization

Historically, during the acute phase of DVT, strict bed rest was commonly prescribed due to concerns that mobilization, including ambulation, could dislodge thrombi and trigger PE. However, recent studies have demonstrated that with appropriate anticoagulation therapy, early mobilization does not increase the risk of new PE or thrombus propagation. In fact, early ambulation may improve leg pain.558–560 If there is no floating thrombus, the patient has mild leg pain, and the general condition is stable, early mobilization and walking are recommended instead of bed rest because this may contribute to improved quality of life. Conversely, if floating thrombi are present, even with anticoagulation therapy, PE risk may still be high, requiring cautious clinical judgment.561 In Japan, studies using the JROAD-DPC database show that the average hospital stay for DVT patients decreased from 14 days in 2012 to 12 days in 2017, coinciding with the increased use of DOACs.562 These agents likely contributed to earlier discharge and outpatient management.

4.2 Compression Therapy (Acute Phase)

Compression therapy is initiated after starting anticoagulation in the acute phase of DVT to relieve symptoms such as swelling and pain, and to prevent long-term complications like PTS. Theoretical benefits of compression therapy include an enhanced muscle pump effect through increased venous pressure during contraction, improved capillary perfusion and reduced edema through enhanced microcirculation, and reduced venous reflux by narrowing the vein diameter and promoting valve closure.

In Japan, approximately 70% of VTE patients receive compression therapy,563 as do nearly half of DVT patients globally.564 Elastic stockings are preferred over elastic bandages due to ease of use and cost-effectiveness. There is no significant difference in effectiveness between 25 and 35 mmHg compression pressure,565 so 25 mmHg is often chosen because of better adherence.566,567

Studies have shown that combining early ambulation with compression therapy under anticoagulation improves acute symptoms (e.g., pain and swelling) without increasing PE risk.568–570 Compression may also promote thrombus recanalization and reduce the incidence of chronic venous obstruction, which leads to PTS. Although some studies question the effectiveness of compression for acute pain relief,571 discrepancies may be due to poor adherence or inconsistent implementation of compression.570

4.3 Compression Therapy (Chronic Phase)

Small studies have suggested that wearing elastic stockings with an ankle pressure of ≥30 mmHg for 2 years can prevent PTS572–574 However, a large RCT comparing stockings to placebo showed no significant difference in PTS incidence.575 Limitations of that study included poor adherence (only 56%) and a lack of compression therapy during the acute phase. In an RCT comparing 1- vs. 2-year stocking use among patients with good adherence, non-inferiority of the 1-year group was not demonstrated, and 2-year wear was recommended.576 For patients without PTS symptoms 6 months after DVT onset (Villalta score), no difference in PTS incidence was found between 6-month and 2-year stocking use, suggesting therapy duration can be individualized based on symptom severity.577 Systematic reviews and meta-analyses have demonstrated the efficacy of compression therapy in preventing PTS, particularly in proximal DVT.578

Elastic stockings rarely cause serious complications and are effective for symptom control in DVT and PTS. If swelling or pain improves, discontinuing use is reasonable. A practical approach is to apply compression stockings during the acute phase and to continue for 6 months. If PTS symptoms remain, continue for up to 2 years.

For patients with established PTS, the effectiveness of compression stockings in mild cases of PTS is uncertain.579 In the case of venous leg ulcers, compression bandages or stockings with ≥30 mmHg ankle pressure are highly recommended.578–583 In patients with stasis dermatitis or lipodermatosclerosis, compression therapy is also recommended despite low-level evidence.578 Compression therapy also prevents ulcer recurrence, as supported by RCTs and systematic reviews.578,584

High-pressure stockings are more difficult to wear and may reduce adherence. Thus, stockings with 20–30 mmHg pressure are recommended as in the acute phase.565,578 Therapeutic compression usually starts from >18 mmHg for symptom relief. For ulcers, pressures ≥40 mmHg are ideal, although lower pressures have also been shown to be effective.583,585,586 Knee-length stockings are generally preferred over thigh-high stockings unless there is significant thigh edema, because the knee-length stockings are cheaper, easier to wear, and similarly effective.587

X. Cancer-Associated Venous Thromboembolism

1. Epidemiology of Cancer-Associated Venous Thromboembolism

It has long been recognized that the incidence of venous thromboembolism (VTE) is higher in cancer patients than in the general population. VTE is not only a serious complication during cancer treatment but is also associated with worsened survival. The incidence of VTE has shown an increasing trend in recent years, with the highest rates of VTE reported in pancreatic, gastric, and primary brain tumors.588,589 Regarding racial differences, prospective epidemiological studies in the US have reported that the incidence of cancer-associated VTE in adults of Asian descent is lower than in other ethnic groups.590 In Japan, the incidence of VTE in patients with solid tumors has been reported to be between 3.3% and 5.9%.591,592 However, many of these cases are asymptomatic distal deep vein thrombosis (DVT), suggesting a high frequency of incidental findings. The incidence of VTE in Japanese patients with pancreatic cancer is also high, and risk factors include obesity (body mass index >25 kg/m2) and administration of chemotherapy.593 However, due to the poor prognosis of pancreatic cancer itself, it has been reported that the occurrence of VTE or intervention with anticoagulant therapy does not contribute to improved survival in such cases.

2. Definition of Active Cancer

Active cancer is defined by the presence of any of the following conditions:515 newly diagnosed cancer within 6 months prior to enrollment; cancer treatment (surgery, chemotherapy, radiation therapy) within the past 6 months; ongoing cancer treatment (surgery, chemotherapy, radiation therapy); recurrent, locally invasive, or metastatic disease; and, in hematologic malignancies, the absence of complete remission.

Active cancer is considered a risk factor for the development of VTE. Conversely, it has been demonstrated that patients with a history of cancer that is now cured do not have a high recurrence risk of VTE, and that their risk is comparable to that of non-cancer patients.594 Therefore, decisions as to whether to continue anticoagulation should be based on the activity of the cancer rather than on the mere history of malignancy.

3. Biomarkers and Risk Assessment

A prospective observational study evaluating D-dimer levels in cancer patients reported a cut-off value of 6.8 μg/mL, with a sensitivity of 96% and specificity of 38% for diagnosing VTE.478 Meta-analyses have shown that the odds ratio for VTE in patients with elevated D-dimer levels vs. those without is between 1.85 and 1.92.595,596 However, D-dimer levels vary widely among cancer patients depending on the underlying disease state. There are currently no coagulation or fibrinolysis biomarkers with sufficient evidence to replace D-dimer. Thus, in the diagnosis of VTE in cancer patients, scoring systems such as the Khorana score597 (proposed by Khorana et al. in 2008) and the Vienna score598 (which incorporates D-dimer and soluble P-selectin) are commonly used.

Regarding the utility of the Khorana score in Japanese patients, the reported VTE prevalence according to risk categories is as follows: low risk (0 points), 1.7%; intermediate risk (1–2 points), 7.3%; and high risk (≥3 points), 11.0%.599 It is of note that these prevalence values are higher than the original report (low, 0.3%; intermediate, 2%; high, 7%), particularly among intermediate-risk patients.

4. Treatment Algorithm

Treatment of cancer-associated VTE should be considered in 3 phases: initial treatment (first 7–10 days), long-term treatment (3–6 months), and extended treatment. In principle, direct oral anticoagulants (DOACs) are administered in the same dosages and regimens as for VTE unrelated to cancer.

For distal-type DVT frequently observed in cancer patients in Japan, there are no relevant international treatment data. The ONCO DVT study, a randomized controlled trial assessing the duration of edoxaban therapy in cancer-associated distal DVT, was recently conducted in Japan.600 In that study, the 12-month treatment group showed fewer VTE events (mainly distal DVT) than the 3-month group, with no significant difference in bleeding risk.

In real-world practice in Japan, analysis of health insurance claims data has shown that the introduction of DOACs has significantly increased the proportion of cancer-associated VTE patients managed in outpatient settings. There was no marked difference in drug selection compared with non-cancer-associated VTE.601 However, the use of initial intensified DOAC therapy as recommended internationally is relatively low, and approximately 80% of patients diagnosed with pulmonary embolism received anticoagulation in inpatient settings.

Because of the high recurrence risk of cancer-associated VTE, international guidelines recommend continuing anticoagulation therapy for at least 6 months during periods of active cancer.602 Japanese epidemiological data also confirm a high recurrence rate in patients with active cancer, supporting the need for extended treatment.594 Conversely, in patients with a history of cancer that is no longer active, the recurrence risk is comparable to that of non-cancer patients, and treatment discontinuation may be considered once cancer activity resolves.603

Cancer patients are generally at high risk of bleeding as well, making it difficult to balance the thrombotic and hemorrhagic risks. Therefore, the duration of anticoagulation must be carefully individualized based on cancer status and patient-specific factors.

For many distal DVTs, a treatment period of 3 months is considered appropriate due to the generally low recurrence risk.464,531 However, international reports have indicated high recurrence rates for distal DVT in patients with cancer, and anticoagulation has shown efficacy even in asymptomatic DVT patients.604–606 Findings from the ONCO DVT study and subsequent subgroup analyses suggest that extended anticoagulation is particularly beneficial in patients with active cancer who are at high thrombotic risk but low bleeding risk.532,600

Conversely, the efficacy of anticoagulation in all distal DVTs has not been fully established. Moreover, among cancer patients who underwent anticoagulation following screening, major bleeding was identified as a significant risk factor for mortality.451 As of March 2025, no large-scale systematic screening programs for cancer-associated VTE have shown a clear benefit of anticoagulation in all distal DVTs.607

XI. Progression to Chronic Conditions (Post-Thrombotic Syndrome and Chronic Thromboembolic Pulmonary Disease) (Recommendation Table 34)

Recommendation Table 34.

Recommendations and Levels of Evidence for the Transition of Acute VTE to Chronic Disease (PTS and CTEPD)

  COR LOE
Clinical evaluation should be performed 3–6 months after the onset of acute PE to identify
symptoms suggestive of recurrence, bleeding, malignancy, persistent or new-onset exercise
limitations, and to consider extending anticoagulation therapy
I B
If shortness of breath or right heart overload occurs 3–6 months after the onset of acute PE,
evaluation for residual thrombus should be considered
IIa C
Symptomatic patients after acute PE who have perfusion defects on lung perfusion scintigraphy
should be referred to a specialized center after the results of echocardiography are also
evaluated
I C
Compression therapy should be considered for patients with proximal DVT to prevent PTS IIa A

COR, Class of Recommendation; CTEPD, chronic thromboembolic pulmonary disease; DVT, deep vein thrombosis; LOE, Level of Evidence; PE, pulmonary embolism; PTS, post-thrombotic syndrome; VTE, venous thromboembolism.

1. Post-Thrombotic Syndrome

Post-thrombotic syndrome (PTS) is a chronic condition resulting from residual thrombus and venous valve destruction following deep vein thrombosis (DVT). PTS is characterized by chronic symptoms and signs of venous stasis, including intractable venous leg ulcers in severe cases.608–610

1.1 Epidemiology of and Risk Factors for PTS

PTS occurs in approximately 20–80% of patients after acute DVT, including mild cases.611–614 A Japanese observational study reported a 13% incidence of PTS within 3 years after DVT.615 Risk factors include extensive thrombus burden,616 recurrent ipsilateral DVT,608,616,617 and the combined presence of deep venous occlusion and valve incompetence.616,618 Obesity, lifestyle factors, and superficial/perforating vein insufficiency also contribute. However, early and appropriate anticoagulation significantly reduces the incidence of PTS.612,619,620

1.2 Diagnosis of PTS

A diagnosis of PTS is made using the Villalta score, which quantifies symptoms and physical signs. A Villalta score ≥5 indicates mild PTS, a score of ≥10 indicates moderate PTS, and a score of ≥15 or the presence of venous leg ulcers indicates severe PTS.621

1.3 Prevention of PTS

Prevention strategies for PTS include proper anticoagulation therapy, the use of compression stockings after DVT onset, and early thrombus removal in select patients.

1.4 Treatment of PTS

PTS is treated similarly to chronic venous insufficiency. This includes lifestyle modification (e.g., reducing the duration of standing or dependent leg positions, weight loss), compression therapy with elastic stockings, and catheter-directed intervention for patients with severe symptoms, such as recurrent ulcers or pain associated with iliac vein lesions. In such patients, the usefulness of catheter-directed therapies, including venous stenting, has been demonstrated.550–552 However, no randomized controlled trials have compared these interventions with conservative therapy, and the procedure should be reserved only for severe cases where conservative measures have proven ineffective. Treatment should be performed in accordance with the appropriate use criteria for venous stent.482

2. Chronic Thromboembolic Pulmonary Disease

Some patients experience persistent exertional dyspnea, reduced exercise tolerance, and decreased quality of life after acute pulmonary embolism (PE), a condition referred to as post-PE syndrome.622–624 Although the pathogenesis and clinical spectrum are not fully understood, patients who have persistent symptoms due to organized thrombi in the pulmonary arteries are diagnosed with chronic thromboembolic pulmonary disease (CTEPD), regardless of the presence of pulmonary hypertension. If pulmonary hypertension is present, the condition is termed chronic thromboembolic pulmonary hypertension (CTEPH).7

At the time of acute PE diagnosis, it is crucial to start anticoagulation therapy promptly to prevent residual thrombus and the development of CTEPD. A follow-up clinical evaluation at 3–6 months after acute PE is recommended to assess for recurrence, bleeding, malignancy, ongoing exercise limitation, or new symptoms that may warrant extended anticoagulation therapy.441,448,449,625 For patients at high risk of developing CTEPH, or those presenting with dyspnea or signs of right heart strain at follow-up, active evaluation for residual thrombus should be considered.2

Compared with lung perfusion scintigraphy, computed tomography (CT) has a lower negative predictive value for diagnosing CTEPH. Therefore, lung perfusion scintigraphy is preferred for evaluating residual thrombus.22,626 Where nuclear medicine examination is unavailable, contrast-enhanced CT with appropriate protocols or dual-energy CT may be alternatives.2,627,628 Symptomatic patients showing signs of residual perfusion defects on imaging should be referred to a specialized center after consideration of echocardiographic findings and other evaluations (Figure 16).

Figure 16.

Acute pulmonary embolism (PE) follow-up with an awareness of chronic thromboembolic pulmonary hypertension (CTEPH). CT, computed tomography.

XII. Prevention of Venous Thromboembolism (Recommendation Table 35)

Recommendation Table 35.

Recommendations and Levels of Evidence for VTE Prevention (Perioperative) in Each Area

  COR LOE
Early mobilization and active exercise are recommended for all at-risk patients I C
Consider wearing compression stockings by intermediate-risk patients IIa A
Intermittent pneumatic compression is used in intermediate-risk patients I A
For high-risk patients, intermittent pneumatic compression or anticoagulation therapy is
recommended
I A
For patients at highest risk, pharmacologic prophylaxis and intermittent pneumatic compression
are used or pharmacologic prophylaxis and compression stockings are used. Patients at high risk
of bleeding are also treated with intermittent pneumatic compression
I A

COR, Class of Recommendation; LOE, Level of Evidence; VTE, venous thromboembolism.

1. Evaluation of Risk Levels for Venous Thromboembolism Prevention

In general surgery, venous thromboembolism (VTE) prevention is primarily aimed at hospitalized patients and focuses on primary prevention. The level of VTE risk in patients undergoing general (non-orthopedic) surgical procedures is categorized into 4 levels: low, moderate, high, and highest (Table 17). Based on these risk levels, appropriate preventive strategies are selected (Table 18).

Table 17.

VTE Risk Stratification for General Surgery, Urology, and Gynecology Surgery (Non-Orthopedic Surgery)

Risk level General surgery, urological, and gynecological surgery
Low risk Non-major surgery for patients aged <60 years
Major surgery for patients aged <40 years
Intermediate risk Non-major surgery for patients aged >60 years or with risk factors
Major surgery for patients aged >40 years or with risk factors
High risk Major cancer surgery for patients aged >40
Highest risk Major surgery for patients with a history of VTE or a thrombophilia

The overall risk level is determined by taking into account the risk of the procedure or disease being prevented and any additional risk factors. If additional risk factors (Table 19) are present, the risk level should be increased by 1 level. There is no strict definition of major surgery, but all abdominal surgeries or other surgeries requiring ≥45 min are considered major, and a comprehensive assessment is made based on factors such as anesthesia method, blood loss, blood transfusion volume, and operative time. VTE, venous thromboembolism.

Table 18.

Risks of VTE and Recommended Prophylaxis

Risk level Recommended prophylaxis
Low risk Early mobilization and active rehabilitation
Intermediate risk Early mobilization and active rehabilitation
Elastic compression stockings or intermittent pneumatic compression
High risk Early mobilization and active rehabilitation
Intermittent pneumatic compression or anticoagulation therapy
Highest risk Early mobilization and active rehabilitation
Anticoagulation therapy in combination with intermittent pneumatic compression or
anticoagulation therapy in combination with elastic compression stockings

In patients undergoing abdominal surgery in Japan, enoxaparin, fondaparinux or low-dose unfractionated heparin is used. In patients with a high risk of bleeding, careful consideration should be given to the use of anticoagulants, and physical prophylaxis such as intermittent pneumatic compression and elastic compression stockings should be used. VTE, venous thromboembolism.

Given the current lack of strong evidence in VTE prevention in Japan, mechanical prophylaxis is emphasized over pharmacologic approaches because of bleeding complications with pharmacologic prophylaxis. For the highest-risk patients, anticoagulant therapy is recommended, but if the bleeding risk is high, mechanical prophylaxis alone may be considered. The risk level associated with each surgery or condition should be assessed comprehensively, including additional risk factors (Table 19). Depending on these risk factors, a higher level of prevention may be considered.

Table 19.

Strength of Additional Risk Factors for VTE

Strength of risk factors Additional risk factors
Weak Obesity
Estrogen therapy
Varicose veins
Moderate Elderly
Prolonged bed rest
Congestive heart failure
Respiratory failure
Malignant disease
Central venous catheter placement
Cancer chemotherapy
Severe infection
Strong History of VTE
Thrombophilia
Lower limb paralysis
Lower limb immobilization in a plaster cast
Active cancer

VTE, venous thromboembolism.

In many facilities, mechanical prophylaxis such as elastic stockings or intermittent pneumatic compression (IPC), which are associated with fewer adverse events, are widely used for patients at low to high risk. For the highest-risk patients (e.g., those with a history of VTE or thrombophilia), anticoagulant therapy is added. Since the introduction of reimbursement for pulmonary embolism (PE) prevention management, the increased use of mechanical prophylaxis and early mobilization, and greater patient awareness of PE, the incidence of perioperative PE has decreased by approximately half.528

For other perioperative VTE risk assessments, the Caprini score is the most widely studied.629,630 However, it has not been broadly adopted in Japan due to its complexity, lack of validation, and inconsistent application.631 In some Asian countries, studies with stricter definitions of high risk have been conducted.629,632

For medical patients, VTE risk can be assessed using the Padua score,633 or the IMPROVE VTE risk score,634 whereas the Khorana score597,635 is used for outpatients with cancer. However, these tools have limited external validation in Japan, and are not widely implemented.636,637 Recently, the COMPASS-CAT score, which offers higher precision for cancer patients, has also been reported.638

In Japan, screening tests are performed in some institutions to detect high-risk patients. Among cancer surgery patients, preoperative D-dimer testing and lower extremity ultrasonography are combined for deep vein thrombosis (DVT) screening. This has led to reports of many asymptomatic distal DVTs.639 Although some studies have demonstrated the clinical utility of screening tests, others have reported no benefit. Due to cost-effectiveness concerns, routine screening is not broadly recommended.607

There is no universally accepted tool for predicting the bleeding risk of pharmacologic prophylaxis. Although the American College of Clinical Pharmacy (ACCP) guidelines list bleeding risk factors640 and scoring systems (such as the IMPROVE bleeding score641), their utility is limited.642 While bleeding risk is also a concern during therapeutic anticoagulation, it is also particularly important during pharmacologic prophylaxis.

2. Methods of VTE Prevention

2.1 Early Ambulation and Active Exercise

Early mobilization and active limb exercise are fundamental to VTE prevention. Encouraging ambulation activates the calf muscle pump and reduces venous stasis in the lower limbs.643 For patients unable to ambulate, leg elevation, massage, and passive or active ankle exercises are recommended.644–646 These methods are safe, free, and should be implemented in all patients unless contraindicated.

2.2 Elastic Stockings

Elastic stockings reduce the total cross-sectional area of the veins by compressing the lower limbs, thereby increasing venous blood flow and reducing stasis.647,648 Compared with other preventive methods, stockings have the advantages of no bleeding risk, simplicity, and relatively low cost. They are effective in moderate-risk patients, but less so when used alone in high-risk or highest-risk patients.649 Much of the evidence for elastic stockings is based on older studies and focuses on asymptomatic VTE as an outcome, which is why the ACCP guidelines assign them a lower recommendation grade.650 However, in Japan, early mobilization combined with elastic stockings, initiated for the prevention of VTE in 2004, has been associated with a near halving of the incidence of perioperative PE.528 Given the safety profile of elastic stockings, their affordability, and their ability to raise VTE awareness among patients and healthcare providers, continuous use before, during, and after surgery is recommended in surgical patients at risk. The risks associated with elastic stockings are the same as those described for therapeutic compression. For more detailed recommendations, refer to the Compression Therapy Guidelines for Venous Diseases 2025.578

2.3 Intermittent Pneumatic Compression

IPC involves periodically inflating cuffs wrapped around the legs to reduce venous stasis, similar to elastic stockings. It is effective even in high-risk patients and is particularly beneficial when bleeding risk precludes pharmacologic prophylaxis.651,652 Combined use with pharmacologic prophylaxis further enhances preventive efficacy.653 Meta-analyses have shown that IPC significantly reduces the incidence of PE and DVT compared with no prophylaxis. Compared with elastic stockings alone, IPC more effectively reduces DVT, although there is no significant difference for PE. Compared with pharmacologic prophylaxis, IPC shows similar effects in preventing PE, DVT, and death, but with less bleeding risk.653 Recent studies have shown that IPC significantly reduces the incidence of proximal DVT in stroke patients with lower-limb paralysis.654 These findings have led to renewed interest in IPC use for stroke rehabilitation. However, evidence as to the efficacy of IPC in long-term paralysis is limited. The ACCP guidelines recommend IPC alone for high-risk patients (e.g., postoperative surgical or orthopedic patients) when bleeding risk is high.640,650

2.4 Low-Dose Unfractionated Heparin

For the prevention of VTE using unfractionated heparin, subcutaneous administration of 5,000 units every 8 or 12 h is common. In postoperative VTE prophylaxis, heparin calcium preparations are used, and a standard regimen involves subcutaneous administration of 5,000 units every 12 h for 7–10 days. Notably, this dosage does not prolong activated partial thromboplastin time (APTT), and unlike low-molecular-weight heparin (LMWH), it is subject to fewer medical insurance restrictions regarding timing of administration and underlying disease conditions, thus allowing for broad use in prophylaxis. Although unfractionated heparin may be sufficiently effective as monotherapy in high-risk patients, in the highest-risk patients combined use with mechanical prophylaxis is recommended.655,656 Therapy should be continued at least until the patient can walk adequately, and, if long-term prevention is necessary, switching to warfarin should be considered. It is important to note that with use beyond 5 days, the risk of heparin-induced thrombocytopenia increases; thus the platelet count should be monitored during extended use. The timing of initiation depends on individual risk, but this method does not require monitoring, is relatively inexpensive, and has a favorable safety profile. However, evaluation of bleeding risk is essential, particularly in relation to spinal or epidural anesthesia. Indeed, there are reports indicating that subcutaneous administration of 2,500 units of unfractionated heparin every 12 h effectively prevented VTE without increasing hemorrhagic complications in patients undergoing spinal or epidural anesthesia.657

2.5 Dose-Adjusted Unfractionated Heparin

This is a method that enhances efficacy by adjusting APTT to the upper limit of the normal range. An initial subcutaneous injection of approximately 3,500 units of unfractionated heparin is administered, followed by subcutaneous injections every 8 h at a dose adjusted by ±500 units based on the APTT measured 4 h after administration to reach the target range. In some cases, continuous intravenous infusion may be used. Although this method is complex, it can be effective as monotherapy in patients at the highest risk.658 However, careful attention must be paid to hemorrhagic complications.

2.6 Dose-Adjusted Warfarin

This method involves the oral administration of warfarin with dose adjustment to achieve a target international normalized ratio of prothrombin time (PT-INR); however, it is generally not implemented as a method of VTE prophylaxis. Because it takes 3–5 days for the effects of oral warfarin to manifest, it should either be initiated preoperatively or be combined with another prophylactic method during the initial phase of administration. Although a PT-INR range of 2.0–3.0 is recommended in Western countries, a PT-INR range of 1.5–2.5 is considered appropriate under current conditions in Japan. Although the need for monitoring is a disadvantage, warfarin is effective even as monotherapy in patients at the highest risk and has the advantages of being inexpensive and orally administrable.659

2.7 LMWH and Factor Xa Inhibitors

New anticoagulants such as LMWH, fondaparinux, and edoxaban exhibit minimal interindividual variability in effect and can be conveniently administered by subcutaneous injection once or twice daily, or orally, without the need for monitoring. In addition, the incidence of adverse effects, such as heparin-induced thrombocytopenia and elevations in liver enzymes, is low. Consequently, LMWH has become the mainstay of both treatment and prevention of VTE in Western countries.640,650 Among the LMWHs used for VTE treatment abroad, enoxaparin is covered by medical insurance in Japan exclusively for VTE prophylaxis. Enoxaparin is approved for use following total hip arthroplasty, total knee arthroplasty, and hip fracture surgery, as well as in postoperative settings of abdominal surgery with a high risk of VTE.660 Administration of 20 mg (2,000 units) enoxaparin twice daily reduced the incidence of asymptomatic DVT after total knee arthroplasty from 60.8% to 29.8%, without a significant increase in hemorrhagic complications.661 In Japan, the Factor Xa inhibitors approved for medical insurance coverage in the prevention of VTE in surgical patients are the subcutaneous injection formulation fondaparinux and the oral agent edoxaban. Fondaparinux is approved for the prevention of VTE in patients undergoing lower limb orthopedic surgery and abdominal surgery who are at high risk of VTE.662–664

3. Assessment and Prevention of VTE in Internal Medicine (Non-Surgical) Inpatients (Recommendation Table 36)

Recommendation Table 36.

Recommendations and Levels of Evidence for VTE Prophylaxis in the Field of Internal Medicine

  COR LOE
Early mobilization and active exercise are recommended for all hospitalized patients I C
Compression therapy using compression stockings or intermittent pneumatic compression may
be considered for hospitalized patients with medical conditions who are at risk of disease *1
IIb C
Intermittent pneumatic compression is performed on acute stroke patients with reduced mobility I A
Pharmacologic prophylaxis may be considered for acute medical hospitalized patients with
disease risk *1 who have (or are expected to have) prolonged mobility restrictions (≥3–4 days)
and who have additional VTE risk *2
IIb B
Consider anticoagulant therapy for the prevention of thrombosis and improvement of the condition
in patients with moderate to severe COVID-19 disease (requiring oxygen administration) and
severe COVID-19 patients (requiring ICU admission or mechanical ventilation) *3
IIa B
Intermittent pneumatic compression should be considered for patients with severe acute medical
illnesses *4
IIa B
For patients with severe acute internal diseases,*4 pharmacologic prophylaxis should be
considered while paying attention to bleeding complications
IIa A
For patients with severe acute internal diseases,*4 the combination of pharmacologic prophylaxis
and intermittent pneumatic compression therapy, and the combination of pharmacologic
prophylaxis and compression stockings are not recommended
III
No benefit
B

*1 Stroke, heart failure, acute myocardial infarction, respiratory failure, acute exacerbation of COPD, acute infection, COVID-19, active cancer, nephrotic syndrome, inflammatory bowel disease, autoimmune disease, myeloproliferative disorder, paroxysmal nocturnal hemoglobinuria, etc. *2 Patients with multiple disease risk factors (e.g., history of VTE, obesity, hormone therapy, advanced age, varicose veins, thrombophilia, etc.; see Table 19). *3 See Chapter 1, Section 4. Association with COVID-19. *4 Severe: ICU admission, mechanical ventilation, etc. COPD, chronic obstructive pulmonary disease; COR, Class of Recommendation; ICU, intensive care unit; LOE, Level of Evidence; VTE, venous thromboembolism.

An analysis by the Japan Medical Safety Research Organization on fatalities related to acute PE found that 4 of 8 deaths occurred in non-surgical, non-trauma patients (e.g., due to cerebral hemorrhage, psychiatric illness, pleuritis).665 In addition, a national epidemiological study using Diagnosis Procedure Combination data reported that, compared with surgical patients, medical inpatients had lower implementation rates of VTE prevention (7.3% vs. 59.2%) and a higher PE incidence (0.119% vs. 0.095%).666 These findings underscore the importance of PE risk management in internal medicine patients as well.

In medical inpatients, reduced physical activity, venous stasis, hypercoagulability, and endothelial dysfunction all increase VTE risk. The total VTE risk level should be assessed by integrating these factors633,634,667,668 while also considering bleeding risk and complications such as skin injury or ischemic necrosis associated with the use of elastic stockings. Preventive strategies should be selected accordingly.

As of March 2025, unfractionated heparin is the only anticoagulant approved in Japan for primary VTE prevention in medical inpatients, whereas LMWH, fondaparinux, and DOACs are used internationally.

The information in this section is primarily targeted to bedridden acute-phase medical patients (e.g., bed rest with bathroom privileges). Unless contraindicated, early mobilization and active exercise are recommended in all disease states. In the acute phase of stroke, IPC is preferred over elastic stockings in patients who cannot walk independently.654,669,670 Prophylactic anticoagulation may be considered in patients at high VTE risk, but only if the expected benefit outweighs the risk of intra- or extracranial hemorrhage. Currently, no predictive tools exist to reliably identify such patients.671 In cases where antithrombotic therapy is already being used for stroke (e.g., ischemic stroke), adding prophylactic anticoagulation increases the risk of hemorrhagic transformation or brain hemorrhage.670 Therefore, its efficacy has not been established. In severe hemorrhagic stroke, subarachnoid hemorrhage, or hemorrhagic infarction, non-pharmacologic methods should be prioritized.670

For acute myocardial infarction, one small randomized controlled trial (RCT) confirmed that the use of elastic stockings reduces the incidence of DVT.672 In cancer patients, especially those with active malignancy and hospitalized for acute illness, or outpatients with limited mobility undergoing chemotherapy (e.g., Khorana score ≥2), prophylactic anticoagulation with LMWH or direct oral anticoagulants has been shown to be effective in international studies.602,673–683 However, these agents are not approved for this indication in Japan, and neither safety data nor domestic evidence are available. Given the high bleeding risk in cancer patients, careful risk–benefit analysis is essential. Therefore, such prophylaxis should be limited to high-risk cancer patients.

In other internal medicine conditions, such as congestive heart failure, acute infections, chronic obstructive pulmonary disease exacerbations, inflammatory disorders, and inflammatory bowel disease, the risk of VTE increases with prolonged immobility (≥3–4 days) and coexisting factors such as a history of VTE, obesity, hormone therapy, advanced age, malignancy, or varicose veins. In these cases, prophylactic anticoagulation with LMWH or fondaparinux has demonstrated efficacy internationally.682–684

VTE risk remains elevated for up to 6 weeks after discharge in high-risk medical patients.634,685–687 Short-term (∼40 days) prophylaxis has been shown to reduce this risk, but the risk of major bleeding also increases.688–691 Therefore, extended prophylaxis is not universally recommended.

In medical intensive care unit (ICU) patients, risk factors often overlap and VTE risk is high. Meta-analyses show that heparin-based prophylaxis (either LMWH or unfractionated heparin) effectively reduces symptomatic PE and DVT in this population.692 Consequently, prophylactic anticoagulation is recommended in Western guidelines.692,693 However, adding IPC to pharmacologic prophylaxis has not shown additional benefit.694 Similarly, no studies have demonstrated the effectiveness of adding elastic stockings to anticoagulation, even in surgical patients.695,696

Because medical ICU patients often have high bleeding risks, mechanical prophylaxis (e.g., IPC) is widely used in Japan in place of anticoagulation. Although RCTs have not definitively demonstrated the efficacy of IPC in ICU patients,697 a network meta-analysis including 5 RCTs (one of which was negative) found that IPC significantly reduced the incidence of VTE compared with no prophylaxis or the use of elastic stockings alone.578,698

XIII. COVID-19 and Venous Thromboembolism (Recommendation Table 37)

Recommendation Table 37.

Recommendations and Levels of Evidence Regarding the Association Between COVID-19, Thrombosis, and VTE

  COR LOE
Clinicians should be careful of thrombosis as a cardiovascular complication when treating patients
with COVID-19
I B
Uniform anticoagulation therapy for patients with mild (no pneumonia) or moderate (no oxygen
administration) COVID-19 is not recommended
III
No benefit
B
Anticoagulation therapy for patients with moderate (oxygen administration) or severe (ICU
admission or mechanical ventilation) COVID-19 should be considered
IIa B

COR, Class of Recommendation; ICU, intensive care unit; LOE, Level of Evidence; VTE, venous thromboembolism.

1. Thrombosis and Venous Thromboembolism in COVID-19

COVID-19 is an acute viral pulmonary disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the primary clinical manifestation is respiratory infection, COVID-19 has been reported to have a high rate of thrombotic complications, especially an elevated risk of venous thromboembolism (VTE), including pulmonary embolism (PE).699,700

Although the exact pathogenesis of VTE in COVID-19 remains unclear, several mechanisms have been proposed, including: development of disseminated intravascular coagulation due to severe infection;701 the frequent need for intensive care unit (ICU) management;702 and the effects of various COVID-19 therapies on platelets and coagulation.703,704

A Chinese observational study reported that 20 of 81 ICU patients with severe COVID-19 developed VTE (25%).705 In an observational study conducted in the Netherlands, VTE occurred in 31% of 184 patients with severe COVID-19.706 Prophylactic anticoagulation therapy had not been administered in any of these patients. The wide variation in reported VTE incidence has been attributed to potential differences depending on whether the subjects were ICU or non-ICU patients, and whether imaging screening was performed. Specifically, the incidence was 40.3% and 9.5% with and without screening ultrasonography, respectively, and 22.7% and 7.9% among ICU and non-ICU patients, respectively.707

2. Epidemiology in Japan

According to a joint questionnaire sent out by the Japanese Society of Phlebology and the Pulmonary Embolism Research Group in August 2020, VTE was reported in 7 (0.6%) COVID-19 patients.708 Of these, 5 (0.4%) had PE. All 5 patients were critically ill, requiring mechanical ventilation during hospitalization.709 A joint survey in December 2020 by the Japanese Society on Thrombosis and Hemostasis, the Japan Atherosclerosis Society, and a Ministry of Health research group reported that of 5,687 hospitalized COVID-19 patients in 109 hospitals, 105 (1.85%) developed thrombotic events: DVT in 41 (0.72%) and PE in 29 (0.51%).710 In an analysis focusing only on those who underwent contrast-enhanced computed tomography, VTE was found in 10 of 45 patients (22.2%). Notably, none of the patients with mild COVID-19 had VTE, whereas 40% of patients with severe COVID-19 did.711

The CLOT-COVID registry, Japan’s largest registry on thrombosis and anticoagulation in COVID-19 patients, reported 55 (1.9%) thrombotic events among 2,894 patients hospitalized between April and September 2021.712 The incidence of thrombotic events increased with disease severity: 0.2%, 1.4%, and 9.5% in mild, moderate, and severe disease, respectively. Overall, thrombotic events in Japan were much lower than in international reports, but were present in a considerable proportion of patients with severe disease.

3. Anticoagulation Therapy and Primary Prevention of Thrombosis

Given the high thrombotic tendency and risk of VTE in COVID-19 patients, several international societies have issued statements recommending universal anticoagulation therapy for all hospitalized patients to prevent thrombosis and improve prognosis.713,714 Various studies have examined the optimal intensity of anticoagulation (prophylactic vs. therapeutic dose). Initial reports were skeptical about the benefits of full-dose therapy,715–717 but more recent large-scale studies have demonstrated its efficacy in moderately ill COVID-19 patients.718

In Japan, given the low thrombotic risk in mild cases of COVID-19 and the potentially higher bleeding risk in Asian compared with Western populations, caution is required.719 Unlike other countries where low-molecular-weight heparin is commonly used, only unfractionated heparin has been approved for VTE prophylaxis in Japan. Therefore, based on domestic data, several Japanese societies jointly issued a guideline titled Clinical Practice Guidelines for Thrombosis Prevention and Anticoagulant Therapy in Novel Coronavirus Disease (COVID-19).720

Appendix 1. Details of Members

Chair

• Yuichi Tamura, MD, PhD, Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital

Members

• Teiji Akagi, MD, PhD, Department of Cardiovascular Medicine, Okayama University

• Masanori Atsukawa, MD, PhD, Division of Gastroenterology and Hepatology, Nipppon Medical School

• Yoshihiro Fukumoto, MD, PhD, FJCS, FAHA, FESC, FJCC, Divsion of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine

• Ayumi Goda, MD, PhD, Department of Cardiovascular Medicine, Kyorin University

• Shinya Goto, MD, PhD, FACC, FAHA, FRSM, Department of Medicine (Cardiology), Tokai University School of Medicine

• Masaru Hatano, MD, PhD, Advanced Medical Center for Heart Failure, The University of Tokyo Hospital

• Masataka Ikeda, MD, PhD, Div of Lower GI, Department of Gastroenterological Surgery, Hyogo Medical University

• Keiichi Ishida, MD, PhD, Department of Cardiovascular Surgery, Chibaken Saiseikai Narashino Hospital

• Masaharu Kataoka, MD, PhD, FJCS, The Second Department of Internal Medicine, University of Occupational and Environmental Health

• Kenya Kusunose, MD, PhD, Department of Cardiovascular Medicine, Nephrology, and Neurology, University of the Ryukyus

• Masataka Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine

• Hiromi Matsubara, MD, PhD, Departtment of Cardiology, NHO Okayama Medical Center

• Makoto Mo, MD, PhD, Department of Cardiovascular Surgery, Yokohama Minami Kyosai Hospital / Namiki Clinic

• Tetsutaro Nagaoka, MD, PhD, Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine

• Takeshi Ogo, MD, PhD, Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center

• Yoshinori Okada, MD, PhD, Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University

• Seiichiro Sakao, MD, PhD, Department of Pulmonary Medicine, International University of Health and Welfare (IUHW), School of Medicine

• Hirofumi Sawada, MD, PhD, Department of Pediatrics, Mie University Graduate School of Medicine

• Toshiro Shinke, MD, PhD, Division of Cardiology, Department of Medicine, Showa Medical University School of Medicine

• Nobuhiro Tanabe, MD, PhD, FCCP, Pulmonary Hypertension Center, ChIbaken Saiseikai Narashino Hospital

• Norikazu Yamada, MD, PhD, FJCS, Department of Cardiology, Kuwana City Medical Center

• Hiroyuki Yamagishi, MD, PhD, Tokyo Metropolitan Children’s Medical Center

• Yugo Yamashita, MD, PhD, Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University

• Shingo Yano, MD, PhD, Div of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medcine

Collaborators

• Kohtaro Abe, MD, PhD, Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University

• Shiro Adachi, MD, PhD, Department of Cardiology, Nagoya University Hospital

• Kazuya Hosokawa, MD, PhD, Center for Advanced Medical Innovation, Kyushu University

• Nobutaka Ikeda, MD, PhD, Division of Cardiovascular Medicine, Toho University Medical Center Ohashi Hospital

• Takumi Inami, MD, PhD, Department of Cardiovascular Medicine, Kyorin University School of Medicine

• Masahiro Jinzaki, MD, PhD, Department of Radiology, Keio University School of Medicine

• Masaru Kato, MD, PhD, The First Department of Internal Medicine, University of Toyama Faculty of Medicine

• Takeshi Kitai, MD, PhD, FHFSA, FESC, Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center

• Shigetoyo Kogaki, MD, Department of Pediatrics and Neonatology, Osaka General Medical Center

• Jun Koizumi, MD, PhD, Department of Comprehensive Radiology, Chiba University Hospital

• Yoshiteru Morio, MD, PhD, Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital

• Mari Nishizaki, MD, Department of Rehabilitation, NHO Okayama Medical Center

• Yoshito Ogihara, MD, PhD, Department of Cardiology, Mie University Hospital

• Keiko Ohta-Ogo, MD, PhD, Department of Pathology, National Cerebral and Cardiovascular Center

• Kunihiro Shigematsu, MD, PhD, Department of Vascular Surgery, International University of Health and Welfare Mita Hospital

• Koichiro Sugimura, MD, PhD, FJCS, Department of Cardiology, International University of Health and Welfare, Narita Hospital

• Yudai Tamura, MD, PhD, Department of Cardiology, Kanazawa Cardiovascular Hospital

• Yu Taniguchi, MD, PhD, Division of Cardiovascular Medicine, Kobe University Hospital

• Ichizo Tsujino, MD, PhD, Division of Respiratory and Cardiovascular Innovative Research/Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University

• Keiko Uchida, MD, PhD, Department of Physiology, Tokyo Medical University

• Takeshi Yamamoto, MD, PhD, FJCS, Division of Cardiovascular Intensive Care, Nippon Medical School Hospital

• Atsushi Yao, MD, PhD, Division for Health Service Promotion, The University of Tokyo

• Nobuhiro Yaoita, MD, PhD, Department of Cardiovasular Medicine, Tohoku University Hospital

Independent Assessment Committee

• Noriaki Emoto, MD, PhD, FJCS, Laboratory of Pharmaceutical Science, Kobe Pharmaceutical University

• Hiroaki Kitaoka, MD, PhD, FJCS, FESC, FJCC, Department of Cardiology and Geriatrics, Kochi University

• Mashio Nakamura, MD, PhD, FJCS, Hidamarinooka Nakamura Medical Clinic

• Hitoshi Ogino, MD, PhD, FJCS, Cardiovascular Surgery, Medial Research Institute Kitano Hospital

• Toru Satoh, MD, PhD, Iruma Heart Hospital

• Hiroshi Watanabe, MD, PhD, Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine

(Listed in alphabetical order; affiliations as of March 2025)

Appendix 2. Disclosure of Potential Conflicts of Interest (COI): JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis (2022/1/1–2024/12/31)

Author Member’s own declaration items COI of the marital partner,
first-degree family members,
or those who share income
and property
COI of the head of the
organization/department to
which the member belongs
(if the member is in a position
to collaborate with the head of
the organization/department)
Employer/
leadership
position
(private
company)
Stakeholder Patent
royalty
Honorarium Payment for
manuscripts
Research grant Scholarship
(educational) grant
Endowed chair Other
rewards
Employer/
leadership
position
(private
company)
Stakeholder Patent
royalty
Research
grant
Scholarship
(educational)
grant
Chair:
Yuichi Tamura
Cardio
Intelligence
Inc.
    Bayer Yakuhin Co., Ltd.
Janssen Pharmaceutical
K.K.
Nippon Shinyaku Co.,
Ltd.
MSD K.K.
DAIICHI SANKYO
COMPANY,
LIMITED
                   
Members:
Teiji Akagi
      Abbott Medical Japan
LLC
Japan Lifeline Co.,Ltd.
Janssen Pharmaceutical
K.K.
                   
Members:
Masanori
Atsukawa
      AbbVie GK
ASKA Pharmaceutical
Co., Ltd.
Gilead Sciences, Inc.
                   
Members:
Yoshihiro
Fukumoto
      AstraZeneca K.K.
Otsuka Pharmaceutical
Co., Ltd.
Kowa Company, Ltd.
DAIICHI SANKYO
COMPANY,
LIMITED
Nippon Boehringer
Ingelheim Co., Ltd.
Bayer Yakuhin Co.,
Ltd.
Janssen
Pharmaceutical K.K.
MSD K.K.
  Alnylam
Pharmaceuticals,
Inc.
Otsuka
Pharmaceutical
Co., Ltd.
Janssen
Pharmaceutical
K.K.
Ionis
Pharmaceuticals,
Inc.
MSD K.K.
Japan Medical
Device
Technology Co.,
Ltd.
Alexion Pharma
G.K.
Insmed
Incorporated
Otsuka Medical
Devices Co., Ltd.
PPD-SNBL K.K.
Nippon Shinyaku
Co., Ltd.
Japan Lifeline
Co.,Ltd.
Bayer Yakuhin Co.,
Ltd.
Mochida
Pharmaceutical
Co., Ltd.
Takeda Science
Foundation
Kimura Memorial
Heart Foundation
             
Members:
Shinya Goto
American
Heart
Association,
Inc.
    Mass General Brigham
Incorporated
Duke University
  Nakatani
Foundation
Fukuda Foundation
for Medical
Technology
    American Heart
Association,
Inc.
         
Members:
Masaru Hatano
      Janssen Pharmaceutical
K.K.
Bayer Yakuhin Co., Ltd.
                   
Members:
Masataka Ikeda
      DAIICHI SANKYO
COMPANY,
LIMITED
Pfizer Japan Inc.
  DAIICHI
SANKYO
COMPANY,
LIMITED
               
Members:
Masaharu
Kataoka
      Bayer Yakuhin Co., Ltd.
Nippon Shinyaku Co.,
Ltd.
Janssen Pharmaceutical
K.K.
AstraZeneca K.K.
  Janssen
Pharmaceutical
K.K.
Takeda Science
Foundation
Boston Scientific
Japan K.K.
Shionogi & Co., Ltd.
Bayer Yakuhin Co.,
Ltd.
Mitsubishi Tanabe
Pharma
Corporation
Japan Lifeline
Co.,Ltd.
           
Members:
Kenya Kusunose
      DAIICHI SANKYO
COMPANY,
LIMITED
ONO
PHARMACEUTICAL
CO., LTD.
                   
Members:
Masataka
Kuwana
      Mochida Pharmaceutical
Co., Ltd.
                   
Members:
Hiromi Matsubara
      Janssen Pharmaceutical
K.K.
Bayer Yakuhin Co., Ltd.
MSD K.K.
Nippon Shinyaku Co.,
Ltd.
  Nippon Shinyaku
Co., Ltd.
               
Members:
Takeshi Ogo
      Nippon Shinyaku Co.,
Ltd.
Janssen Pharmaceutical
K.K.
      Nippon Shinyaku
Co., Ltd.
           
Members:
Seiichiro Sakao
      Nippon Shinyaku Co.,
Ltd.
                   
Members:
Hirofumi Sawada
          Janssen
Pharmaceutical
K.K.
               
Members:
Toshiro Shinke
      Abbott Medical Japan
LLC
  Abbott Medical
Japan LLC
Abbott Medical
Japan LLC
Otsuka
Pharmaceutical
Co., Ltd.
Kaneka Medix
Corporation
NIPRO
CORPORATION
BIOTRONIK
Japan, Inc.
Philips Japan, Ltd.
Fukuda Denshi Co.,
Ltd.
Boston Scientific
Japan K.K.
medtronic.co.jp
Japan Lifeline
Co.,Ltd.
OrbusNeich
Medical K. K.
             
Members:
Nobuhiro Tanabe
      Janssen Pharmaceutical
K.K.
Nippon Shinyaku Co.,
Ltd.
MSD K.K.
                   
Members:
Norikazu Yamada
      Bayer Yakuhin Co., Ltd.                    
Members:
Hiroyuki
Yamagishi
      AstraZeneca K.K.
Janssen Pharmaceutical
K.K.
Sanofi K.K.
                   
Members:
Yugo Yamashita
      DAIICHI SANKYO
COMPANY,
LIMITED
  DAIICHI
SANKYO
COMPANY,
LIMITED
Bayer Yakuhin Co.,
Ltd.
               
Members:
Shingo Yano
      DAIICHI SANKYO
COMPANY,
LIMITED
AstraZeneca K.K.
  Nagasaki University Fuji Pharma Co.,
Ltd.
             
Collaborators:
Kohtaro Abe
      Nippon Shinyaku Co.,
Ltd.
Janssen Pharmaceutical
K.K.
  DAIICHI
SANKYO
COMPANY,
LIMITED
KONICA
MINOLTA, INC.
Janssen
Pharmaceutical
K.K.
Mochida
Pharmaceutical
Co., Ltd.
               
Collaborators:
Shiro Adachi
      Nippon Shinyaku Co.,
Ltd.
Bayer Yakuhin Co., Ltd.
Janssen Pharmaceutical
K.K.
  MSD K.K.
Bayer Yakuhin Co.,
Ltd.
Mochida
Pharmaceutical
Co., Ltd.
Janssen
Pharmaceutical
K.K.
               
Collaborators:
Kazuya
Hosokawa
          KONICA
MINOLTA, INC.
               
Collaborators:
Nobutaka Ikeda
      Nippon Shinyaku Co.,
Ltd.
                   
Collaborators:
Takumi Inami
      Bayer Yakuhin Co., Ltd.
Janssen Pharmaceutical
K.K.
MSD K.K.
                   
Collaborators:
Masahiro Jinzaki
          CANON
MEDICAL
SYSTEMS
CORPORATION
KONICA
MINOLTA
JAPAN, INC.
  Nihon Medi-Physics
Co., Ltd.
           
Collaborators:
Masaru Kato
      Asahi Kasei Pharma
Corporation
AbbVie GK
Eli Lilly Japan K.K.
Eisai Co., Ltd.
CHUGAI
PHARMACEUTICAL
CO., LTD.
Janssen Pharmaceutical
K.K.
Astellas Pharma Inc.
Pfizer Japan Inc.
Nippon Boehringer
Ingelheim Co., Ltd.
Mitsubishi Tanabe
Pharma Corporation
Nippon Shinyaku Co.,
Ltd.
Novartis Pharma K.K.
  Janssen
Pharmaceutical
K.K.
               
Collaborators:
Takeshi Kitai
      AstraZeneca K.K.
Otsuka Pharmaceutical
Co., Ltd.
ONO
PHARMACEUTICAL
CO., LTD.
TSUMURA & CO.
Pfizer Japan Inc.
  Kowa Company,
Ltd.
Meiji Yasuda
Research
Institute, Inc
               
Collaborators:
Yoshito Ogihara
      DAIICHI SANKYO
COMPANY,
LIMITED
  Janssen
Pharmaceutical
K.K.
Bayer Yakuhin Co.,
Ltd.
DAIICHI
SANKYO
COMPANY,
LIMITED
IQVIA Services
Japan G.K.
ZEON MEDICAL
INC.
Otsuka
Pharmaceutical
Co., Ltd.
Abbott Medical
Japan LLC
Mochida
Pharmaceutical
Co., Ltd.
             
Collaborators:
Koichiro
Sugimura
      Bayer Yakuhin Co., Ltd.
Nippon Shinyaku Co.,
Ltd.
Novartis Pharma K.K.
Janssen Pharmaceutical
K.K.
DAIICHI SANKYO
COMPANY,
LIMITED
TOA EIYO LTD.
                   
Collaborators:
Yu Taniguchi
          Janssen
Pharmaceutical
K.K.
    Janssen
Pharmaceutical
K.K.
Nippon
Shinyaku Co.,
Ltd.
MSD K.K.
Bayer Yakuhin
Co., Ltd.
Pfizer Japan Inc.
         
Collaborators:
Ichizo Tsujino
      Janssen Pharmaceutical
K.K.
Nippon Shinyaku Co.,
Ltd.
  Janssen
Pharmaceutical
K.K.
  Mochida
Pharmaceutical
Co., Ltd.
Nippon Shinyaku
Co., Ltd.
Nippon Boehringer
Ingelheim Co.,
Ltd.
MEDICAL
SYSTEM
NETWORK Co.,
Ltd.
HOKUYAKU
TAKEYAMA
Holdings,Inc.
KANEKA
CORPORATION
           
Collaborators:
Takeshi
Yamamoto
      Pfizer Japan Inc.                    
Independent
Assessment
Committee:
Noriaki Emoto
      Janssen Pharmaceutical
K.K.
                   
Independent
Assessment
Committee:
Hiroaki Kitaoka
      AstraZeneca K.K.
Pfizer Japan Inc.
Bristol-Myers Squibb
K.K.
Alnylam Japan
Alexion Pharma G.K.
                   
Independent
Assessment
Committee:
Hitoshi Ogino
      Japan Lifeline Co.,Ltd.                    

Notation of corporation is omitted.

 

The following persons have no conflict of interest to declare:

Members: Ayumi Goda

Members: Keiichi Ishida

Members: Makoto Mo

Members: Tetsutaro Nagaoka

Members: Yoshinori Okada

Collaborators: Shigetoyo Kogaki

Collaborators: Jun Koizumi

Collaborators: Yoshiteru Morio

Collaborators: Mari Nishizaki

Collaborators: Keiko Ohta-Ogo

Collaborators: Kunihiro Shigematsu

Collaborators: Yudai Tamura

Collaborators: Keiko Uchida

Collaborators: Atsushi Yao

Collaborators: Nobuhiro Yaoita

Independent Assessment Committee: Mashio Nakamura

Independent Assessment Committee: Toru Satoh

Independent Assessment Committee: Hiroshi Watanabe

All costs associated with the development of this guideline were borne by the Japanese Circulation Society, and no funding was received from any private companies or for-profit organizations

References
 
© 2026, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top